Publications

Alves C, Batel-Marques F, Macedo AF Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis J Cardiovasc Pharmacol Ther 2011 Dec 1. [Epub ahead of print]

Banerjee A, Lane DA, Torp-Pedersen C, Lip GY Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study Thromb Haemost 2011 Dec 21;107(3). [Epub ahead of print]

Bergqvist D, Arcelus JI, Felicissimo P for the ETHOS investigators Post-discharge compliance to venous thromboembolism prophylaxis in high-risk orthopaedic surgery. Results from the ETHOS registry Thromb Haemost 2011 Dec 21;107(2). [Epub ahead of print]

Fanikos J, Rao A, Seger AC, Piazza G, Catapane E, Chen X, Goldhaber SZ Venous thromboembolism prophylaxis for medical service-mostly cancer-patients at hospital discharge Am J Med 2011 Dec;124(12):1143-50

Fukuda T, Honda Y, Kamisato C, Morishima Y, Shibano T Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents Thromb Haemost 2011 Dec 21;107(2). [Epub ahead of print]

Gao Q, Fu X, Wei JW, Chen X, Huang Y, Wang J, Anderson CS, Wong KS China QUEST Study Investigators. Use of oral anticoagulation among stroke patients with atrial fibrillation in China: the ChinaQUEST (Quality evaluation of stroke care and treatment) registry study Int J Stroke 2011 Dec 14

Garwood CL, Hwang JM, Moser LR Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies Pharmacotherapy 2011 Dec;31(12):1208-20

Gulseth MP, Wittkowsky AK, Fanikos J, Spinler SA, Dager WE, Nutescu EA Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness Pharmacotherapy 2011 Dec;31(12):1232-49

Holmes M, Carroll C, Papaioannou D Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: A NICE single technology appraisal Pharmacoeconomics 2011 Dec 20. [Epub ahead of print]

Härtter S, Yamamura N, Stangier J, Reilly PA, Clemens A Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate Thromb Haemost 2011 Dec 21;107(2). [Epub ahead of print]

Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF LIFENOX Investigators. Low-molecular-weight heparin and mortality in acutely ill medical patients N Engl J Med 2011 Dec 29;365(26):2463-72

Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, Le Flem L, Rohde G, Martinoli JL for the Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls Thromb Haemost 2011 Dec 21;107(2). [Epub ahead of print]

Akl EA, Labedi N, Terrenato I, Barba M, Sperati F, Sempos EV, Muti P, Cook D, Schünemann H Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer Cochrane Database Syst Rev 2011 Nov 9;11:CD009447

Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI; the ADOPT Trial Investigators Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients N Engl J Med 2011 Nov 13. [Epub ahead of print]

Haas S, Hohmann V, Bramlage P Prevention of venous thromboembolism using enoxaparin in day surgery: Results of the SMART noninterventional study Clin Appl Thromb Hemost 2011 Nov 14. [Epub ahead of print]

Krauel K, Hackbarth C, Fürll B, Greinacher A Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies Blood 2011 Nov 2. [Epub ahead of print]

Mandema JW, Boyd RA, Dicarlo LA Therapeutic index of anticoagulants for prevention of venous thromboembolism following orthopedic surgery: a dose-response meta-analysis Clin Pharmacol Ther 2011 Nov 2. [Epub ahead of print]

Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; the ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 2011 Nov 13. [Epub ahead of print]

Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ; on behalf of the RE-LY Investigators Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial Ann Intern Med 2011 Nov 15;155(10):660-667

Qaseem A, Chou R, Humphrey LL, Starkey M, Shekelle P; for the Clinical Guidelines Committee of the American College of Physicians Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians Ann Intern Med 2011 Nov 1;155(9):625-632

Schiro TA, Sakowski J, Romanelli RJ, Jukes T, Newman J, Hudnut A, Leonard T Improving adherence to best-practice guidelines for venous thromboembolism risk assessment and prevention Am J Health Syst Pharm 2011 Nov 15;68(22):2184-8

Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW; the TRACER Investigators Thrombin-receptor antagonist vorapaxar in acute coronary syndromes N Engl J Med 2011 Nov 13. [Epub ahead of print]

Walkey AJ, Wiener RS, Ghobrial JM, Curtis LH, Benjamin EJ Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis JAMA 2011 Nov 13. [Epub ahead of print]

Wang QS, Chen C, Chen XY, Han JH, Soo Y, Leung TW, Mok V, Wong KS Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the fraxiparin in stroke study for the treatment of ischemic stroke (FISS-tris) study Stroke 2011 Nov 10. [Epub ahead of print]

Wang Y, Liu ZH, Zhang HL, Luo Q, Zhao ZH, Zhao Q. Predictive value of D-dimer test for recurrent venous thromboembolism at hospital discharge in patients with acute pulmonary embolism. J Thromb Thrombolysis 2011 Nov;32(4):410-6

Almeida GD, Noblat LD, Passos LC, do Nascimento HF. Quality of Life analysis of patients in chronic use of oral anticoagulant: an observational study. Health Qual Life Outcomes. 2011 Oct 25;9(1):91. [Epub ahead of print]

Cha MJ, Kim YD, Nam HS, Kim J, Lee DH, Heo JH. Stroke mechanism in patients with non-valvular atrial fibrillation according to the CHADS(2) and CHA(2) DS(2) -VASc scores. Eur J Neurol. 2011 Oct 4. [Epub ahead of print]

Fleming TR, Emerson SS. Evaluating rivaroxaban for nonvalvular atrial fibrillation - regulatory considerations. N Engl J Med. 2011 Oct 5. [Epub ahead of print]

Fraenkel L, Street RL Jr, Fried TR. Development of a tool to improve the quality of decision making in atrial fibrillation. BMC Med Inform Decis Mak. 2011 Oct 6;11(1):59. [Epub ahead of print]

Gerotziafas GT, Baccouche H, Sassi M, Galea V, Chaari M, Hatmi M, Samama MM, Elalamy I. Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban. Thromb Res. 2011 Oct 12. [Epub ahead of print]

Giralt-Steinhauer E, Cuadrado-Godia E, Ois A, Jiménez-Conde J, Rodríguez-Campello A, Planellas L, Jimena-García S, Rubio MA, Roquer-González J. CHA₂DS₂-VASc score and prognosis in ischemic strokes with atrial fibrillation. J Neurol. 2011 Oct 8. [Epub ahead of print]

Godier A, Miclot A, Le Bonniec B, Durand M, Fischer AM, Emmerich J, Marchand-Leroux C, Lecompte T, Samama CM Evaluation of prothrombin complex concentrate and recombinant activated Factor VII to reverse rivaroxaban in a rabbit model Anesthesiology 2011 Oct 28. [Epub ahead of print]

Hamadah A, Alwasaidi T, Le Gal G, Carrier M, Wells PS, Scarvelis D, Gonsalves C, Forgie M, Kovacs MJ, Rodger MA. Baseline imaging after therapy for unprovoked venous thromboembolism: a randomised controlled comparison of baseline imaging for diagnosis of suspected recurrence. J Thromb Haemost. 2011 Oct 11. [Epub ahead of print]

Lamy A, Tong W, Gao P, Chrolavicius S, Gafni A, Yusuf S, Connolly SJ. The cost of clopidogrel use in atrial fibrillation in the ACTIVE-A trial. Can J Cardiol. 2011 Oct 7. [Epub ahead of print]

Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Haertter S, Staab A. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011 Oct 5. [Epub ahead of print]

Matsumoto M, Okazaki S, Sakaguchi M, Ohara N, Furukado S, Nagano K, Kuwagata Y, Shimazu T, Yoshimine T, Kitagawa K. Preadmission therapeutic anticoagulation reduces cerebral infarct volume in patients with nonvalvular atrial fibrillation. Eur Neurol. 2011 Oct 21;66(5):277-282. [Epub ahead of print]

Merrill A, Millham F. Increased risk of postoperative deep vein thrombosis and pulmonary embolism in patients with inflammatory bowel disease: a study of national surgical quality improvement program patients. Arch Surg. 2011 Oct 17. [Epub ahead of print]

Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmaco. 2011 Oct 1;50(10):675-86

Navarese EP, DE Luca G, Castriota F, Kozinski M, Gurbel PA, Gibson CM, Andreotti F, Buffon A, Siller-Matula JM, Sukiennik A, DE Servi S, Kubica J. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J Thromb Haemost. 2011 Oct 8;9(10):1902-1915.

No authors listed. Should dabigatran replace warfarin for stroke prevention in AF? Drug Ther Bull. 2011 Oct;49(10):114-7.

Parry TJ, Huang Z, Chen C, Connelly MA, Perzborn E, Andrade-Gordon P, Damiano BP. Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis. Blood Coagul Fibrinolysis. 2011 Oct 7. [Epub ahead of print]

Piazza G, Goldhaber SZ, Lessard DM, Goldberg RJ, Emery C, Spencer FA. Venous thromboembolism in patients with symptomatic atherosclerosis. Thromb Haemost. 2011 Oct 20;106(6). [Epub ahead of print]

Pink J, Lane S, Pirmohamed M, Hughes DA Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses BMJ 2011 Oct 31;343:d6333

Poli D, Antonucci E, Grifoni E, Paoletti O, Rancan E, Dentali F, Testa S. Risk of bleeding in low-risk atrial fibrillation patients on warfarin waiting for elective cardioversion. Thromb Res. 2011 Oct 3. [Epub ahead of print]

Ryttberg L, Diamantopoulos A, Forster F, Lees M, Fraschke A, Björholt I. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden. Expert Rev Pharmacoecon Outcomes Res. 2011 Oct;11(5):601-15

Schmidt M, Horvath-Puho E, Thomsen RW, Smeeth L, Toft Sørensen H. Acute infections and venous thromboembolism. J Intern Med. 2011 Oct 25. [Epub ahead of print]

Singh K, Yakoub D, Giangola P, Decicca M, Patel CA, Marzouk F, Giangola G. Early follow-up and treatment recommendations for isolated calf deep venous thrombosis. J Vasc Surg. 2011 Oct 7. [Epub ahead of print]

Solayar GN, Walsh PM, Mulhall K The effect of a new direct Factor Xa inhibitor on human osteoblasts: an in-vitro study comparing the effect of rivaroxaban with enoxaparin BMC Musculoskelet Disord 2011 Oct 28;12(1):247. [Epub ahead of print]

Spirk D, Husmann M, Hayoz D, Baldi T, Frauchiger B, Engelberger R, Amann-Vesti B, Baumgartner I, Kucher N Predictors of in-hospital mortality in elderly patients with acute venous thrombo-embolism: the SWIss Venous ThromboEmbolism Registry (SWIVTER) Eur Heart J 2011 Oct 27. [Epub ahead of print]

Takeuchi S, Wada K, Nagatani K, Otani N, Osada H, Nawashiro H Intravenous tissue plasminogen activator treatment for ischemic stroke in dabigatran-treated patients Acta Neurochir (Wien) 2011 Oct 25. [Epub ahead of print]

Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, Bendszus M, Heiland S, van Ryn J, Veltkamp R. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011 Oct 13. [Epub ahead of print]

van Veen JJ, Maclean RM, Hampton KK, Laidlaw S, Kitchen S, Toth P, Makris M. Protamine reversal of low molecular weight heparin: clinically effective? Blood Coagul Fibrinolysis. 2011 Oct 8;22(7):565-70.

Andersen LV, Mortensen LS, Lip GY, Lindholt JS, Faergeman O, Henneberg EW, Frost L. Atrial fibrillation and upper limb thromboembolectomy: a national cohort study. J Thromb Haemost. 2011 Sep;9(9):1738-43

Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011 Sep 6 [Epub ahead of print]

Erkens PM, Gandara E, Wells PS, Shen AY, Bose G, Le Gal G, Rodger M, Prins MH, Carrier M Does the Pulmonary Embolism Severity Index accurately identify low risk patients eligible for outpatient treatment? Thromb Res 2011 Sep 8 [Epub ahead of print]

Gattellari M, Goumas C, Aitken R, Worthington JM Outcomes for Patients with Ischaemic Stroke and Atrial Fibrillation: The PRISM Study (A Program of Research Informing Stroke Management). Cerebrovasc Dis 2011 Sep 15;32(4):370-382 [Epub ahead of print]

Guanella R, Ducruet T, Johri M, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Ginsberg JS, Lamping DL, Shrier I, Kahn SR Economic burden and cost determinants of deep vein thrombosis during two years following diagnosis: a prospective evaluation. J Thromb Haemost 2011 Sep 22 [Epub ahead of print]

Haas FJ, Kluft C, Biesma DH, Schutgens RE. Patients with deep venous thrombosis and thrombophilia risk factors have a specific prolongation of the lag time in a chromogenic thrombin generation assay. Blood Coagul Fibrinolysis. 2011 Sep;22(6):506-11

Hariharan S, Madabushi R. Clinical Pharmacology Basis of Deriving Dosing Recommendations for Dabigatran in Patients With Severe Renal Impairment. J Clin Pharmacol. 2011 Sep 28. [Epub ahead of print]

Hart RG, Pearce LA, Asinger RW, Herzog CA Warfarin in Atrial Fibrillation Patients with Moderate Chronic Kidney Disease. Clin J Am Soc Nephrol 2011 Sep 8 [Epub ahead of print]

Hong HJ, Kim YD, Cha MJ, Kim J, Lee DH, Lee HS, Nam CM, Nam HS, Heo JH Early neurological outcomes according to CHADS(2) score in stroke patients with non-valvular atrial fibrillation. Eur J Neurol 2011 Sep 14 [Epub ahead of print]

Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T Excess Costs Associated with Patients with Chronic Thromboembolic Pulmonary Hypertension in a US Privately Insured Population. Appl Health Econ Health Policy. 2011 Sep 2. [Epub ahead of print]

Kralev S, Schneider K, Lang S, Süselbeck T, Borggrefe M Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS One 2011;6(9):e24964 Epub 2011 Sep 21

Lehr T, Haertter S, Liesenfeld KH, Staab A, Clemens A, Reilly PA, Friedman J Dabigatran Etexilate in Atrial Fibrillation Patients with Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation. J Clin Pharmaco 2011 Sep 28 [Epub ahead of print]

Nieuwlaat R, Connolly BJ, Hubers LM, Cuddy SM, Eikelboom JW, Yusuf S, Connolly SJ Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: A nested case control analysis of the ACTIVE W study. Thromb Res 2011 Sep 15 [Epub ahead of print]

Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G, Poli D, Testa S, Tiraferri E, Tosetto A, Tripodi A, Manotti C Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA) Thromb Haemost 2011 Sep 22;106(5)

Poli D, Miniati M The incidence of recurrent venous thromboembolism and chronic thromboembolic pulmonary hypertension following a first episode of pulmonary embolism Curr Opin Pulm Med 2011 Sep;17(5):392-7

Rubboli A, Dewilde W, Huber K, Eeckhout E, Herzfeld I, Valencia J, Windecker S, Airaksinen KE, Lip GY The Management of Patients on Oral Anticoagulation Undergoing Coronary Stent Implantation: A Survey among Interventional Cardiologists from Eight European Countries. J Interv Cardiol 2011 Sep 26 [Epub ahead of print]

Sonnevi K, Tchaikovski SN, Holmström M, Rosing J, Bremme K, Lärfars G Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years. Thromb Haemost 2011 Sep 22;106(5) [Epub ahead of print]

Sørensen HT, Horvath-Puho E, Lash TL, Christiansen CF, Pesavento R, Pedersen L, Baron JA, Prandoni P Heart disease may be a risk factor for pulmonary embolism without peripheral deep venous thrombosis. Circulation 2011 Sep 27;124(13):1435-41 Epub 2011 Sep 6

Tichelaar V, de Jong H, Nijland H, Kluin-Nelemans H, Meijer K, Mulder A Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays. Thromb Haemost 2011 Sep 8;106(5) [Epub ahead of print]

Welles CC, Whooley MA, Na B, Ganz P, Schiller NB, Turakhia MP. The CHADS(2) score predicts ischemic stroke in the absence of atrial fibrillation among subjects with coronary heart disease: Data from the Heart and Soul Study. Am Heart J. 2011 Sep;162(3):555-61. Epub 2011 Aug 9.

Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA The Use of Dabigatran Immediately After Atrial Fibrillation Ablation. J Cardiovasc Electrophysiol 2011 Sep 28 [Epub ahead of print]

Yoshida K, Wada H, Hasegawa M, Wakabayashi H, Ando H, Oshima S, Matsumoto T, Shimokariya Y, Noma K, Yamada N, Uchida A, Nobori T, Sudo A Monitoring for anti-Xa activity for prophylactic administration of Fondaparinux in patients with artificial joint replacement. Int J Hematol 2011 Sep 22 [Epub ahead of print]

Aoun SG, Rahme RJ, Batjer HH, Bendok BR New guidelines for the management of cerebral venous thrombosis Neurosurgery 2011 Aug;69(2):N15-7

Asmis LM, Alberio L, Angelillo-Scherrer A, Korte W, Mendez A, Reber G, Seifert B, Stricker H, Tsakiris DA, Wuillemin WA. Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests a study in 9 Swiss laboratories. Thromb Res. 2011 Aug 11. [Epub ahead of print]

Atay JK, Fiumara K, Piazza G, Fanikos J, Goldhaber SZ. Hospital Budget Implications of Substituting Dabigatran for Warfarin in an Anticoagulation Service. Clin Appl Thromb Hemost. 2011 Aug 25. [Epub ahead of print]

Baglin T Using the laboratory to predict recurrent venous thrombosis Int J Lab Hematol 2011 Aug;33(4):333-42

Bishara R, Telman G, Bahouth F, Lessick J, Aronson D. Transient atrial fibrillation and risk of stroke after acute myocardial infarction. Thromb Haemost. 2011 Aug 25;106(4). [Epub ahead of print]

Chang R, Horne MK 3rd, Shawker TH, Kam AW, Chen EA, Joe GO, Ching WL, Mao E, Wyrick DA Jr, Lozier JN Low-dose, once-daily, intraclot injections of alteplase for treatment of acute deep venous thrombosis J Vasc Interv Radiol 2011 Aug;22(8):1107-16. Epub 2011 Jun 12

Coutinho J, de Bruijn SF, Deveber G, Stam J. Anticoagulation for cerebral venous sinus thrombosis. Cochrane Database Syst Rev. 2011 Aug 10;(8):CD002005

Dennis M, Mordi N, Graham C, Sandercock P. The Timing, Extent, Progression and Regression of Deep Vein Thrombosis in Immobile Stroke Patients: observational Data from the CLOTS Multicentre Randomised Trials. J Thromb Haemost. 2011 Aug 23. [Epub ahead of print]

Easton JD Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation) Curr Atheroscler Rep 2011 Aug;13(4):314-20

Fisher WD Impact of venous thromboembolism on clinical management and therapy after hip and knee arthroplasty Can J Surg 2011 Aug 1;54(4):7310. [Epub ahead of print]

Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011 Aug 28. [Epub ahead of print]

Goto S, Ikeda Y, Shimada K, Uchiyama S, Origasa H, Kobayashi H; The J-TRACE Investigators. One-Year Cardiovascular Event Rates in Japanese Outpatients With Myocardial Infarction, Stroke, and Atrial Fibrillation. Circ J. 2011 Aug 20. [Epub ahead of print]

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; the ARISTOTLE Committees and Investigators. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011 Aug 27. [Epub ahead of print]

Harenberg J, Krämer R, Giese C, Marx S, Weiss C, Wehling M. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombolysis. 2011 Aug 3. [Epub ahead of print]

Hippisley-Cox J, Coupland C. Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study. BMJ. 2011 Aug 16;343:d4656

Hull RD, Liang J, Townshend G Long-term Low-Molecular-Weight Heparin and the Post-Thrombotic Syndrome: A Systematic Review Am J Med 2011 Aug;124(8):756-65

Kunisawa S, Ikai H, Imanaka Y. Incidence and Prevention of Postoperative Venous Thromboembolism: Are They Meaningful Quality Indicators in Japanese Health Care Settings? World J Surg. 2011 Aug 31. [Epub ahead of print]

Montero Ruiz E, Utrilla GB, Alvarez JL, Perrin RS. Effectiveness and safety of thromboprophylaxis with enoxaparin in medical inpatients. Thromb Res. 2011 Aug 29. [Epub ahead of print]

Moore KT, Plotnikov AN, Thyssen A, Vaccaro N, Ariyawansa J, Burton PB. Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban. J Cardiovasc Pharmacol. 2011 Aug 4. [Epub ahead of print]

Oh S, Kim SJ, Ryu SK, Kim GM, Chung CS, Lee KH, Bang OY. The determinants of stroke phenotypes were different from the predictors (CHADS2 and CHA2DS2-VASc) of stroke in patients with atrial fibrillation : a comprehensive approach. BMC Neurol. 2011 Aug 24;11(1):107. [Epub ahead of print]

Parikh AM, Spencer FA, Lessard D, Emery C, Baylin A, Linkletter C, Goldberg RJ. Venous Thromboembolism in Patients With Reduced Estimated GFR: A Population-Based Perspective. Am J Kidney Dis. 2011 Aug 26. [Epub ahead of print]

Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Aug 10. [Epub ahead of print]

Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, Palareti G; for the Italian Federation of Anticoagulation Clinics (FCSA). Bleeding Risk in Very Old Patients on Vitamin K Antagonist Treatment: Results of a Prospective Collaborative Study on Elderly Patients Followed by Italian Centres for Anticoagulation. Circulation. 2011 Aug 16;124(7):824-829. Epub 2011 Aug 1

Providência R, Botelho A, Trigo J, Quintal N, Nascimento J, Mota P, Leitão-Marques A. Possible refinement of clinical thromboembolism assessment in patients with atrial fibrillation using echocardiographic parameters. Europace. 2011 Aug 24. [Epub ahead of print]

Rathbun SW, Stoner JA, Whitsett TL. Treatment of Upper-Extremity Deep-Vein Thrombosis. J Thromb Haemost. 2011 Aug 12. [Epub ahead of print]

Rizos T, Wagner A, Jenetzky E, Ringleb PA, Becker R, Hacke W, Veltkamp R. Paroxysmal Atrial Fibrillation Is More Prevalent than Persistent Atrial Fibrillation in Acute Stroke and Transient Ischemic Attack Patients. Cerebrovasc Dis. 2011 Aug 31;32(3):276-282. [Epub ahead of print]

Rodríguez-Mañero M, Cordero A, Bertomeu-González V, Moreno-Arribas J, Bertomeu-Martínez V, Mazón P, Fácila L, Cosín J, Lekuona I, Galve E, González-Juanatey JR Impact of New Criteria for Anticoagulant Treatment in Atrial Fibrillation Rev Esp Cardiol 2011 Aug;64(8):649-653. Epub 2011 Jun 8

Saad EB, d'Avila A, Costa IP, Aryana A, Slater C, Costa RE, Inácio LA Jr, Maldonado P, Neto DM, Camiletti A, Camanho LE, Polanczyk CA. Very Low Risk of Thromboembolic Events in Patients Undergoing Successful Catheter Ablation of Atrial Fibrillation with a CHADS2 Circ Arrhythm Electrophysiol. 2011 Aug 13. [Epub ahead of print]

Samama MM, Mendell J, Guinet C, Le Flem L, Kunitada S. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res. 2011 Aug 16. [Epub ahead of print]

Stangier J, Stähle H, Rathgen K, Roth W, Reseski K, Körnicke T. Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, With Coadministration of Digoxin. J Clin Pharmacol. 2011 Aug 25. [Epub ahead of print]

Steg PG, Mehta SR, Jukema JW, Lip GY, Gibson CM, Kovar F, Kala P, Garcia-Hernandez A, Renfurm RW, Granger CB; on behalf of the RUBY-1 investigators. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J. 2011 Aug 31. [Epub ahead of print]

Turpie AG. Rivaroxaban for the prevention and treatment of venous thromboembolism. Fundam Clin Pharmacol. 2011 Aug 18. [Epub ahead of print]

Whitworth JM, Schneider KE, Frederick PJ, Finan MA, Reed E, Fauci JM, Straughn JM Jr, Rocconi RP Double prophylaxis for deep venous thrombosis in patients with gynecologic oncology who are undergoing laparotomy: does preoperative anticoagulation matter? Int J Gynecol Cancer 2011 Aug;32(2):129-37

Wong PC, Crain EJ, Watson CA, Schumacher WA A small-molecule factor Xia inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits J Thromb Thrombolysis 2011 Aug;32(2):129-37

Xenos ES, Vargas HD, Davenport DL. Association of blood transfusion and venous thromboembolism after colorectal cancer resection. Thromb Res. 2011 Aug 26. [Epub ahead of print]

Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L; the APPRAISE-2 Investigators Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome N Engl J Med 2011 Jul 24. [Epub ahead of print]

Bernier MC, Desjardins K, Filiatrault J, Sauriol MA, Martineau J, Gilbert E, Caron S, Lalonde L Implementation and evaluation of a pharmacy-led thromboprophylaxis campaign in a community hospital J Thromb Thrombolysis 2011 Jul 17. [Epub ahead of print]

Blondon M, Righini M, Bounameaux H, Veenstra DL Fondaparinux for isolated superficial-vein thrombosis of the legs: a cost-effectiveness analysis Chest 2011 Jul 14. [Epub ahead of print]

Chen WT, Michael White C, Phung OJ, Kluger J, Ashaye A, Sobieraj D, Makanji S, Tongbram V, Baker WL, Coleman CI Are the risk factors listed in warfarin prescribing information associated with anticoagulation-related bleeding? A systematic literature review Int J Clin Pract 2011 Jul;65(7):749-63. doi:10.1111/j.1742-1241.2011.02694.x.

Emmerechts J, Vanassche T, Loyen S, Van Linthout I, Cludts K, Kauskot A, Long C, Jacquemin M, Hoylaerts MF, Verhamme P Partial versus complete factor VIII inhibition in a mouse model of venous thrombosis Thromb Res 2011 Jul 19. [Epub ahead of print]

Ferro JM, Crassard I, Coutinho JM, Canhão P, Barinagarrementeria F, Cucchiara B, Derex L, Lichy C, Masjuan J, Massaro A, Matamala G, Poli S, Saadatnia M, Stolz E, Viana-Baptista M, Stam J, Bousser MG; Second International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT 2) Investigators Decompressive Surgery in Cerebrovenous Thrombosis: A Multicenter Registry and a Systematic Review of Individual Patient Data Stroke 2011 Jul 28. [Epub ahead of print]

Goltz JP, Schmid JS, Ritter CO, Knödler P, Petritsch B, Kirchner J, Hahn D, Kickuth R Identification of risk factors for catheter-related thrombosis in patients with totally implantable venous access ports in the forearm J Vasc Access 2011 Jul 13.[Epub ahead of print]

Hannon N, Callaly E, Moore A, Ní Chróinín D, Sheehan O, Marnane M, Merwick A, Kyne L, Duggan J, McCormack PM, Dolan E, Crispino-O'Connell G, Harris D, Horgan G, Williams D, Kelly PJ Improved Late survival and disability after stroke with therapeutic anticoagulation for atrial fibrillation: A population study Stroke 2011 Jul 21. [Epub ahead of print]

Harenberg J, Marx S, Wehling M, Krejczy M New Anticoagulants - Promising and Failed Developments Br J Pharmacol 2011 Jul 8.[Epub ahead of print]

Hobbs FD, Leach I Challenges of stroke prevention in patients with atrial fibrillation in clinical practice QJM 2011 Jul 12. [Epub ahead of print]

Huo MH New oral anticoagulants in venous thromboembolism prophylaxis in orthopaedic patients: Are they really better? Thromb Haemost 2011 Jul 4;106(1):45-57. Epub 2011 May 5

Kaeberich A, Reindl I, Raaz U, Maegdefessel L, Vogt A, Linde T, Steinseifer U, Perzborn E, Hauroeder B, Buerke M, Werdan K, Schlitt A Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study J Thromb Thrombolysis 2011 Jul 20. [Epub ahead of print]

Kang BJ, Lee YK, Kim HJ, Ha YC, Koo KH Deep Venous Thrombosis and Pulmonary Embolism are Uncommon in East Asian Patients after Total Hip Arthroplasty Clin Orthop Relat Res 2011 Jul 12. [Epub ahead of print]

Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T. Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States Curr Med Res Opin 2011 Jul 27. [Epub ahead of print]

Kwong LM. Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data. Vasc Health Risk Manag. 2011; 7:461-6. Epub 2011 Jul 18

Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy Menopause 2011 Jul 27. [Epub ahead of print]

Langer F, Bokemeyer C Crosstalk between cancer and haemostasis. Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor Hamostaseologie 2011 Jul 12;31(4). [Epub ahead of print]

Leizorovicz A, Siguret V, Mottier D Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: The Innohep(®) in Renal Insufficiency Study (IRIS). Thromb Res 2011 Jul;128(1):27-34.

Lim SH, Calkins H, Sinha SK Update on the Management of Atrial Fibrillation: Anticoagulation and Medical Therapy Curr Cardiol Rep 2011 Jul 9. [Epub ahead of print]

Ogilvie IM, Welner SA, Cowell W, Lip GY Ischaemic stroke and bleeding rates in 'real-world' atrial fibrillation patients Thromb Haemost 2011 Jul 4;106(1):34-44. Epub 2011 May 26

Partida RA, Giugliano RP Edoxaban: pharmacological principles, preclinical and early-phase clinical testing Future Cardiol 2011 Jul;7(4):459-70

Pedersen AB, Mehnert F, Johnsen SP, Husted S, Sorensen HT Venous Thromboembolism in Patients Having Knee Replacement and Receiving Thromboprophylaxis: A Danish Population-Based Follow-up Study J Bone Joint Surg Am 2011 Jul 20;93(14):1281-7

Romualdi E, Donadini MP, Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN Extension study). Expert Rev Cardiovasc Ther. 2011 Jul; 9(7):841-4

Watanabe M, Qureshi AI, Siddiqui FM Periprocedural Management of Patients on Dabigatran Etexilate Treatment AJNR Am J Neuroradiol 2011 Jul 28. [Epub ahead of print]

Zakai NA, McClure LA Racial Differences in Venous Thromboembolism J Thromb Haemost 2011 Jul 28. [Epub ahead of print]

Ageno W, Agnelli G, Imberti D, Moia M, Palareti G, Pistelli R, Verso M Prevalence of risk factors for venous thromboembolism in the Italian population: results of a cross-sectional study from the Master Registry Intern Emerg Med 2011 Jun 10. [Epub ahead of print]

Alexander D, Jeremias A Rivaroxaban in the contemporary treatment of acute coronary syndromes Expert Opin Investig Drugs 2011 Jun;20(6):849-57

Alhusban A, Fagan SC Secondary prevention of stroke in the elderly: a review of the evidence Am J Geriatr Pharmacother 2011 Jun;9(3):143-52. Epub 2011 May 12

Andreou AP, Crawley JT Thrombomodulin analogues for the treatment of ischemic stroke J Thromb Haemost 2011 Jun;9(6):1171-3. doi:10.1111/j.1538-7836.2011.04292.x

Auriel E, Gur AY, Uralev O, Brill S, Shopin L, Karni A, Shenhar Tsarfaty S, Bornstein NM Characteristics of first ever ischemic stroke in the very elderly: Profile of vascular risk factors and clinical outcome Clin Neurol Neurosurg 2011 Jun 13. [Epub ahead of print]

Banerjee A, Marín F, Lip GY The Improved but Unfinished Business of Stroke Risk Stratification in Atrial Fibrillation Rev Esp Cardiol 2011 Jun 16. [Epub ahead of print]

Boriani G, Botto GL, Padeletti L, Santini M, Capucci A, Gulizia M, Ricci R, Biffi M, De Santo T, Corbucci G, Lip GY; for the Italian AT-500 Registry Investigators Improving Stroke Risk Stratification Using the CHADS2 and CHA2DS2-VASc Risk Scores in Patients With Paroxysmal Atrial Fibrillation by Continuous Arrhythmia Burden Monitoring Stroke 2011 Jun;42(6):1768-1770

Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Finazzi G, Gangat N, Tefferi A, Barbui T Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients Blood 2011 Jun 2;117(22):5857-9

Carrier M, Rodger MA, Wells PS, Righini M, LE Gal G Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysis J Thromb Haemost 2011 Jun;9(6):1119-25. doi: 10.1111/j.1538-7836.2011.04254.x.

Chen WT, White CM, Phung OJ, Kluger J, Ashaye AO, Sobieraj DM, Makanji S, Tongbram V, Baker WL, Coleman CI Association Between CHADS2 Risk Factors and Anticoagulation-Related Bleeding: A Systematic Literature Review Mayo Clin Proc 2011 Jun;86(6):509-21.

Delbeck M, Nickel KF, Perzborn E, Ellinghaus P, Strassburger J, Kast R, Laux V, Schäfer S, Schermuly RT, von Degenfeld G A role for coagulation factor Xa in experimental pulmonary arterial hypertension Cardiovasc Res 2011 Jun 15. [Epub ahead of print]

Douma RA, Mos IC, Erkens PM, Nizet TA, Durian MF, Hovens MM, van Houten AA, Hofstee HM, Klok FA, Ten Cate H, Ullmann EF, Büller HR, Kamphuisen PW, Huisman MV; for the Prometheus Study Group Performance of 4 Clinical Decision Rules in the Diagnostic Management of Acute Pulmonary Embolism: A Prospective Cohort Study Ann Intern Med 2011 Jun 7;154(11):709-718.

Falvo N, Bonithon-Kopp C, Rivron Guillot K, Todolí JA, Jiménez-Gil M, Di Micco P, Monreal M; the RIETE Investigators. Heparin-associated thrombocytopenia in 24,401 patients with venous thromboembolism. Findings from the RIETE Registry J Thromb Haemost 2011 Jun 15. doi: 10.1111/j.1538-7836.2011.04402.x. [Epub ahead of print]

Freeman JV, Zhu RP, Owens DK, et al Compared with warfarin, high-dose dabigatran might be cost-effective for preventing stroke in older patients with nonvalvular AF Ann Intern Med 2011 Jun 21;154(12):JC612.

Friedman RJ, Sengupta N, Lees M Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban Expert Rev Pharmacoecon Outcomes Res 2011 Jun;11(3):299-306.

Gaita F, Blandino A Atrial fibrillation: Left atrial fibrosis-a promising stroke risk factor? Nat Rev Cardiol 2011 Jun;8(6):307-8

Georgescu A, Alexandru N, Nemecz M, Titorencu I, Popov D Enoxaparin reduces adrenergic contraction of resistance arterioles in aging and in aging associated with diabetes via engagement of MAP kinase pathway Blood Coagul Fibrinolysis 2011 Jun;22(4):310-6

Ghanima W, Kleven IW, Enden T, Rosales A, Wik HS, Pederstad L, Holme PA, Sandset PM Recurrent venous thrombosis, post-thrombotic syndrome and quality of life after catheter-directed thrombolysis in severe proximal deep vein thrombosis J Thromb Haemost 2011 Jun;9(6):1261-3. doi: 10.1111/j.1538-7836.2011.04298.x

Gosk-Bierska I, McBane RD, Wu Y, Mruk J, Tafur A, McLeod T, Wysokinski WE Platelet factor XIII gene expression and embolic propensity in atrial fibrillation Thromb Haemost 2011 Jun 9;106(1). [Epub ahead of print]

Hobbs FD, Roalfe AK, Lip GY, Fletcher K, Fitzmaurice DA, Mant J; on behalf of the Birmingham Atrial Fibrillation in the Aged (BAFTA) investigators and Midland Research Practices Consortium (MidReC) network Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial BMJ 2011 Jun 23;342:d3653. doi: 10.1136/bmj.d3653.

Jowett S, Bryan S, Mant J, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Hobbs FD Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation Stroke 2011 Jun;42(6):1717-21

Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, Kitchen S, Makris M; British Committee for Standards in Haematology Guidelines on oral anticoagulation with warfarin - fourth edition Br J Haematol 2011 Jun 14. doi: 10.1111/j.1365-2141.2011.08753.x. [Epub ahead of print]

LE Gal G, Carrier M, Kovacs MJ, Betancourt MT, Kahn SR, Wells PS, Anderson DA, Chagnon I, Solymoss S, Crowther M, Righini M, Delluc A, White RH, Vickars L, Rodger M Residual vein obstruction as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study J Thromb Haemost 2011 Jun;9(6):1126-1132. doi: 10.1111/j.1538-7836.2011.04240.x.

Lecumberri R, Panizo E, Gomez-Guiu A, Varea S, García-Quetglas E, Serrano M, García-Mouriz A, Marqués M, Gómez-Outes A, Páramo JA Economic impact of an electronic alert system to prevent venous thromboembolism in hospitalised patients. J Thromb Haemost 2011 Jun;9(6):1108-15. doi: 10.1111/j.1538-7836.2011.04282.x

Loewen P, Dahri K Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules Ann Hematol 2011 Jun 14. [Epub ahead of print]

Mani H, Hesse C, Stratmann G, Lindhoff-Last E Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time Thromb Haemost 2011 Jun 9;106(1). [Epub ahead of print]

Ogawa S, Koretsune Y, Yasaka M, Aizawa Y, Atarashi H, Inoue H, Kamakura S, Kumagai K, Mitamura H, Okumura K, Sugi K, Yamashita T Antithrombotic Therapy in Atrial Fibrillation Circ J 2011 Jun 9. [Epub ahead of print]

Ogawa S, Shinohara Y, Kanmuri K Safety and Efficacy of the Oral Direct Factor Xa Inhibitor Apixaban in Japanese Patients With Non-Valvular Atrial Fibrillation Circ J 2011 Jun 14. [Epub ahead of print]

Olesen JB, Fauchier L, Lane DA, Taillandier S, Lip GY Risk factors for stroke and thromboembolism in relation to age amongst patients with atrial fibrillation: The Loire Valley Atrial Fibrillation Project Chest 2011 Jun 16. [Epub ahead of print]

Pai M, Evans NS, Shah SJ, Green D, Cook D, Crowther MA Statins in the prevention of venous thromboembolism: A meta-analysis of observational studies Thromb Res 2011 Jun 2. [Epub ahead of print]

Paliwal R, Paliwal SR, Agrawal GP, Vyas SP Biomimetic Solid Lipid Nanoparticles for Oral Bioavailability Enhancement of Low Molecular Weight Heparin and Its Lipid Conjugates: In Vitro and in Vivo Evaluation. Mol Pharm 2011 Jun 2. [Epub ahead of print]

Sahm L, Quinn L, Madden M, Richards HL Does satisfaction with information equate to better anticoagulant control? Int J Clin Pharm 2011 Jun;33(3):543-8

Schulman S, Majeed A A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery. Drug Saf 2011 Jun 1;34(6):449-63. doi: 10.2165/11587290-000000000-00000

Shah SV, Gage BF Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation Circulation 2011 Jun 7;123(22):2562-70. Epub 2011 May 23.

Spirk D, Ugi J, Korte W, Husmann M, Hayoz D, Baldi T, Frauchiger B, Banyai M, Aujesky D, Baumgartner I, Kucher N Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer. The SWIss Venous ThromboEmbolism Registry (SWIVTER) II. Thromb Haemost 2011 Jun 6;105(6):962-7

Tremollieres F, Brincat M, Erel CT, Gambacciani M, Lambrinoudaki I, Moen MH, Schenck-Gustafsson K, Vujovic S, Rozenberg S, Rees M EMAS position statement: Managing menopausal women with a personal or family history of VTE Maturitas 2011 Jun;69(2):195-8

Tuiskula KA, Sullivan KM, Abraham G, Lahoz MR Revising warfarin patient education materials to meet a National Patient Safety Goal Am J Health Syst Pharm 2011 Jun 1;68(11):974-8

Violi F, Lip GY, Basili S Peripheral artery disease and atrial fibrillation: a potentially dangerous combination Intern Emerg Med 2011 Jun 11. [Epub ahead of print]

Wasmer K, Eckardt L Management of atrial fibrillation around the world: a comparison of current ACCF/AHA/HRS, CCS, and ESC guidelines Europace 2011 Jun 28. [Epub ahead of print]

Zhang ZG, Lü TS, Yuan HY Neuroprotective effects of ultra-low-molecular-weight heparin in vitro and vivo models of ischemic injury Fundam Clin Pharmacol 2011 Jun;25(3):300-3. doi: 10.1111/j.1472-8206.2010.00845.x

Zondag W, Mos IC, Creemers-Schild D, Hoogerbrugge AD, Dekkers OM, Dolsma J, Eijsvogel M, Faber LM, Hofstee HM, Hovens MM, Jonkers GJ, van Kralingen KW, Kruip MJ, Vlasveld T, de Vreede MJ, Huisman MV; on behalf of The Hestia Study Investigators Outpatient treatment in patients with acute pulmonary embolism: The Hestia Study J Thromb Haemost 2011 Jun 4. doi: 10.1111/j.1538-7836.2011.04388.x. [Epub ahead of print]

den Exter PL, Hooijer J, Dekkers OM, Huisman MV Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients J Clin Oncol 2011 Jun 10;29(17):2405-9

Amin AN, Lin J, Thompson S, Wiederkehr D Real-World Rates of In-hospital and Postdischarge Deep-Vein Thrombosis and Pulmonary Embolism in At-Risk Medical Patients in the United States Clin Appl Thromb Hemost 2011 May 17. [Epub ahead of print]

Atarashi H, Inoue H, Okumura K, Yamashita T, Kumagai N, Origasa H; The J-RHYTHM Registry Investigators Present Status of Anticoagulation Treatment in Japanese Patients With Atrial Fibrillation Circ J 2011 May 25;75(6):1328-1333

Ay C, Dunkler D, Simanek R, Thaler J, Koder S, Marosi C, Zielinski C, Pabinger I Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the vienna cancer and thrombosis study J Clin Oncol 2011 May 20;29(15):2099-103

Berghaus TM, Thilo C, von Scheidt W, Schwaiblmair M The Impact of Age on the Delay in Diagnosis in Patients With Acute Pulmonary Embolism Clin Appl Thromb Hemost 2011 May 17. [Epub ahead of print]

Bhuvaneswaran JS, Premchand RK, Iyengar SS, Rajeev Khare, Chabra CB, Padmanabhan TN, Sharma SK, Jain A, Pandian SA, Rajdev S, Modi N, Kumar V Tenecteplase in the treatment of acute pulmonary thrombo-embolism J Thromb Thrombolysis 2011 May;31(4):445-8

Blomstrom Lundqvist C, Lip GY, Kirchhof P What are the costs of atrial fibrillation? Europace 2011 May;13 Suppl 2:ii9-12

Christensen TD Self-management of oral anticoagulation therapy - methodological and clinical aspects Dan Med Bull 2011 May;58(5):B4284

Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos A, Tapson V Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol J Thromb Thrombolysis 2011; Feb 27. [Epub ahead of print]

Conen D, Chae CU, Glynn RJ, Tedrow UB, Everett BM, Buring JE, Albert CM Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation JAMA 2011 May 25;305(20):2080-7. PubMed PMID: 21610240; PubMed Central PMCID: PMC3105776.

Cross J, Weisters M, Aslam R, Keeling D, Handa A Have You Been HIT? Angiology 2011 May 8. [Epub ahead of print]

Davenport DL, Xenos ES Early Outcomes and Risk Factors in Venous Thrombectomy: An Analysis of the American College of Surgeons NSQIP Dataset Vasc Endovascular Surg 2011 May;45(4):325-8

Deitelzweig SB, Lin J, Lin G Preventing Venous Thromboembolismc Following Orthopedic Surgery in the United States: Impact of Special Populations on Clinical Outcomes Clin Appl Thromb Hemost 2011 May 17. [Epub ahead of print]

Della Rocca G, Biggi F, Grossi P, Imberti D, Landolfi R, Palareti G, Randelli F, D Prisco D Italian intersociety consensus statement on antithrombotic prophylaxis in hip and knee replacement and in femoral neck fracture surgery Minerva Anestesiol 2011 May 20. [Epub ahead of print]

Deshmukh A, Hilleman DE, Del Core M, Nair CK Antithrombotic Regimens in Patients With Indication for Long-Term Anticoagulation Undergoing Coronary Interventions-Systematic Analysis, Review of Literature, and Implications on Management Am J Ther 2011 May 4. [Epub ahead of print]

Dinh T, Baur LH, Pisters R, Kamp O, Verheugt FW, Smeets JL, Cheriex EC, Tieleman RG, Prins MH, Crijns HJ; for the TIARA pilot study group Feasibility of TEE-guided stroke risk assessment in atrial fibrillation-background, aims, design and baseline data of the TIARA pilot study Neth Heart J 2011 May;19(5):214-222.

Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE LY) Trial Circulation 2011 May 16. [Epub ahead of print]

Formiga F, Ferrer A, Mimbrera D, Badia T, Fernández C, Pujol R; Grupo de Estudio Octabaix High Rate of Anticoagulation Therapy in Oldest Old Subjects with Atrial Fibrillation: The Octabaix Study J Am Med Dir Assoc 2011 May 27. [Epub ahead of print]

Gattellari M, Leung DY, Ukoumunne OC, Zwar N, Grimshaw J, Worthington JM Study protocol: the DESPATCH study: Delivering stroke prevention for patients with atrial fibrillation - a cluster randomised controlled trial in primary healthcare Implement Sci 2011 May 20;6(1):48. [Epub ahead of print]

Gibson CM, Mega JL, Burton P, Goto S, Verheugt F, Bode C, Plotnikov A, Sun X, Cook-Bruns N, Braunwald E Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome Am Heart J 2011 May;161(5):815-821.e6

Gurwitz JH Pharmacogenomics: Is This the Final Chapter in the Remarkable Story of Warfarin? J Am Med Dir Assoc 2011 May 13. [Epub ahead of print]

Ha SI, Choi DH, Ki YJ, Yang JS, Park G, Chung JW, Koh YY, Chang KS, Hong SP Stroke prediction using mean platelet volume in patients with atrial fibrillation. Platelets 2011 May 23. [Epub ahead of print]

Harder S Renal Profiles of Anticoagulants J Clin Pharmacol 2011 May 24. [Epub ahead of print]

Ho LY, Siu CW, Yue WS, Lau CP, Lip GY, Tse HF Safety and efficacy of oral anticoagulation therapy in Chinese patients with concomitant atrial fibrillation and hypertension. J Hum Hypertens 2011 May;25(5):304-10

Hong KS, Yegiaian S, Lee M, Lee J, Saver JL Declining stroke and vascular event recurrence rates in secondary prevention trials over the past 50 years and consequences for current trial design. Circulation 2011 May 17;123(19):2111-9

Jönsson KM, Wieloch M, Sterner G, Nyman U, Elmståhl S, Engström G, Svensson PJ Glomerular filtration rate in patients with atrial fibrillation on warfarin treatment: A subgroup analysis from the AURICULA registry in Sweden Thromb Res 2011 May 25. [Epub ahead of print]

Kamel H, Johnson DR, Hegde M, Go AS, Sidney S, Sorel M, Hills NK, Johnston SC Detection of Atrial Fibrillation After Stroke and the Risk of Recurrent Stroke. J Stroke Cerebrovasc Dis 2011 May 3. [Epub ahead of print]

Kodumuri V, Adigopula S, Singh P, Swaminathan P, Md RA, Khosla S Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis. Am J Ther 2011 May;18(3):180-9

Kotowycz MA, Filion KB, Joza J, Dube D, Reynolds MR, Pilote L, Eisenberg MJ, Essebag V In-Hospital Management of Atrial Fibrillation: The CHADS(2) Score Predicts Increased Cost. Can J Cardiol 2011 May 3. [Epub ahead of print]

Kristinsson SY, Turesson I The association of cancer and venous thrombosis: yes, Trousseau is right...again! Leuk Lymphoma 2011 May;52(5):734-5

Levy MM, Bach C, Fisher-Snowden R, Pfeifer JD Upper extremity deep venous thrombosis: reassessing the risk for subsequent pulmonary embolism. Ann Vasc Surg 2011 May;25(4):442-7

Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane DA, Levi M, Marin F, Palareti G, Kirchhof P; Document reviewers:, Collet JP, Rubboli A, Poli D, Camm J Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace 2011 May;13(5):723-46

Meinertz T, Kirch W, Rosin L, Pittrow D, Willich SN, Kirchhof P; for the ATRIUM investigators Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin Res Cardiol 2011 May 1. [Epub ahead of print]

Mishra N, Vercauteren E, Develter J, Bammens R, Declerck PJ, Gils A Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms. Thromb Haemost 2011 May 5;106(1). [Epub ahead of print]

Nakamura M, Okano Y, Minamiguchi H, Munemasa M, Sonoda M, Yamada N, Hanzawa K, Aoyagi N, Tsujimoto H, Sarai N, Nakajima H, Kunieda T Multidetector-row computed tomography-based clinical assessment of fondaparinux for treatment of acute pulmonary embolism and acute deep vein thrombosis in Japanese patients. Circ J 2011 May 25;75(6):1424-32.

Ogilvie IM, Welner SA, Cowell W, Lip GY Characterization of the Proportion of Untreated and Antiplatelet Therapy Treated Patients With Atrial Fibrillation Am J Cardiol 2011 May 3. [Epub ahead of print]

Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, Tijssen JG, Van de Werf F, Wallentin L; for the RE-DEEM investigators Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial Eur Heart J 2011 May 7. [Epub ahead of print]

Olesen JB, Lip GY, Hansen PR, Lindhardsen J, Ahlehoff O, Andersson C, Weeke P, Hansen ML, Gislason GH, Torp-Pedersen C Bleeding risk in 'real world' patients with atrial fibrillation: Comparison of two established bleeding prediction schemes in a nationwide cohort J Thromb Haemost 2011 May 27. doi: 10.1111/j.1538-7836.2011.04378.x. [Epub ahead of print]

Potpara TS, Stankovic GR, Beleslin BD, Polovina MM, Marinkovic JM, Ostojic MC, Lip GY A 12-year follow-up study of patients with newly-diagnosed lone atrial fibrillation: Implications of arrhythmia progression on prognosis: The Belgrade Atrial Fibrillation Study Chest 2011 May 26. [Epub ahead of print]

Ramacciotti E, Blackburn S, Hawley AE, Vandy F, Ballard-Lipka N, Stabler C, Baker N, Guire KE, Rectenwald JE, Henke PK, Myers DD Jr, Wakefield TW Evaluation of Soluble P-Selectin as a Marker for the Diagnosis of Deep Venous Thrombosis. Clin Appl Thromb Hemost 2011 May 17. [Epub ahead of print]

Ramo BA, Griffin AM, Gill CS, McDonald DJ, Wunder JS, Ferguson P, Bell RS, Phillips SE, Schwartz HS, Holt GE Incidence of symptomatic venous thromboembolism in oncologic patients undergoing lower-extremity endoprosthetic arthroplasty. J Bone Joint Surg Am 2011 May;93(9):847-54

Ribeiro DD, Lijfering WM, Barreto SM, Silva IB, Chalup MM, Rosendaal FR, Rezende SM Past provoking venous thrombosis risk situations on the risk of a recurrent thrombotic event: A cohort study. Thromb Res 2011 May 18. [Epub ahead of print]

Sandhu RK, Bakal JA, Ezekowitz JA, McAlister FA The epidemiology of atrial fibrillation in adults depends on locale of diagnosis. Am Heart J 2011 May;161(5):986-992.e1

Sato S, Yazawa Y, Itabashi R, Tsukita K, Fujiwara S, Furui E Pre-admission CHADS(2) score is related to severity and outcome of stroke. J Neurol Sci 2011 May 11. [Epub ahead of print]

Schmidt M, Christiansen CF, Horvath-Puhó E, Glynn RJ, Rothman KJ, Sørensen HT Nonsteroidal anti-inflammatory drug use and risk of venous thromboembolism. J Thromb Haemost 2011 May 19. doi: 10.1111/j.1538-7836.2011.04354.x. [Epub ahead of print]

Stafford L, Stafford A, Hughes J, Angley M, Bereznicki L, Peterson G Drug-related problems identified in post-discharge medication reviews for patients taking warfarin. Int J Clin Pharm 2011 May 19. [Epub ahead of print]

Tapson VF Acute pulmonary embolism: comment on "time trends in pulmonary embolism in the United States" Arch Intern Med 2011 May 9;171(9):837-9

Tomek A, Matoska V, Eisert C, Serebruany VL Optimization of anticoagulation with warfarin for stroke prevention: pharmacogenetic considerations Am J Ther 2011 May;18(3):e55-66

Wellman JC, Kraus PS, Burton BL, Ensor CR, Nesbit TW, Ross PA, Thomas ML, Streiff MB Development and implementation of a pharmacist managed inpatient anticoagulation monitoring program Am J Health Syst Pharm 2011 May 15;68(10):934-9

Wieloch M, Själander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA Eur Heart J 2011 May 26. [Epub ahead of print]

Wiener RS, Schwartz LM, Woloshin S Time trends in pulmonary embolism in the United States: evidence of overdiagnosis Arch Intern Med 2011 May 9;171(9):831-7

Wolzt M, Samama MM, Kapiotis S, Ogata K, Mendell J, Kunitada S Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux Thromb Haemost 2011 May 5;105(6). [Epub ahead of print]

van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer J Clin Oncol 2011 May 20;29(15):2071-6. Epub 2011 Apr 18.

Akl EA, Gunukula S, Barba M, Yosuico VE, van Doormaal FF, Kuipers S, Middeldorp S, Dickinson HO, Bryant A, Schünemann H Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation Cochrane Database Syst Rev 2011 Apr 13;4:CD006652

Akl EA, Vasireddi SR, Gunukula S, Barba M, Sperati F, Terrenato I, Muti P, Schünemann H Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer Cochrane Database Syst Rev 2011 Apr 13;4:CD006649

Akl EA, Vasireddi SR, Gunukula S, Yosuico VE, Barba M, Sperati F, Cook D, Schünemann H Anticoagulation for patients with cancer and central venous catheters Cochrane Database Syst Rev 2011 Apr 13;4:CD006468

Bahia A, Albert RK The modified wells score accurately excludes pulmonary embolus in hospitalized patients receiving heparin prophylaxis J Hosp Med 2011 Apr;6(4):190-4. doi: 10.1002/jhm.827

Bauersachs R, Schellong SM, Haas S, Tebbe U, Gerlach HE, Abletshauser C, Sieder C, Melzer N, Bramlage P, Riess H CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency Thromb Haemost 2011 Apr 20;105(6). [Epub ahead of print]

Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L, Alexander JH Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor J Thromb Thrombolysis 2011 Apr 23. [Epub ahead of print]

Bereczky Z, Muszbek L Factor XIII and venous thromboembolism Semin Thromb Hemost 2011 Apr;37(3):305-14

Burghaus R, Coboeken K, Gaub T, Kuepfer L, Sensse A, Siegmund HU, Weiss W, Mueck W, Lippert J Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation PLoS One 2011 Apr 22;6(4):e17626

Cacciapuoti F Some considerations about the hypercoagulable states and their treatments Blood Coagul Fibrinolysis 2011 Apr;22(3):155-9

Clayton TC, Gaskin M, Meade TW Recent respiratory infection and risk of venous thromboembolism: case-control study through a general practice database Int J Epidemiol 2011 Apr 21. [Epub ahead of print]

Cleland JG, Coletta AP, Buga L, Antony R, Pellicori P, Freemantle N, Clark AL Clinical trials update from the American Heart Association Meeting 2010:EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT Eur J Heart Fail 2011; Apr;13(4):460-5.

Cook D, Meade M, Guyatt G, Walter SD, Heels-Ansdell D, Geerts W, Warkentin TE, Cooper DJ, Zytaruk N, Vallance S, Berwanger O, Rocha M, Qushmaq I, Crowther M PROphylaxis for ThromboEmbolism in Critical Care Trial protocol and analysis plan J Crit Care 2011 Apr;26(2):223.e1-9

Dechartres A, Albaladejo P, Mantz J, Samama CM, Collet JP, Steg PG, Ravaud P, Tubach F Delphi-consensus weights for ischemic and bleeding events to be included in a composite outcome for RCTs in thrombosis prevention PLoS One 2011 Apr 7;6(4):e18461

Di Minno MN, Tufano A, Ageno W, Prandoni P, Di Minno G Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update. Intern Emerg Med 2011 Apr 2. [Epub ahead of print]

Fan J, Li X, Cheng Y, Yao C, Zhong N; Investigators Group Measurement of D-dimer as aid in risk evaluation of VTE in elderly patients hospitalized for acute illness: a prospective, multicenter study in China Clin Invest Med 2011 Apr 1;34(2):E96-104

Georgiou A, Lang S, Rosenfeld D, Westbrook JI The use of computerized provider order entry to improve the effectiveness and efficiency of coagulation testing Arch Pathol Lab Med 2011 Apr;135(4):495-8

Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S In Vitro and In Vivo P-glycoprotein Transport Characteristics of Rivaroxaban J Pharmacol Exp Ther 2011 Apr 22. [Epub ahead of print]

He K, Luettgen JM, Zhang D, He B, Grace JE Jr, Xin B, Pinto DJ, Wong PC, Knabb RM, Lam PY, Wexler RR, Grossman SJ Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Eur J Drug Metab Pharmacokinet 2011 Apr 2. [Epub ahead of print]

Henwood PC, Kennedy TM, Thomson L, Galanis T, Tzanis GL, Merli GJ, Kraft WK The incidence of deep vein thrombosis detected by routine surveillance ultrasound in neurosurgery patients receiving dual modality prophylaxis. J Thromb Thrombolysis 2011 Apr 21. [Epub ahead of print]

Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Maclehose R, Konety S, Alonso A Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011 Apr 12;123(14):1501-8

JCS Joint Working Group Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). Circ J 2011 Apr 25;75(5):1258-81

Jenkins I, Helmons PJ, Martin-Armstrong LM, Montazeri ME, Renvall M High rates of venous thromboembolism prophylaxis did not increase the incidence of heparin-induced thrombocytopenia. Jt Comm J Qual Patient Saf 2011 Apr;37(4):163-9

Jeske WP, Walenga JM, Samama MM, Hoppensteadt D, Mayuga M, Fareed J Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels Blood Coagul Fibrinolysis 2011 Apr;22(3):206-10.

Kang DK, Sung Sun J, Park KJ, Lim HS Usefulness of Combined Assessment With Computed Tomographic Signs of Right Ventricular Dysfunction and Cardiac Troponin T for Risk Stratification of Acute Pulmonary Embolism. Am J Cardiol 2011 Apr 27. [Epub ahead of print]

Kearon C Extended anticoagulation for unprovoked venous thromboembolism: a majority of patients should be treated J Thromb Thrombolysis 2011; Apr;31(3):295-300.

Khan M, Kamal AK Atrial fibrillation, is warfarin the only option for stroke prevention? J Pak Med Assoc 2011 Apr;61(4):406-7

Lassila R, Antovic JP, Armstrong E, Baghaei F, Dalsgaard-Nielsen J, Hillarp A, Holme PA, Holmström M, Johnsson H, Joutsi-Korhonen L, Sandset PM Practical viewpoints on the diagnosis and management of heparin-induced thrombocytopenia. Semin Thromb Hemost 2011 Apr;37(3):328-36

Lemaine V, McCarthy C, Kaplan K, Mehrara B, Pusic AL, Cordeiro PG, Disa JJ Venous thromboembolism following microsurgical breast reconstruction: an objective analysis in 225 consecutive patients using low-molecular-weight heparin prophylaxis. Plast Reconstr Surg 2011 Apr;127(4):1399-406

Lyman GH Venous thromboembolism in the patient with cancer: Focus on burden of disease and benefits of thromboprophylaxis Cancer 2011; Apr 1;117(7):1334-49. doi: 10.1002/cncr.25714. Epub 2010 Nov 8.

Mandalà M, Tondini C The impact of thromboprophylaxis on cancer survival: focus on pancreatic cancer. Expert Rev Anticancer Ther 2011 Apr;11(4):579-88

Nutescu E, Chuatrisorn I, Hellenbart E Drug and dietary interactions of warfarin and novel oral anticoagulants: an update J Thromb Thrombolysis 2011; Apr;31(3):326-43.

Ossi RG, Meschia JF, Barrett KM Hospital-based management of acute ischemic stroke following intravenous thrombolysis Expert Rev Cardiovasc Ther 2011 Apr;9(4):463-72

Poli D, Testa S, Antonucci E, Grifoni E, Paoletti O, Lip GY Bleeding and stroke risk in a 'real world' prospective primary prevention cohort of atrial fibrillation patients Chest 2011 Apr 21. [Epub ahead of print]

Rao GH, Thethi I, Fareed J Vascular disease: obesity and excess weight as modulators of risk. Expert Rev Cardiovasc Ther 2011 Apr;9(4):525-34

Rasmussen LH, Larsen TB, Due KM, Tjønneland A, Overvad K, Lip GY Impact of vascular disease in predicting stroke, and death in patients with atrial fibrillation: The Danish Diet, Cancer and Health (DCH) cohort study. J Thromb Haemost 2011 Apr 19. doi: 10.1111/j.1538-7836.2011.04308.x.

Rothberg MB, Lindenauer PK, Lahti M, Pekow PS, Selker HP Risk factor model to predict venous thromboembolism in hospitalized medical patients. J Hosp Med 2011 Apr;6(4):202-9.

Rupin A, Marx I, Vallez MO, Mennecier P, Gloanec P, de Nanteuil G, Verbeuren TJ S35972, a direct acting thrombin inhibitor with a high oral bioavailability and antithrombotic efficacy. J Thromb Haemost 2011 Apr 11. doi: 10.1111/j.1538-7836.2011.04286.x. [Epub ahead of print]

Santangeli P, Di Biase L, Sanchez JE, Horton R, Natale A Atrial Fibrillation Ablation without Interruption of Anticoagulation. Cardiol Res Pract 2011 Apr 26;2011:837841

Scudday T, Brasel K, Webb T, Codner P, Somberg L, Weigelt J, Herrmann D, Peppard W Safety and Efficacy of Prophylactic Anticoagulation in Patients with Traumatic Brain Injury. J Am Coll Surg 2011 Apr 2. [Epub ahead of print]

Seliverstov I Practical management approaches to anticoagulation non-compliance, health literacy, and limited English proficiency in the outpatient clinic setting. J Thromb Thrombolysis 2011 Apr;31(3):321-5

Siccama RN, Janssen KJ, Verheijden NA, Oudega R, Bax L, van Delden JJ, Moons KG Systematic review: diagnostic accuracy of clinical decision rules for venous thromboembolism in elderly. Ageing Res Rev 2011 Apr;10(2):304-13.

Singh P, Arrevad PS, Peterson GM, Bereznicki LR Evaluation of antithrombotic usage for atrial fibrillation in aged care facilities J Clin Pharm Ther 2011; Apr;36(2):166-71. doi: 10.1111/j.1365 2710.2010.01167.x.

Siu CW, Jim MH, Lau CP, Tse HF Low molecular weight heparin versus unfractionated heparin for thromboprophylaxis in patients with acute atrial fibrillation: A randomized control trial. Acute Card Care 2011 Apr 25. [Epub ahead of print]

Skeppholm M, Kallner A, Malmqvist K, Blombäck M, Wallén H Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome? Thromb Res 2011 Apr 13. [Epub ahead of print]

Stewart RA Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation. Curr Opin Cardiol 2011 Apr 30. [Epub ahead of print]

Verhamme P, Tangelder M, Verhaeghe R, Ageno W, Glazer S, Prins M, Jacquemin M, Büller H; TB-402 Study Group Single intravenous administration of TB-402 for the prophylaxis of venous thromboembolism after total knee replacement: a dose-escalating, randomized, controlled trial J Thromb Haemost 2011 Apr;9(4):664-71. doi: 10.1111/j.1538-7836.2011.04221.x.

Weigelt JA, Lal A, Riska R Venous thromboembolism prophylaxis in surgical patients: identifying a patient group to maximize performance improvement Jt Comm J Qual Patient Saf 2011 Apr;37(4):178-83.

Wong KL, Daguman R, Lim KH, Shen L, Lingaraj K Incidence of deep vein thrombosis following total hip arthroplasty: a Doppler ultrasonographic study J Orthop Surg (Hong Kong) 2011 Apr;19(1):50-3

Zamagni E, Brioli A, Tacchetti P, Zannetti B, Pantani L, Cavo M Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis Semin Thromb Hemost 2011 Apr;37(3):209-19

[No authors listed] Edoxaban tosylate Am J Cardiovasc Drugs 2011;11(2):129-35. doi: 10.2165/11533660-000000000-00000

Clark BM, d'Ancona G, Kinirons M, Hunt BJ, Hopper A Effective quality improvement of thromboprophylaxis in acute medicine BMJ Qual Saf 2011; Mar 8. [Epub ahead of print]

Douketis JD Dabigatran as anticoagulant therapy for atrial fibrillation: which patients should receive it, which patients may not need it, and other practical aspects of patient management Pol Arch Med Wewn 2011 Mar;121(3):73-80

Fareed J, Adiguzel C, Thethi I Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism Thromb J 2011 Mar 28;9(1):5

Gersh BJ, Freedman JE, Granger CB Antiplatelet and Anticoagulant Therapy for Stroke Prevention in Patients With Non-valvular Atrial Fibrillation: Evidence Based Strategies and New Developments Rev Esp Cardiol 2011 Mar 14. [Epub ahead of print]

Giorgi MA, Cohen Arazi H, Gonzalez CD, Di Girolamo G Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban Expert Opin Pharmacother 2011 Mar;12(4):567-77. Epub 2011 Jan 22.

Goff T, Kontakis G, Giannoudis PV Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb surgery: an update Expert Opin Drug Saf 2011; Mar 15. [Epub ahead of print]

Gorin L, Fauchier L, Nonin E, Charbonnier B, Babuty D, Lip GY Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter. Implications of undertreatment and overtreatment in real life clinical practice: The Loire Valley Atrial Fibrillation Project Chest 2011; Mar 24. [Epub ahead of print]

Hori M, Connolly SJ, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L; the RE-LY Investigators Efficacy and Safety of Dabigatran vs. Warfarin in Patients With Atrial Fibrillation Circ J 2011 Mar 25;75(4):800-805.

Hull R Essay for the CIHR/CMAJ award: the role of low-molecular weight heparin therapy venous thromboembolism CMAJ 2011 Mar 21. [Epub ahead of print]

Imberti D, Bianchi C, Zambon A, Parodi A, Merlino L, Gallerani M, Corrao G Venous thromboembolism after major orthopaedic surgery: a population-based cohort study. Intern Emerg Med 2011 Mar 26. [Epub ahead of print]

Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, Jenkins JS, Kline JA, Michaels AD, Thistlethwaite P, Vedantham S, White RJ, Zierler BK; on behalf of the American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Peripheral Vascular Disease, and Council on Arteriosclerosis, Thrombosis and Vascular Biology Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement From the American Heart Association Circulation 2011 Mar 21. [Epub ahead of print]

Lane DA, Kamphuisen PW, Minini P, Büller HR, Lip GY BLEEDING RISK IN ATRIAL FIBRILLATION PATIENTS: The AMADEUS study Chest 2011; Mar 17. [Epub ahead of print]

Marinigh R, Lane DA, Lip GY Severe renal impairment and stroke prevention in atrial fibrillation implications for thromboprophylaxis and bleeding risk J Am Coll Cardiol 2011; Mar 22;57(12):1339-48.

Marongiu F, Tosetto A, Palareti G Special indications for vitamin K antagonists: a review Intern Emerg Med 2011; Mar 5. [Epub ahead of print]

McKellar SH, Abel S, Camp CL, Suri RM, Ereth MH, Schaff HV Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves J Thorac Cardiovasc Surg 2011 Mar 21. [Epub ahead of print]

McManus RJ, Fitzmaurice DA, Murray E, Taylor C Thromboembolism Clin Evid (Online) 2011; Mar 8;2011. pii: 0208.

Misselwitz F, Berkowitz SD, Perzborn E The discovery and development of rivaroxaban Ann N Y Acad Sci 2011; Mar;1222(1):64-75. doi:10.1111/j.1749-6632.2011.05971.x.

Piazza G, Goldhaber SZ, Lessard DM, Goldberg RJ, Emery C, Spencer FA Venous thromboembolism in heart failure: preventable deaths during and after hospitalization Am J Med 2011; Mar;124(3):252-9.

Ruiz Ortiz M, Romo E, Mesa D, Delgado M, Ibáñez CL, Anguita M, Castillo JC, Arizón JM, de Lezo JS Outcomes and Safety of Antithrombotic Treatment in Patients Aged 80 Years or Older With Nonvalvular Atrial Fibrillation Am J Cardiol 2011; Mar 18. [Epub ahead of print]

Samama MM Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment Drugs Aging 2011 Mar 1;28(3):177-93. doi: 10.2165/11586730-000000000-00000.

Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J, Bradley-Kennedy C, Plumb JM Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective Thromb Haemost Mar 22;105(5)

Spyropoulos AC, Anderson FA Jr, Fitzgerald G, Decousus H, Pini M, Chong BH, Zotz RB, Bergmann JF, Tapson V, Froehlich JB, Monreal M, Merli GJ, Pavanello R, Turpie AG, Nakamura M, Piovella F, Kakkar AK, Spencer FA; for the IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) Investigators Predictive and Associative Models to Identify Hospitalized Medical Patients at Risk for Venous Thromboembolism. Chest 2011 Mar 24. [Epub ahead of print]

Steffel J, Braunwald E Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism Eur Heart J 2011; Mar 18. [Epub ahead of print]

Watkins PB, Desai M, Berkowitz SD, Peters G, Horsmans Y, Larrey D, Maddrey W Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery Drug Saf 2011; Mar 1;34(3):243-52. doi:10.2165/11586600-000000000-00000.

Wright JD, Lewin SN, Shah M, Burke WM, Lee SM, Sun X, Herzog TJ Quality of Venous Thromboembolism Prophylaxis in Patients Undergoing Oncologic Surgery Ann Surg 2011; Mar 9. [Epub ahead of print]

Akl EA, Vasireddi SR, Gunukula S, Barba M, Sperati F, Terrenato I, Muti P, Schünemann H Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer Cochrane Database Syst Rev 2011 Feb 16;2:CD006649

American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines, Wann LS, Curtis AB, Ellenbogen KA, Estes NA 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran) J Am Coll Cardiol 2011 Feb 10. [Epub ahead of print]

Baser O, Supina D, Sengupta N, Wang L, Kwong L Clinical and cost outcomes of venous thromboembolism in Medicare patients undergoing total hip replacement or total knee replacement surgery Curr Med Res Opin 2011 Feb;27(2):423-9. Epub 2010 Dec 30

Berlot G, Calderan C, Vergolini A, Bianchi M, Viviani M, Bussani R, Torelli L, Lucangelo U Pulmonary embolism in critically ill patients receiving antithrombotic prophylaxis: A clinical-pathologic study J Crit Care 2011 Feb;26(1):28-33

Bogatkevich GS, Ludwicka-Bradley A, Nietert PJ, Akter T, van Ryn J, Silver RM Anti-inflammatory and anti-fibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease Arthritis Rheum 2011 Feb DOI: 10.1002/art.30255

Broukhim M, Halperin JL Stroke prevention in the high-risk atrial fibrillation patient: Medical management Curr Cardiol Rep 2011 Feb;13(1):9-17

Bucci C, Geerts WH, Sinclair A, Fremes SE Comparison of the effectiveness and safety of low-molecular weight heparin versus unfractionated heparin anticoagulation after heart valve surgery Am J Cardiol 2011 Feb15;107(4):591-4. Epub 2010 Dec 22

Chandrasekar S, Loomba R, Shah P, Arora R The need for novel anticoagulation therapy in acute coronary syndrome Am J Ther 2011 Feb 10. [Epub ahead of print]

Connolly SJ Atrial fibrillation in 2010: advances in treatment and management Nat Rev Cardiol 2011 Feb;8(2):67-8

Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; the AVERROES Steering Committee and Investigators Apixaban in Patients with Atrial Fibrillation N Engl J Med 2011 Feb 10. [Epub ahead of print]

Cosmi B, Legnani C, Cini M, Guazzaloca G, Palareti G D-dimer and residual vein obstruction as risk factors for recurrence during and after anticoagulation withdrawal in patients with a first episode of provoked deep-vein thrombosis Thromb Haemost 2011; Feb 28;105(5). [Epub ahead of print]

Cowan C, Fay M, Griffith K, Jenkinson D Anticoagulation in AF. Anticoagulation uptake remains poor in high risk patients. BMJ 2011; Feb 22;342:d1153. doi: 10.1136/bmj.d1153.

Deitelzweig SB, Johnson BH, Lin J, Schulman KL Prevalence of clinical venous thromboembolism in the USA: Current trends and future projections Am J Hematol 2011 Feb;86(2):217-20. doi: 10.1002/ajh.21917

Donadini MP, Ageno W Which patients with unprovoked VTE should receive extended anticoagulation? the minority. J Thromb Thrombolysis 2011 Feb 13. [Epub ahead of print]

Douketis J, Tosetto A, Marcucci M, Baglin T, Cosmi B, Cushman M, Kyrle P, Poli D, Tait RC, Iorio A Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis BMJ 2011 Feb 24;342:d813. doi: 10.1136/bmj.d813. Review.

Eriksson BI, Quinlan DJ, Eikelboom JW Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism Annu Rev Med 2011 Feb 18;62:41-57

Fisher WD New oral anticoagulants and outpatient prophylaxis of venous thromboembolism Am J Manag Care 2011 Feb;17(1 Suppl):S15-21

Gheorghiade M, Thyssen A, Zolynas R, Nadar VK, Greenberg BH, Mehra M, Sun X, Tian H, Plotnikov AN, Burton P Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure J Heart Lung Transplant 2011 Feb;30(2):218-26. Epub 2010 Oct 13

Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, Creager MA, Culebras A, Eckel RH, Hart RG, Hinchey JA, Howard VJ, Jauch EC, Levine SR, Meschia JF, Moore WS, Nixon JV, Pearson TA; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Epidemiology and Prevention; Council for High Blood Pressure Research,; Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association Stroke 2011 Feb;42(2):517-84. Epub 2010 Dec 2

Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Rocha E, Pozo-Hernández C, Vargas-Castrillón E New parenteral anticoagulants in development Ther Adv Cardiovasc Dis 2011 Feb;5(1):33-59. Epub 2010 Nov 2

Huang J, Cao Y, Liao C, Wu L, Gao Fc Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials Thromb Haemost 2011 Feb 1;105(2):245-53. Epub 2010 Oct 12

Huo MH, Spyropoulos AC The eighth American College of Chest Physicians guidelines on venous thromboembolism prevention: implications for hospital prophylaxis strategies J Thromb Thrombolysis 2011 Feb;31(2):196-208

Höchtl T, Farhan S, Wojta J, Huber K New anticoagulant agents in acute coronary syndromes Heart 2011 Feb;97(3):244-52. Review

Iwahana H, Ishikawa S, Ishikawa J, Kabutoya T, Kayaba K, Gotoh T, Kajii E Atrial Fibrillation Is a Major Risk Factor for Stroke, Especially in Women: The Jichi Medical School Cohort Study J Epidemiol 2011 Feb 5. [Epub ahead of print]

Kaatz S, Paje D Update in bridging anticoagulation J Thromb Thrombolysis 2011 Feb 15. [Epub ahead of print]

Karakas M, Baumert J, Herder C, Rottbauer W, Meisinger C, Koenig W, Thorand B Soluble thrombomodulin in coronary heart disease: lack of association in the MONICA/KORA case-cohort study J Thromb Haemost 2011 Feb 14. doi: 10.1111/j.1538-7836.2011.04229.x

Kearon C Extended anticoagulation for unprovoked venous thromboembolism: a majority of patients should be treated J Thromb Thrombolysis 2011 Feb 18. [Epub ahead of print]

Kim YD, Cha MJ, Kim J, Lee DH, Lee HS, Nam CM, Nam HS, Heo JH. Ischaemic cardiovascular mortality in patients with non-valvular atrial fibrillation according to CHADS2 score Thromb Haemost 2011 Feb 8;105(4). [Epub ahead of print]

Knepper J, Ramacciotti E, Wakefield TW Novel anticoagulants: a discussion of clinical use in the treatment and prevention of venous thromboembolism Phlebology 2011;26(1):3-7

Kwong LM Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty. Am J Manag Care 2011 Feb;17(1 Suppl):S22-6

Lindahl TL, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Hillarp A; and from the expert group on coagulation of the External Quality Assurance in Laboratory Medicine in Sweden Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays Thromb Haemost 2011 Feb 1;105(2):371-8. Epub 2010 Nov 23

Lip GY Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for Thromboprophylaxis in Atrial Fibrillation Am J Med 2011 Feb;124(2):111-4. Epub 2010 Sep 29

Lip GY Chronic renal disease and stroke in atrial fibrillation: balancing the prevention of thromboembolism and bleeding risk Europace 2011 Feb;13(2):145-8. Epub 2010 Dec 7

Lip GY, Rasmussen LH, Olsson SB, Zetterstrand S, Stahre C, Bylock A, Aunes-Jansson M, Eriksson U, Wåhlander K; Steering Committee Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy Thromb Res 2011 Feb;127(2):91-9. Epub 2010 Dec 18

Loke YK, Kwok CS Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison J Clin Pharm Ther 2011 Feb;36(1):111-24. doi: 10.1111/j.1365-2710.2010.01162.x.

Paciaroni M, Agnelli G, Venti M, Alberti A, Acciarresi M, Caso V Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta-analysis of controlled studies J Thromb Haemost 2011 Feb 16. doi: 10.1111/j.1538-7836.2011.04241.x. [Epub ahead of print]

Paikin JS, Wright DS, Eikelboom JW Effectiveness and safety of combined antiplatelet and anticoagulant therapy: A critical review of the evidence from randomized controlled trials Blood Rev 2011 Feb 26. [Epub ahead of print]

Phung OJ, Kahn SR, Cook DJ, Murad MH Dosing frequency of unfractionated heparin thromboprophylaxis: A meta-analysis Chest 2011; Feb 24. [Epub ahead of print]

Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S Safety of Percutaneous Left Atrial Appendage Closure: Results From the Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF (PROTECT AF) Clinical Trial and the Continued Access Registry Circulation 2011 Feb 1;123(4):417-24. Epub 2011 Jan 17

Samama MM, Guinet C Review: Laboratory assessment of new anticoagulants Clin Chem Lab Med 2011 Feb 3. [Epub ahead of print]

Saposnik G, Kapral MK, Liu Y, Hall R, O'Donnell M, Raptis S, Tu JV, Mamdani M, Austin PC; on behalf of the Investigators of the Registry of the Canadian Stroke Network and the Stroke Outcomes Research Canada (SORCan) Working Group IScore: A Risk Score to Predict Death Early After Hospitalization for an Acute Ischemic Stroke Circulation 2011 Feb 22;123(7):739-749. Epub 2011 Feb 7

Spirk D, Banyai M, Jacomella V, Frank U, Baldi T, Baumgartner I, Amann-Vesti B, Kucher N, Husmann M Outpatient management of acute deep vein thrombosis: Results from the OTIS-DVT registry Thromb Res 2011 Feb 4. [Epub ahead of print]

Spirk D, Husmann M, Willenberg T, Banyai M, Frank U, Baldi T, Amann-Vesti B, Baumgartner I, Kucher N Inconsistencies in the planning of the duration of anticoagulation among outpatients with acute deep-vein thrombosis. Results from the OTIS-DVT Registry Thromb Haemost 2011 Feb 1;105(2):239-44. Epub 2010 Sep 30

Streif W, Ageno W Direct thrombin and factor Xa inhibitors in children: a quest for new anticoagulants for children Wien Med Wochenschr 2011; Feb;161(3-4):73-79.

Streiff MB Anticoagulation in the management of venous thromboembolism in the cancer patient J Thromb Thrombolysis 2011 Feb 18. [Epub ahead of print]

van Iersel T, Stroissnig H, Giesen P, Wemer J, Wilhelm-Ogunbiyi K Phase I study of Solulin, a novel recombinant soluble human thrombomodulin analogue Thromb Haemost 2011 Feb 1;105(2):302-12. Epub 2010 Nov 23

Ahrens I, Lip GY, Peter K What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation? Thromb Haemost 2011 Jan 12;105(4). [Epub ahead of print]

Bozzato S, Rancan E, Ageno W Fondaparinux for the treatment of superficial vein thrombosis in the legs: the CALISTO study Expert Opin Pharmacother 2011 Jan 20. [Epub ahead of print]

Brewer ES, Reznikov B, Liberman RF, Baker RA, Rosenblatt MS, David CA, Flacke S Incidence and predictors of intracranial hemorrhage after minor head trauma in patients taking anticoagulant and antiplatelet medication J Trauma 2011 Jan;70(1):E1-5

Brito V, Ciapponi A, Kwong J Factor Xa inhibitors for acute coronary syndromes Cochrane Database Syst Rev 2011 Jan 19;1:CD007038

Carrier M, Le Gal G, Tay J, Wu C, Lee AY Rates of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Immunomodulatory Therapy with Thalidomide or Lenalidomide: A Systematic Review and Meta-Analysis J Thromb Haemost 2011 Jan 21. doi: 10.1111/j.1538-7836.2011.04215.x. [Epub ahead of print]

Chung LH, Chen WM, Chen CF, Chen TH, Liu CL Deep vein thrombosis after total knee arthroplasty in asian patients without prophylactic anticoagulation Orthopedics 2011 Jan 3;34(1). doi: 10.3928/01477447-20101123-05

Coutts SB, Sylaja PN, Choi YB, Al-Khathami A, Sivakumar C, Jeerakathil TJ, Sarma PS, Hill MD The ASPIRE Approach for TIA Risk Stratification Can J Neurol Sci 2011 Jan;38(1):78-81.

Dangayach NS, Kane K, Moonis M Paroxysmal atrial fibrillation in cryptogenic stroke Ther Clin Risk Manag 2011 Jan 28;7:33-7

Dossett LA, Riesel JN, Griffin MR, Cotton BA Prevalence and Implications of Preinjury Warfarin Use: An Analysis of the National Trauma Databank Arch Surg 2011 Jan 17. [Epub ahead of print]

Eckman MH, Singer DE, Rosand J, Greenberg SM Moving the Tipping Point: The Decision to Anticoagulate Patients With Atrial Fibrillation Circ Cardiovasc Qual Outcomes 2011 Jan 1;4(1):14-21

Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ; the RE-NOVATE II Study Group Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial Thromb Haemost 2011 Jan 12;105(4). [Epub ahead of print]

Fasullo S, Scalzo S, Maringhini G, Ganci F, Cannizzaro S, Basile I, Cangemi D, Terrazzino G, Parrinello G, Sarullo FM, Baglini R, Paterna S, Di Pasquale P Six-Month Echocardiographic Study in Patients With Submassive Pulmonary Embolism and Right Ventricle Dysfunction: Comparison of Thrombolysis With Heparin Am J Med Sci 2011 Jan;341(1):33-39.

Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide and propafenone, for the management of atrial fibrillation Europace 2011 Jan 11. [Epub ahead of print]

Freyburger G, Macouillard G, Labrouche S, Sztark F Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacement Thromb Res 2011 Jan 28. [Epub ahead of print]

Fuller CJ, Reisman M Stroke Prevention in Atrial Fibrillation: Atrial Appendage Closure Curr Cardiol Rep 2011 Jan 12. [Epub ahead of print]

Hariharan P, Takayesu JK, Kabrhel C Association between the Pulmonary Embolism Severity Index (PESI) and short-term clinical deterioration Thromb Haemost 2011 Jan 12;105(4). [Epub ahead of print] PubMed PMID: 21225095

Holmes DR Atrial fibrillation and stroke management: present and future Semin Neurol 2010 Nov;30(5):528-36. Epub 2011 Jan 4

Jensen CD, Steval A, Partington PF, Reed MR, Muller SD Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: A RETROSPECTIVE COHORT STUDY J Bone Joint Surg Br 2011 Jan;93(1):91-5.

Kuwashiro T, Yasaka M, Itabashi R, Nakagaki H, Miyashita F, Naritomi H, Minematsu K Effect of prothrombin complex concentrate on hematoma enlargement and clinical outcome in patients with anticoagulant-associated intracerebral hemorrhage Cerebrovasc Dis 2011;31(2):170-6

Laporte S, Liotier J, Bertoletti L, Kleber FX, Pineo GF, Chapelle C, Moulin N, Mismetti P Individual patient data meta-analysis of enoxaparin versus unfractionated heparin for venous thromboembolism prevention in medical patients J Thromb Haemost 2011 Jan 13. doi: 10.1111/j.1538-7836.2011.04182.x. [Epub ahead of print]

Lee A, Crowther M Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure J Thromb Thrombolysis 2011 Jan 28. [Epub ahead of print]

Lee CJ, Ansell JE Direct Thrombin Inhibitors Br J Clin Pharmacol 2011 Jan 17. doi: 10.1111/j.1365-2125.2011.03916.x. [Epub ahead of print]

Levin D, Smith DB, Cumbler E, Carter J, Glasheen JJ, Jones W Warfarin therapy does not increase risk of symptomatic intracerebral hemorrhage in eligible patients after intravenous thrombolysis Arch Neurol 2011 Jan;68(1):135

Meddahi S, Samama MM Direct inhibitors of thrombin, hirudin, bivalirudin, and dabigatran etexilate J Mal Vasc 2011 Feb;36(1):24-32. Epub 2011 Jan 15. French

Mitka M New alternative to warfarin may help reduce stroke risk in patients with AF JAMA 2011 Jan 5;305(1):25-6

Moreau C, Pautas E, Gouin-Thibault I, Golmard JL, Mahé I, Mulot C, Loriot MA, Siguret V Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes J Thromb Haemost 2011 Jan 21. doi: 10.1111/j.1538-7836.2011.04213.x. [Epub ahead of print]

Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, Flaker G, Brugada J, Kamensky G, Parekh A, Reilly PA, Yusuf S, Connolly SJ. Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion Circulation. 2011 Jan 3. [Epub ahead of print]

Nakagawa K, Hirai T, Takashima S, Fukuda N, Ohara K, Sasahara E, Taguchi Y, Dougu N, Nozawa T, Tanaka K, Inoue H Chronic Kidney Disease and CHADS(2) Score Independently Predict Cardiovascular Events and Mortality in Patients With Nonvalvular Atrial Fibrillation Am J Cardiol 2011 Jan 17. [Epub ahead of print]

No authors listed Local INR control had some effect on the benefits of dabigatran over warfarin for major bleeding in atrial fibrillation Ann Intern Med 2011 Jan 18;154(2):JC1-6

Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study BMJ 2011 Jan 31;342:d124. doi: 10.1136/bmj.d124

Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, Rossi D, Gentilini F, Crippa C, Galli M, Nozzoli C, Ria R, Marasca R, Montefusco V, Baldini L, Elice F, Callea V, Pulini S, Carella AM, Zambello R, Benevolo G, Magarotto V, Tacchetti P, Pescosta N, Cellini C, Polloni C, Evangelista A, Caravita T, Morabito F, Offidani M, Tosi P, Boccadoro M Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide:A Phase III, Open-Label, Randomized Trial J Clin Oncol 2011 Jan 31. [Epub ahead of print]

Piccioli A, Prandoni P Approach to Venous Thromboembolism in the Cancer Patient Curr Treat Options Cardiovasc Med 2011 Jan 19. [Epub ahead of print]

Pistulli R, Oberle V, Figulla HR, Yilmaz A, Pfeifer R. Fondaparinux cross-reacts with heparin antibodies in vitro in a patient with fondaparinux-related thrombocytopenia Blood Coagul Fibrinolysis 2011 Jan;22(1):76-8.

Poli D, Lip GY, Antonucci E, Grifoni E, Lane D Stroke risk stratification in a "real-world" elderly anticoagulated atrial fibrillation population J Cardiovasc Electrophysiol 2011 Jan;22(1):25-30

Rajasekhar A, Lottenberg R, Lottenberg L, Liu H, Ang D Pulmonary embolism prophylaxis with inferior vena cava filters in trauma patients: a systematic review using the meta-analysis of observational studies in epidemiology (MOOSE) guidelines J Thromb Thrombolysis 2011 Jan 11. [Epub ahead of print]

Samama CM, Godier A Perioperative deep vein thrombosis prevention: what works, what does not work and does it improve outcome? Curr Opin Anaesthesiol 2011 Jan 19. [Epub ahead of print]

Sukeik M, Alshryda S, Haddad FS, Mason JM Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement J Bone Joint Surg Br 2011 Jan;93(1):39-46. PubMed PMID: 21196541.

Tsiridis E, Gamie Z, George MJ, Hamilton-Baille D, West RM, Giannoudis PV Early postoperative bleeding in polytrauma patients treated with fondaparinux: literature review and institutional experience Curr Vasc Pharmacol 2011 Jan;9(1):42-7.

Turpie AG, Esmon C Venous and arterial thrombosis - pathogenesis and the rationale for anticoagulation Thromb Haemost 2011 Jan 12;105(4). [Epub ahead of print]

Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice J Thromb Haemost2011 Jan;9(1):39-48

Van der Velde EF, Toll DB, Ten Cate-Hoek AJ, Oudega R, Stoffers HE, Bossuyt PM, Büller HR, Prins MH, Hoes AW, Moons KG, van Weert HC Comparing the diagnostic performance of 2 clinical decision rules to rule out deep vein thrombosis in primary care patients Ann Fam Med 2011 Jan-Feb;9(1):31-6

Weitz JI Factor Xa and thrombin as targets for new oral anticoagulants Thromb Res2011 Jan;127S2:S5-S12.

Wu TC, Kasam M, Harun N, Hallevi H, Bektas H, Acosta I, Misra V, Barreto AD, Gonzales NR, Lopez GA, Grotta JC, Savitz SI Pharmacological Deep Vein Thrombosis Prophylaxis Does Not Lead to Hematoma Expansion in Intracerebral Hemorrhage With Intraventricular Extension Stroke 2011 Jan 21. [Epub ahead of print]

Yang SS, Yu CS, Yoon YS, Yoon SN, Lim SB, Kim JC Symptomatic Venous Thromboembolism in Asian Colorectal Cancer Surgery Patients World J Surg 2011 Jan 25. [Epub ahead of print] PubMed PMID: 21264469

Akl EA, Vasireddi SR, Gunukula S, Yosuico VE, Barba M, Terrenato I, Sperati F, Schünemann H Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation Cochrane Database Syst Rev2010 Dec 8;12:CD006466. PubMed PMID: 21154368.

Beyer-Westendorf J, Halbritter K, Platzbecker E, Damme U, Neugebauer B, Kuhlisch E, Schellong S Central adjudication of venous ultrasound in VTE screening trials-reasons for failure J Thromb Haemost 2010 Dec 8. doi: 10.1111/j.1538-7836.2010.04166.x. [Epub ahead of print]

Cabral KP, Ansell J, Hylek EM Future Directions of Stroke Prevention in Atrial Fibrillation: The Potential Impact of Novel Anticoagulants and Stroke Risk Stratification J Thromb Haemost 2010 Dec 22. doi: 10.1111/j.1538-7836.2010.04179.x. [Epub ahead of print]

Cheng A, Nazarian S, Brinker JA, Tompkins C, Spragg DD, Leng CT, Halperin H, Tandri H, Sinha SK, Marine JE, Calkins H, Tomaselli GF, Berger RD, Henrikson CA Continuation of Warfarin During Pacemaker or ICD Implantation: A Randomized Clinical Trial Heart Rhythm 2010 Dec 10. [Epub ahead of print]

Chung N, Jeon HK, Lien LM, Lai WT, Tse HF, Chung WS, Lee TH, Chen SA Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation Thromb Haemost 2010 Dec 6;105(3). [Epub ahead of print]

Dewhurst M, Adams P Regarding Ethnic Distribution of Electrocardiographic Predictors of Atrial Fibrillation and Its Impact on Understanding the Ethnic Distribution of Ischemic Stroke in the Atherosclerosis Risk in Communities Study (ARIC) Stroke 2010 Dec 16. [Epub ahead of print]

EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 2010 Dec 23;363(26):2499-510.

From AM, Hoganson DD, Erwin PJ Does a longer duration of oral factor Xa therapy increase the risk of bleeding or transaminitis? Thromb Res 2010 Dec 13. [Epub ahead of print]

Gao F, Zhou YJ, Wang ZJ, Yang SW, Nie B, Liu XL, Jia DA, Yan ZX Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation Int J Cardiol 2010 Dec 22. [Epub ahead of print]

Guerrouij M, Uppal CS, Alklabi A, Douketis JD The clinical impact of bleeding during oral anticoagulant therapy : Assessment of morbidity, mortality and post-bleed anticoagulant management J Thromb Thrombolysis 2010 Dec 23. [Epub ahead of print]

Guijarro R, Montes J, San Román C, Arcelus JI, Barillari G, Granero X, Monreal M Venous thromboembolism and bleeding after total knee and hip arthroplasty. Findings from the Spanish National Discharge Database. Thromb Haemost 2010 Dec 21;105(4). [Epub ahead of print]

Hylek EM. Therapeutic potential of oral factor Xa inhibitors N Engl J Med 2010 Dec 23;363(26):2559-61.

Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis Lancet 2010 Dec 11;376(9757):2032-9. Epub 2010 Dec 3. Review.

Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators Apixaban versus enoxaparin for thromboprophylaxis after hip replacement N Engl J Med 2010 Dec 23;363(26):2487-98.

Luettgen JM, Knabb RM, He K, Pinto DJ, Rendina AR. Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma J Enzyme Inhib Med Chem 2010 Dec 20. [Epub ahead of print]

Mavrakanas T, Bounameaux H. The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism Pharmacol Ther 2010 Dec 23. [Epub ahead of print]

Meijer K, Kim YK, Carter D, Schulman S. A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery Thromb Haemost 2010 Dec 21;105(2). [Epub ahead of print]

Mercaldi CJ, Ciarametaro M, Hahn B, Chalissery G, Reynolds MW, Sander SD, Samsa GP, Matchar DB. Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation Stroke 2011 Jan;42(1):112-8. Epub 2010 Dec 9. PubMed PMID: 21148442.

No authors listed Review: Graduated compression stockings reduce deep venous thrombosis in hospitalized patients Ann Intern Med 2010 Dec 21;153(12):JC66. PubMed PMID: 21173407

Peedicayil A, Weaver A, Li X, Carey E, Cliby W, Mariani A. Incidence and timing of venous thromboembolism after surgery for gynecological cancer Gynecol Oncol 2010 Dec 21. [Epub ahead of print]

Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor Nat Rev Drug Discov 2010 Dec 17. [Epub ahead of print]

Radaelli F, Paggi S, Terruzzi V, Meucci G, Manes G, Saibeni S, Soncini M, Masci E, Conte D. Management of warfarin-associated coagulopathy in patients with acute gastrointestinal bleeding: A cross-sectional physician survey of current practice Dig Liver Dis 2010 Dec 16. [Epub ahead of print]

Schirmer SH, Baumhäkel M, Neuberger HR, Hohnloser SH, van Gelder IC, Lip GY, Böhm M. Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments J Am Coll Cardiol 2010 Dec 14;56(25):2067-76.

Stein PD, Sostman HD, Dalen JE, Bailey DL, Bajc M, Goldhaber S, Goodman LR, Gottschalk A, Hull RD, Matta F, Pistolesi M, Tapson V, Weg JG, Wells PS, Woodard PK. Controversies in Diagnosis of Pulmonary Embolism Clin Appl Thromb Hemost 2010 Dec 15. [Epub ahead of print]

Turpie AG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Kakkar AK Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies Thromb Haemost 2010 Dec 6;105(3). [Epub ahead of print]

Wolfram O, Hammwoehner M, Gramley F, Goette A Update on Pharmacologic Approaches To Prevent Thromboembolism in Atrial Fibrillation: Are Thrombin and Factor Xa Inhibitors the Ultimate Answer? Curr Vasc Pharmacol 2010 Dec 14. [Epub ahead of print]

van Zaane B, Squizzato A, Reuwer AQ, van Zanten AP, Twickler MT, Dekkers OM, Cannegieter SC, Büller HR, Gerdes VE, Brandjes DP Prolactin and Venous Thrombosis. Indications for a Novel Risk Factor? Arterioscler Thromb Vasc Biol 2010 Dec 16. [Epub ahead of print]

Alberts VP, Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Stricker BH, Breteler MM Heart failure and the risk of stroke: the Rotterdam Study Eur J Epidemiol 2010 Nov 9. [Epub ahead of print] PubMed PMID: 21061046.

Angeloni G, Alberti S, Romagnoli E, Banzato A, Formichi M, Cucchini U, Pengo V Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion: a prospective cohort study Intern Emerg Med 2010 Nov 17. [Epub ahead of print]

Baber U, Howard VJ, Halperin JL, Soliman EZ, Zhang X, McClellan W, Warnock DG, Muntner P Association of Chronic Kidney Disease with Atrial Fibrillation Among Adults in the United States: Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study Circ Arrhythm Electrophysiol 2010 Nov 13. [Epub ahead of print] PubMed PMID: 21076159.

Bal S, Ojha P, Hill MD Stroke Prevention Treatment of Patients with Atrial Fibrillation: Old and New Curr Neurol Neurosci Rep 2010 Nov 19. [Epub ahead of print]

Bianchini EP, Fazavana J, Picard V, Borgel D Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives Blood 2010 Nov 3. [Epub ahead of print]

Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial N Engl J Med 2010 Nov 4;363(19):1875-6

DeFeo K, Hayes C, Chernick M, Van Ryn J, Gilmour SK Use of dabigatran etexilate to reduce breast cancer progression Cancer Biol Ther 2010 Nov 3;10(10). [Epub ahead of print]

Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di Pasquale G, Yusuf S; for the RE-LY study group Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial Lancet Neurol 2010 Dec;9(12):1157-1163. Epub 2010 Nov 6

Donohue MM, Tirschwell DL Implications of Pharmacogenetic Testing for Patients Taking Warfarin or Clopidogrel Curr Neurol Neurosci Rep 2010 Nov 3. [Epub ahead of print]

Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation Ann Intern Med 2010 Nov 3. [Epub ahead of print]

Harrington DW Choosing the Right Heparin Prophylaxis Strategy in Medical Patients at Risk for Developing VTE: An Evidence-Based Approach Hosp Pract (Minneap) 2010 Nov;38(4):18-28

Lane DA, Lip GY Dabigatran in atrial fibrillation: balancing secondary stroke prevention against bleeding risk Lancet Neurol 2010 Dec;9(12):1140-1142. Epub 2010 Nov 6

Merriman E, Kaplan Z, Butler J, Malan E, Gan E, Tran H Rivaroxaban and false positive lupus anticoagulant testing Thromb Haemost 2010 Nov 23;105(2). [Epub ahead of print]

Teichert M, Eijgelsheim M, Uitterlinden AG, Buhre PN, Hofman A, De Smet PA, Visser LE, Stricker BH Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes Pharmacogenet Genomics 2010 Nov 6. [Epub ahead of print]

Wong J, Abrishami A, El Beheiry H, Mahomed NN, Roderick Davey J, Gandhi R, Syed KA, Muhammad Ovais Hasan S, De Silva Y, Chung F Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial J Bone Joint Surg Am 2010 Nov 3;92(15):2503-13

Yang F, Chou D, Schweitzer P, Hanon S Warfarin in haemodialysis patients with atrial fibrillation: what benefit? Europace 2010 Nov 2. [Epub ahead of print]

Yang J, Xu K, Seiffert D Challenges and promises of developing thrombin receptor antagonists Recent Pat Cardiovasc Drug Discov 2010 Nov 1;5(3):162-70.

Abdel-Razeq HN, Hijjawi SB, Jallad SG, Ababneh BA Venous thromboembolism risk stratification in medically-ill hospitalized cancer patients. A comprehensive cancer center experience J Thromb Thrombolysis. 2010 Oct;30(3):286-93

Andersen KK, Andersen ZJ, Olsen TS Age- and Gender-Specific Prevalence of Cardiovascular Risk Factors in 40 102 Patients With First-Ever Ischemic Stroke. A Nationwide Danish Study. Stroke. 2010 Oct 21. [Epub ahead of print]

Bafunno V, Margaglione M Review: Genetic basis of thrombosis Clin Chem Lab Med 2010 Oct 29. [Epub ahead of print] PubMed PMID: 21034258.

Barrett YC, Wang Z, Frost C, Shenker A Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay Thromb Haemost 2010 Oct 26;104(6). [Epub ahead of print]

Becker RC, Gibson CM, Jennings LK, Morrow DA Antiplatelet therapy in acute coronary syndrome (ACS): applying new science to clinical decisions Am J Cardiol 2010 Oct 15;106(8):S2-3.

Cohen AT Asia-Pacific Thrombosis Advisory Board consensus paper on prevention of venous thromboembolism after major orthopaedic surgery Thromb Haemost 2010 Oct 12;104(5). [Epub ahead of print]

De Breucker S, Herzog G, Pepersack T Could geriatric characteristics explain the under-prescription of anticoagulation therapy for older patients admitted with atrial fibrillation? A retrospective observational study. Drugs Aging 2010 Oct 1;27(10):807-13. doi: 10.2165/11537900-000000000-00000.

Dobesh P The importance of appropriate prophylaxis for the prevention of venous thromboembolism in at-risk medical patients Int J Clin Pract 2010 Oct;64(11):1554-62. doi: 10.1111/j.1742-1241.2010.02447.x.

Douketis J, Tosetto A, Marcucci M, Baglin T, Cushman M, Eichinger S, Palareti G, Poli D, Tait RC, Iorio A Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism Ann Intern Med 2010 Oct 19;153(8):523-31.

Eagle KA, Cannom DS, Garcia DA Management of Atrial Fibrillation: Translating Clinical Trial Data into Clinical Practice Am J Med 2010 Oct 5. [Epub ahead of print]

Eriksson M, Stecksén A, Glader EL, Norrving B, Appelros P, Hulter Åsberg K, Stegmayr B, Terént A, Asplund K; for the Riks-Stroke Collaboration. Discarding Heparins as Treatment for Progressive Stroke in Sweden 2001 to 2008 Stroke 2010 Nov;41(11):2552-2558. Epub 2010 Oct 7

Ezekowitz MD, Aikens TH, Brown A, Ellis Z The evolving field of stroke prevention in patients with atrial fibrillation Stroke 2010 Oct;41(10 Suppl):S17-20.

Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE Warfarin Discontinuation After Starting Warfarin for Atrial Fibrillation Circ Cardiovasc Qual Outcomes 2010 Oct 19. [Epub ahead of print]

Green L, Lawrie AS, Patel S, Hossain F, Chitolie A, Mackie IJ, Haddad FS, Machin SJ The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation Br J Haematol 2010 Oct 18. [Epub ahead of print]

Hillarp A, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Lindahl TL. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost. 2010 Oct 7. [Epub ahead of print]

Huisman MV, Quinlan DJ, Dahl OE, Schulman S. Enoxaparin Versus Dabigatran or Rivaroxaban for Thromboprophylaxis After Hip or Knee Arthroplasty: Results of Separate Pooled Analyses of Phase III Multicenter Randomized Trials. Circ Cardiovasc Qual Outcomes. 2010 Oct 5. [Epub ahead of print]

Iorio A, Kearon C, Filippucci E, Marcucci M, Macura A, Pengo V, Siragusa S, Palareti G. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med. 2010 Oct 25;170(19):1710-6.

Kleijer BC, Heerdink ER, Egberts TC, Jansen PA, van Marum RJ Antipsychotic drug use and the risk of venous thromboembolism in elderly patients. J Clin Psychopharmacol. 2010 Oct;30(5):526-30.

Kory PD, Pellecchia CM, Shiloh AL, Mayo PH, Koenig S Accuracy of Ultrasonography Performed by Critical Care Physicians for the Diagnosis of Deep Venous Thrombosis Chest 2010 Oct 28. [Epub ahead of print]

Lip GY, Frison L, Halperin JL, Lane DA. Identifying Patients at High Risk for Stroke Despite Anticoagulation. A Comparison of Contemporary Stroke Risk Stratification Schemes in an Anticoagulated Atrial Fibrillation Cohort. Stroke. 2010 Oct 21. [Epub ahead of print]

Lowe GD. Management of deep vein thrombosis to reduce the incidence of post-thrombotic syndrome. Phlebology. 2010 Oct;25 Suppl 1:9-13.

Maestre A, Sánchez R, Rosa V, Aujesky D, Lorenzo A, Barillari G, Monreal M; RIETE Investigators. Clinical characteristics and outcome of inpatients versus outpatients with venous thromboembolism: findings from the RIETE Registry. Eur J Intern Med. 2010;21(5):377-82.

Marinigh R, Lip GY, Lane DA. Stroke prevention in atrial fibrillation patients. Expert Opin Pharmacother. 2010 Oct;11(14):2331-50

Nick AM, Schmeler KM, Frumovitz MM, Soliman PT, Spannuth WA, Burzawa JK, Coleman RL, Wei C, dos Reis R, Ramirez PT. Risk of thromboembolic disease in patients undergoing laparoscopic gynecologic surgery. Obstet Gynecol. 2010 D117 Oct;116(4):956-61. PubMed PMID: 20859161.

O'Connell C, Razavi P, Ghalichi M, Boyle S, Vasan S, Mark L, Caton A, Duddalwar V, Boswell W, Grabow K, Liebman HA Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging MDCT scanning J Thromb Haemost 2010 Oct 18. doi: 10.1111/j.1538-7836.2010.04114.x. [Epub ahead of print] PubMed PMID: 20955348.

Piazza G, Goldhaber SZ. Fibrinolysis for acute pulmonary embolism. Vasc Med. 2010 Oct;15(5):419-28. PubMed PMID: 20926501.

Roskell NS, Lip GY, Noack H, Clemens A, Plumb JM. Treatments for stroke prevention in atrial fibrillation: A network meta-analyses and indirect comparisons versus dabigatran etexilate. Thromb Haemost. 2010 Oct 21;102(2). [Epub ahead of print]

Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010 Oct;160(4):635-41.

Samama MM, Kunitada S, Oursin A, Depasse F, Heptinstall S. Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults. Thromb Res. 2010 Oct;126(4):e286-93

Schellong SM, Haas S, Greinacher A, Schwanebeck U, Sieder C, Abletshauser C, Bramlage P, Riess H. An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opin Pharmacother. 2010 Oct 18. [Epub ahead of print]

Stein PD, Hull RD, Matta F, Willyerd GL. Modest Response in Translation to Home Management of Deep Venous Thrombosis. Am J Med. 2010 Oct 18. [Epub ahead of print] PubMed PMID: 20961524.

The Equinox Investigators Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis J Thromb Haemost 2010 Oct 7. doi: 10.1111/j.1538-7836.2010.04100.x. [Epub ahead of print]

Tripodi A, Chantarangkul V, Guinet C, Samama MM The INR calibrated for Rivaroxaban-(INRrivaroxaban) has the potential to normalize PT results for Rivaroxaban-treated patients: results of an in-vitro study J Thromb Haemost 2010 Oct 13. [Epub ahead of print]

Weber R, Diener HC, Weimar C Prevention of cardioembolic stroke in patients with atrial fibrillation Expert Rev Cardiovasc Ther 2010 Oct;8(10):1405-15

Di Nisio M, Ferrante N, De Tursi M, Iacobelli S, Cuccurullo F, Büller HR, Feragalli B, Porreca E Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy Thromb Haemost 2010;104(5).

Dobesh P The importance of appropriate prophylaxis for the prevention of venous thromboembolism in at-risk medical patients Int J Clin Pract 2010;64(11):1554-1562.

Galanaud JP, Genty C, Sevestre MA, Brisot D, Lausecker M, Gillet JL, Rolland C, Righini M, Leftheriotis G, Bosson JL, Quere I; the OPTIMEV SFMV investigators Predictive factors for concurrent deep-vein thrombosis and symptomatic venous thromboembolic recurrence in case of superficial venous thrombosis. The OPTIMEV study. Thromb Haemost 2010 Sep 30;105(1). [Epub ahead of print] PubMed PMID: 20886192.

Garcia DA, Lopes RD, Hylek EM New-onset atrial fibrillation and warfarin initiation: High risk periods and implications for new antithrombotic drugs Thromb Haemost 2010 Sep 30;104(6). [Epub ahead of print]

Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrøm SZ, Poulsen HE, Køber L, Torp-Pedersen C. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433-41.

Janssen KJ, van der Velde EF, Ten Cate-Hoek AJ, Prins MH, van Weert HC, Stoffers HE, Büller HR, Oudega R, Hoes AW, Toll DB, Moons KG. Optimisation of the diagnostic strategy for suspected deep-vein thrombosis in primary care. Thromb Haemost. 2010 Sep 30;105(1). [Epub ahead of print] PubMed PMID: 20886183.

Lecumberri R, Soler S, Del Toro J, Barba R, Rosa V, Ciammaichella MM, Monreal M; the RIETE Investigators. Effect of the time of diagnosis on outcome in patients with acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2010 Sep 30;105(1). [Epub ahead of print]

Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial fibrillation patients implications for thromboprophylaxis: Implications for thromboprophylaxis. J Am Coll Cardiol. 2010;56(11):827-37.

Sadanaga T, Kohsaka S, Ogawa S. D-dimer levels in combination with clinical risk factors can effectively predict subsequent thromboembolic events in patients with atrial fibrillation during oral anticoagulant therapy. Cardiology. 2010;117(1):31-6. Epub 2010 Sep 30

Samama MM. The mechanism of action of rivaroxaban - an oral, direct Factor Xa inhibitor - compared with other anticoagulants. Thromb Res. 2010 Sep 29. [Epub ahead of print]

Tick LW, Doggen CJ, Rosendaal FR, Faber WR, Bousema MT, Mackaay AJ, Van Balen P, Kramer MH Predictors of the post-thrombotic syndrome with non-invasive venous examinations in patients six weeks after a first episode of deep venous thrombosis J Thromb Haemost 2010 Sep 22. [Epub ahead of print]

Weitz JI, Cao C, Eriksson BI, Fisher W, Kupfer S, Raskob G, Spaeder J, Turpie AG A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery Thromb Haemost 2010 Sep 30;104(6). [Epub ahead of print]

Wittkowsky AK, Spinler SA, Dager W, Gulseth MP, Nutescu EA Dosing guidelines, not protocols, for managing warfarin therapy Am J Health Syst Pharm 2010;67(18):1554-6.

van Es J, Douma RA, Gerdes VE, Kamphuisen PW, Büller HR; Medscape Acute pulmonary embolism. Part 2: treatment Nat Rev Cardiol 2010 Sep 14. [Epub ahead of print]

Agarwal V, Phung OJ, Tongbram V, Bhardwaj A, Coleman CI Statin use and the prevention of venous thromboembolism: a meta-analysis Int J Clin Pract. 2010;64(10):1375-83.

Bacci C, Maglione M, Favero L, Perini A, Di Lenarda R, Berengo M, Zanon E Management of patients undergoing anticoagulant treatment. Results from a large, multicentre, prospective, case-control study. Thromb Haemost 2010 Aug 30;104(5). [Epub ahead of print]

Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, De Bon E, Tormene D, Pagnan A, Prandoni P A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: The Padua Prediction Score J Thromb Haemost 2010 Aug 25. [Epub ahead of print]

Baser O, Supina D, Sengupta N, Wang L, Kwong L Impact of postoperative venous thromboembolism on Medicare recipients undergoing total hip replacement or total knee replacement surgery Am J Health Syst Pharm 2010;67(17):1438-45.

Becker RC, Alexander JH, Newby K, Yang H, Barrett Y, Mohan P, Wang J, Harrington RA, Wallentin LC Effect of apixaban, an oral and direct Factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome Thromb Haemost 2010 Aug 30;104(5). [Epub ahead of print]

Diamantopoulos A, Lees M, Wells PS, Forster F, Ananthapavan J, McDonald H Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada Thromb Haemost 2010 Aug 30;104(4). [Epub ahead of print]

Erkens PM, Gandara E, Wells P, Shen AY, Bose G, Le Gal G, Rodger M, Prins MH, Carrier M Safety of outpatient treatment in acute pulmonary embolism J Thromb Haemost 2010 Aug 23. [Epub ahead of print]

Fuji T, Fujita S, Tachibana S, Kawai Y A dose-ranging study evaluating the oral Factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty J Thromb Haemost 2010 Aug 12. [Epub ahead of print]

Kuzniatsova N, Lip GY. How do we get better at identifying patients with atrial fibrillation who are at 'truly low risk' or 'truly high risk' of stroke? J Neurol Sci. 2010 Aug 30. [Epub ahead of print]

Levy JH, Key NS, Azran MS Novel oral anticoagulants: Implications in the perioperative setting. Anesthesiology. 2010 Aug 9. [Epub ahead of print]

Linkins L, O'Donnell M, Julian JA, Kearon C Intracranial and fatal bleeding according to indication for long-term oral anticoagulant therapy. J Thromb Haemost. 2010 Aug 12. [Epub ahead of print]

Löwenberg EC, Meijers JC, Monia BP, Levi M. Coagulation Factor XI as a novel target for antithrombotic treatment. J Thromb Haemost. 2010 Aug 17. [Epub ahead of print]

Marinigh R, Lip GY, Lane DA Stroke prevention in atrial fibrillation patients. Expert Opin Pharmacother. 2010 Aug 18. [Epub ahead of print]

Marsh JD, Keyrouz SG Stroke prevention and treatment. J Am Coll Cardiol. 2010;56(9):683-691.

Naccarato M, Chiodo Grandi F, Dennis M, Sandercock PA Physical methods for preventing deep vein thrombosis in stroke. Cochrane Database Syst Rev. 2010;8:CD001922.

Panova-Noeva M, Falanga A Treatment of thromboembolism in cancer patients. Expert Opin Pharmacother. 2010;11(12):2049-58

Romualdi E, Ageno W Oral Xa Inhibitors. Hematol Oncol Clin North Am. 2010;24(4):727-737

Samama MM, Amiral J, Guinet C, Perzborn E, Depasse F. An optimised, rapid chromogenic assay, specific for measuring direct Factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost. 2010 Aug 30;104(5). [Epub ahead of print]

Siracuse JJ, Robich MP, Gautum S, Kasper EM, Moorman DW, Hauser CJ Antiplatelet agents, warfarin, and epidemic intracranial hemorrhage. Surgery. 2010 Aug 19. [Epub ahead of print]

Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ; on behalf of the RE-LY investigators Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial Lancet 2010 Aug 27. [Epub ahead of print]

Weber R, Diener HC Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention J Cell Mol Med 2010 Aug 25. [Epub ahead of print]

Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral Factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation Thromb Haemost 2010;104(3). [Epub ahead of print]

Zhang H, Löwenberg EC, Crosby JR, Macleod AR, Zhao C, Gao D, Black C, Revenko AS, Meijers JC, Stroes ES, Levi M, Monia BP Inhibition of the intrinsic coagulation pathway Factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk Blood 2010 Aug 31. [Epub ahead of print]

Ahrens I, Lip GY, Peter K New oral anticoagulant drugs in cardiovascular disease Thromb Haemost 2010;104(1)

Ait Mokhtar O, Bonello L, Armero S, Sbragia P, Paganelli F Early and late outcomes of clopidogrel and coumadin combination for patients on oral anticoagulants undergoing coronary stenting Cardiovasc Revasc Med 2010;11(3):159-62

Bauer KA New oral anticoagulants in development: potential for improved safety profiles Rev Neurol Dis 2010;7(1):1-8

Bereznicki LR, Peterson GM New antithrombotics for atrial fibrillation Cardiovasc Ther 2010 Jul 14. [Epub ahead of print]

Dean SM, Abraham W Venous thromboembolic disease in congestive heart failure Congest Heart Fail 2010;16(4):164-9.

Dubois EA, Cohen AF Dabigatran etexilate Br J Clin Pharmacol 2010;70(1):14-5

Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J Dabigatran: An oral novel potent reversible nonpeptide inhibitor of thrombin Arterioscler Thromb Vasc Biol 2010 Jul 29. [Epub ahead of print]

Garcia-Ortega P, Asencio J Dabigatran offers the simplest solution for thromboprophylaxis after orthopaedic surgery in patients allergic to low-molecular-weight heparins Br J Haematol 2010 Jul 7 [Epub ahead of print]

Kapoor A, Chuang W, Radhakrishnan N, Smith KJ, Berlowitz D, Segal JB, Katz JN, Losina E Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review. Pharmacoeconomics. 2010;28(7):521-38

Konishi N, Hiroe K, Kawamura M Differential effects of TAK-442, a novel orally active direct Factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on Factor V-mediated feedback on coagulation cascade and bleeding. Thromb Haemost. 2010 Jul 20;104(3)[Epub ahead of print]

Lee CJ, Badhwar G, Ansell JE Oral IIa inhibitors. Hematol Oncol Clin North Am. 2010;24(4):739-53, ix.

Lip GY, Lane DA Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med. 2010 Jul 21 [Epub ahead of print]

Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY Underuse of oral anticoagulants in atrial fibrillation: a systematic review Am J Med 2010;123(7):638-645

Röther J, Crijns H Prevention of stroke in patients with atrial fibrillation: the role of new antiarrhythmic and antithrombotic drugs. Cerebrovasc Dis. 2010;30(3):314-22

Schulman S, Anderson DR, Bungard TJ, Jaeger T, Kahn SR, Wells P, Jo-Anne Wilson S Direct and indirect costs of management of long-term warfarin therapy in Canada. J Thromb Haemost. 2010 Jul 16. [Epub ahead of print]

Walfridsson H, Johansson B, Englund A, Kennebäck G, Schwieler J, Kongstad O, Wåhlander K, Malm AR, Edvardsson N Effects of AZD0837, a novel direct thrombin inhibitor, on the electrophysiological properties of the human heart: A randomized, double-blind, parallel-group, placebo-controlled study Clin Drug Investig 2010;30(7):461-71

Walsh TS, Stanworth SJ, Prescott RJ, Lee RJ, Watson DM, Wyncoll D, Writing Committee of the Intensive Care Study of Coagulopathy (ISOC) Investigators Prevalence, management, and outcomes of critically ill patients with prothrombin time prolongation in United Kingdom intensive care units Crit Care Med 2010 Jul 15 [Epub ahead of print]

Arnold JD, Dart BW, Barker DE, Maxwell RA, Burkholder HC, Mejia VA, Smith PW, Longley JM Gold Medal Forum Winner. Unfractionated heparin three times a day versus enoxaparin in the prevention of deep vein thrombosis in trauma patients. Am Surg 2010;76(6)

Asberg S, Henriksson KM, Farahmand B, Asplund K, Norrving B, Appelros P, Stegmayr B, Hulter Åsberg K, Terént A Ischemic stroke and secondary prevention in clinical practice. A cohort study of 14,529 patients in the Swedish Stroke Register Stroke 2010 Jun 3 [Epub ahead of print]

Benavente L, Calleja S, de la Vega V, Garcia-Garcia J, Lahoz CH Oral anticoagulation in elderly patients as secondary prevention of cardioembolic strokes Int Arch Med 2010;3(1):8

Dahl OE, Huisman MV Dabigatran etexilate: advances in anticoagulation therapy Expert Rev Cardiovasc Ther 2010;8(6):771-4

Dahl OE, Quinlan DJ, Bergqvist D, Eikelboom JW A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty J Thromb Haemost 2010 Jun 24 [Epub ahead of print]

Ebner T, Wagner K, Wienen W Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability and pharmacological activity Drug Metab Dispos 2010 Jun 15 [Epub ahead of print]

Fanikos J, Stevens LA, Labreche M, Piazza G, Catapane E, Novack L, Goldhaber SZ Adherence to pharmacological thromboprophylaxis orders in hospitalized patients Am J Med 2010;123(6):536-41.

George J, Doney A, Palmer CN, Lang CC Pharmacogenetics testing: implications for cardiovascular therapeutics with clopidogrel and warfarin. Cardiovasc Ther 2010;28(3):135-8

Karthikeyan G, Eikelboom JW Apixaban in acute coronary syndromes. Cardiovasc Ther. 2010 Jun 11 [Epub ahead of print]

Kovacs MJ, Kahn SR, Wells PS, Anderson DA, Chagnon I, Le Gal G, Solymoss S, Crowther M, Perrier A, Ramsay T, Betancourt MT, Rodger MA Patients with a first symptomatic unprovoked DVT are at higher risk of recurrent VTE than patients with a first unprovoked PE. J Thromb Haemost. 2010 Jun 19. [Epub ahead of print]

Levy JH, Azran M Anesthetic concerns for patients with coagulopathy. Curr Opin Anaesthesiol. 2010;23(3):400-5

Michelena HI, Powell BD, Brady PA, Friedman PA, Ezekowitz MD Gender in atrial fibrillation: Ten years later. Gend Med. 2010;7(3):206-217

Novacek G, Weltermann A, Sobala A, Tilg H, Petritsch W, Reinisch W, Mayer A, Haas T, Kaser A, Feichtenschlager T, Fuchssteiner H, Knoflach P, Vogelsang H, Miehsler W, Platzer R, Tillinger W, Jaritz B, Schmid A, Blaha B, Dejaco C, Eichinger S Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology. 2010 Jun 11 [Epub ahead of print]

Paikin JS, Eikelboom JW, Cairns JA, Hirsh J New antithrombotic agents-insights from clinical trials. Nat Rev Cardiol. 2010 Jun 29. [Epub ahead of print]

Piccini JP, Lopes RD, Mahaffey KW Oral Factor Xa inhibitors for the prevention of stroke in atrial fibrillation. Curr Opin Cardiol 2010 Jun 1. [Epub ahead of print]

Raskob G, Cohen AT, Eriksson BI, Puskas D, Shi M, Bocanegra T, Weitz JI Oral direct Factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost. 2010 Jun 29

Robinson MT, Rabinstein AA, Meschia JF, Freeman WD Safety of recombinant activated Factor VII in patients with warfarin-associated hemorrhages of the central nervous system. Stroke. 2010 Jun 3 [Epub ahead of print]

Rose P, McManus A, Arya R, Scriven N, Farren T, Nokes T, Bacon S, Cooper D, O'Shaughnessy D, Paneesha S Risk factors for cancer-associated venous thromboembolism in outpatient deep venous thrombosis clinics. Br J Haematol. 2010 Jun 17. [Epub ahead of print]

Sattari M, Lowenthal DT Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban. Am J Ther. 2010 Jun 9 [Epub ahead of print]

Schützer KM, Svensson MK, Zetterstrand S, Eriksson UG, Wåhlander K Reversible elevations of serum creatinine levels but no effect on glomerular filtration during treatment with the direct thrombin inhibitor AZD0837. Eur J Clin Pharmacol. 2010 Jun 10 [Epub ahead of print]

Shah MA, Capanu M, Soff G, Asmis T, Kelsen D Risk factors for developing a new venous thromboembolism in ambulatory patients with non-hematologic malignancies and impact on survival for gastroesophageal malignancies. J Thromb Haemost. 2010 Jun 14 [Epub ahead of print]

Siddiqui FM, Qureshi AI. Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation. Expert Opin Pharmacother. 2010 Jun;11(8):1403-11.

Thomas S, Van Kampen M Should orthopedic outpatients with lower limb casts be given deep vein thrombosis prophylaxis? Clin Appl Thromb Hemost 2010 Jun 13 [Epub ahead of print]

Treasure T, Hill J NICE guidance on reducing the risk of venous thromboembolism in patients admitted to hospital J R Soc Med 2010;103(6):210-2

Walenga JM, Adiguzel C Drug and dietary interactions of the new and emerging oral anticoagulants Int J Clin Pract 2010;64(7):956-67

Wong PC, Jiang X Apixaban, a direct Factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: Comparison with direct inhibitors of factor VIIa, XIa and thrombin Thromb Haemost 2010 Jun 29;104. [Epub ahead of print]

Wong PC, Luettgen JM, Rendina AR, Kettner CA, Xin B, Knabb RM, Wexler R, Priestley ES BMS-593214, an active site-directed Factor VIIa inhibitor: Enzyme kinetics, antithrombotic and antihaemostatic studies Thromb Haemost 2010 Jun 29;104. [Epub ahead of print]

Aliot E, Breithardt G, Brugada J, Camm J, Lip GY, Vardas PE, Wagner M; Atrial Fibrillation AWareness And Risk Education group; Atrial Fibrillation Association; European Heart Rhythm Association; Stroke Alliance for Europe; World Heart Federation An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality Europace 2010 May;12(5):626-33.

Becattini C, Lignani A, Agnelli G New anticoagulants for the prevention of venous thromboembolism Drug Des Devel Ther 2010;4:49-60

Borris LC Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty Arch Orthop Trauma Surg 2010;130(5):583-9

Carrier M, Le Gal G, Wells PS, Rodger MA Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism Ann Intern Med 2010 May 4;152(9):578-89.

Chong CT, Lew TW, Kuperan P, Tan JJ, Tan HL, Kwek TK Rapid reversal of coagulopathy in warfarin-related intracranial haemorrhages with prothrombin complex concentrates Anaesth Intensive Care 2010;38(3):474-80

Crowther MA, Garcia D, Ageno W, Wang L, Witt DM, Clark NP, Blostein MD, Kahn SR, Schulman S, Kovacs M, Rodger MA, Wells P, Anderson D, Ginsberg J, Selby R, Siragusa S, Silingardi M, Dowd MB, Kearon C Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. Results of a prospective cohort study. Thromb Haemost 2010 May 10;104(1). [Epub ahead of print]

Cushman M, Callas PW, Denenberg JO, Bovill EG, Criqui MH Risk factors for peripheral venous disease resemble those for venous thrombosis: the San Diego population study J Thromb Haemost 2010 May 21. [Epub ahead of print]

Decousus H, Tapson VF, Bergmann JF, Chong BH, Froehlich JB, Kakkar AK, Merli GJ, Monreal M, Nakamura M, Pavanello R, Pini M, Piovella F, Spencer FA, Spyropoulos AC, Turpie AG, Zotz RB, Fitzgerald G, Anderson FA; for the IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) Investigators Factors at Admission Associated With Bleeding Risk in Medical Patients: Findings From IMPROVE Chest 2010 May 7. [Epub ahead of print]

Desai HV, Aronow WS, Gandhi K, Bakerywala S, Laimuanpuii J, Sharma M, Peterson SJ Association of warfarin use with CHADS(2) score in 441 patients with nonvalvular atrial fibrillation and no contraindications to warfarin Prev Cardiol 2010 Fall;13(4):172-4. doi: 10.1111/j.1751-7141.2010.00073.x.

Friedman RJ, Dahl OE, Rosencher N, Caprini JA, Kurth AA, Francis CW, Clemens A, Hantel S, Schnee JM, Eriksson BI; for the RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials Thromb Res 2010 May 14. [Epub ahead of print]

Harber CR, Nathanson MH Rivaroxaban for thromboembolism prophylaxis after orthopaedic surgery. Anaesthesia. 2010;65(6):552-5

Healy B, Beasley R, Weatherall M Venous thromboembolism following prolonged cast immobilisation for injury to the tendo Achillis. J Bone Joint Surg Br. 2010 May;92(5):646-50

Kamel H, Hegde M, Johnson DR, Gage BF, Johnston SC Cost-effectiveness of outpatient cardiac monitoring to detect atrial fibrillation after ischemic stroke. Stroke. 2010 May 27 [Epub ahead of print]

Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation - friend or foe? Thromb Haemost. 2010 May 10;104(1). [Epub ahead of print]

Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T, Kirchhof P, Marín F. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2010 May 6. [Epub ahead of print]

McNally MA The impact of national guidelines for the prophylaxis of venous thromboembolism on the complications of arthroplasty of the lower limb. J Bone Joint Surg Br. 2010;92(5):747

Orfeo T, Butenas S, Brummel-Ziedins KE, Gissel M, Mann KG Anticoagulation by Factor Xa inhibitors J Thromb Haemost 2010 May 21 [Epub ahead of print]

Payne JH Aspects of anticoagulation in children. Br J Haematol. 2010 May 26 [Epub ahead of print]

Ruff CT, Braunwald E. Will Warfarin Ever Be Replaced? J Cardiovasc Pharmacol Ther. 2010 May 18. [Epub ahead of print]

Sadanaga T, Sadanaga M, Ogawa S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J Am Coll Cardiol. 2010 May 18;55(20):2225-31.

Smith DE, Borg Xuereb C, Pattison HM, Lip GY, Lane DA. Trial of an educational intervention on patients' knowledge of atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT). BMC Cardiovasc Disord. 2010 May 20;10(1):21. [Epub ahead of print]

Stein PD, Matta F, Musani MH, Diaczok B. Silent pulmonary embolism in patients with deep venous thrombosis: a systematic review. Am J Med. 2010 May;123(5):426-31.

Traby L, Kaider A, Schmid R, Kranz A, Quehenberger P, Kyrle PA, Eichinger S The effects of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients. A randomised controlled trial Thromb Haemost 2010 May 10;104(1). [Epub ahead of print]

Trujillo TC Emerging anticoagulants for venous thromboembolism prevention Am J Health Syst Pharm 2010;67(10 Suppl 6):S17-25

Uchiyama S, Shibata Y, Hirabayashi T, Mihara B, Hamashige N, Kitagawa K, Goto S, Origasa H, Shimada K, Kobayashi H, Isozaki M, Ikeda Y; J-TRACE Investigators Risk factor profiles of stroke, myocardial infarction, and atrial fibrillation: a Japanese Multicenter Cooperative Registry J Stroke Cerebrovasc Dis 2010 May;19(3):190-7.

Zimetbaum PJ, Thosani A, Yu HT, Xiong Y, Lin J, Kothawala P, Emons M Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med 2010 May;123(5):446-53.

Amin A, Spyropoulos AC, Dobesh P, Shorr A, Hussein M, Mozaffari E, Benner JS Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start). J Thromb Thrombolysis 2010 Apr;29(3):326-39.

Baglin T Defining the population in need of thromboprophylaxis - making hospitals safer Br J Haematol 2010 Apr 26. [Epub ahead of print]

Bauersachs RM, Riess H, Hach-Wunderle V, Gerlach H, Carnarius H, Eberle S, Rabe E, Schellong SM Impact of gender on the clinical presentation and diagnosis of deep-vein thrombosis Thromb Haemost 2010;103(4):710-7

Bergmann JF, Cohen AT, Tapson VF, Goldhaber SZ, Kakkar AK, Deslandes B, Huang B, Anderson FA Jr, ENDORSE Investigators Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey Thromb Haemost 2010;103(4):736-48

Billett HH, Scorziello BA, Giannattasio ER, Cohen HW Low molecular weight heparin bridging for atrial fibrillation: is VTE thromboprophylaxis the major benefit? J Thromb Thrombolysis 2010 Apr 20. [Epub ahead of print]

Browne AM, Cronin CG, English C, Nimhuircheartaigh J, Murphy JM, Bruzzi JF Unsuspected Pulmonary Emboli in Oncology Patients Undergoing Routine Computed Tomography Imaging J Thorac Oncol 2010 Apr 23. [Epub ahead of print]

Brækkan SK, Borch KH, Mathiesen EB, Njølstad I, Wilsgaard T, Hansen JB Body Height and Risk of Venous Thromboembolism: The Tromso Study Am J Epidemiol 2010 Apr 23. [Epub ahead of print]

Cohen H, Machin SJ Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants? Lupus 2010;19(4):486-91

Coleman R, MacCallum P Treatment and secondary prevention of venous thromboembolism in cancer Br J Cancer 2010 Apr 13;102 Suppl 1:S17-23.

Eichinger S, Heinze G, Jandeck LM, Kyrle PA Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model Circulation 2010 Apr 13;121(14):1630-6. Epub 2010 Mar 29.

Epstein RS, Moyer TP, Aubert RE, O'Kane DJ, Xia F, Verbrugge RR, Gage BF, Teagarden JR Warfarin Genotyping Reduces Hospitalization Rates Results From the MM-WES (Medco-Mayo Warfarin Effectiveness Study) J Am Coll Cardiol 2010 Apr 7. [Epub ahead of print]

Fauchier L, Lip GY Guidelines for antithrombotic therapy in atrial fibrillation: understanding the reasons for non-adherence and moving forwards with simplifying risk stratification for stroke and bleeding Europace 2010 Apr 12. [Epub ahead of print]

Friberg L, Hammar N, Rosenqvist M Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation Eur Heart J 2010 Apr;31(8):967-75. Epub 2009 Jan 27.

Kakkar AK, Macbeth F. Antithrombotic therapy and survival in patients with malignant disease. Br J Cancer. 2010 Apr 13;102 Suppl 1:S24-9.

Kowey PR, Reiffel JA, Myerburg R, Naccarelli GV, Packer DL, Pratt CM, Reiter MJ, Waldo AL; AFFECTS Scientific Advisory Committee and Investigators. Warfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS Registry). Am J Cardiol 2010 Apr 15;105(8):1130-4. Epub 2010 Feb 20.

Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, Pirmohamed M, Caldwell MD, Limdi N, Burmester JK, Dowd MB, Angchaisuksiri P, Bass AR, Chen J, Eriksson N, Rane A, Lindh JD, Carlquist JF, Horne BD, Grice G, Milligan PE, Eby C, Shin J, Kim H, Kurnik D, Stein CM, McMillin G, Pendleton RC, Berg RL, Deloukas P, Gage BF. Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing. Clin Pharmacol Ther 2010 Apr 7. [Epub ahead of print]

Lijfering WM, Middeldorp S, Veeger NJ, Hamulyák K, Prins MH, Büller HR, van der Meer J Risk of Recurrent Venous Thrombosis in Homozygous Carriers and Double Heterozygous Carriers of Factor V Leiden and Prothrombin G20210A. Circulation 2010 Apr 5. [Epub ahead of print]

Linkins LA, Weitz JI. New and emerging anticoagulant therapies for venous thromboembolism. Curr Treat Options Cardiovasc Med. 2010;12(2):142-55.

Lovelock CE, Cordonnier C, Naka H, Al-Shahi Salman R, Sudlow CL; The Edinburgh Stroke Study Group, Sorimachi T, Werring DJ, Gregoire SM, Imaizumi T, Lee SH, Briley D, Rothwell PM. Antithrombotic Drug Use, Cerebral Microbleeds, and Intracerebral Hemorrhage. A Systematic Review of Published and Unpublished Studies. Stroke. 2010 Apr 29. [Epub ahead of print]

Mandalà M, Barni S, Prins M, Labianca R, Tondini C, Russo L, Milesi A, Cremonesi M, Zaccanelli M, Regonesi C, Moro C, Falanga A Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol. 2010 Apr;21(4):871-6. Epub 2009 Aug 27.

McMillin GA, Melis R, Wilson A, Strong MB, Wanner NA, Vinik RG, Peters CL, Pendleton RC Gene-Based Warfarin Dosing Compared With Standard of Care Practices in an Orthopedic Surgery Population: A Prospective, Parallel Cohort Study. Ther Drug Monit 2010 Apr 8. [Epub ahead of print]

Melillo SN, Scanlon JV, Exter BP, Steinberg M, Jarvis CI. Rivaroxaban for Thromboprophylaxis in Patients Undergoing Major Orthopedic Surgery (June) (CE). Ann Pharmacother 2010 Apr 27. [Epub ahead of print]

Meschia JF, Merrill P, Soliman EZ, Howard VJ, Barrett KM, Zakai NA, Kleindorfer D, Safford M, Howard G. Racial disparities in awareness and treatment of atrial fibrillation: the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Stroke 2010 Apr;41(4):581-7. Epub 2010 Feb 26.

Nieuwlaat R, Barker L, Kim YK, Haynes RB, Eikelboom JW, Yusuf S, Connolly SJ. Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. Thromb Res 2010 Apr;125(4):e128-31. Epub 2009 Nov 22.

Nilsson KR Jr, Al-Khatib SM, Zhou Y, Pieper K, White HD, Maggioni AP, Kober L, Granger CB, Lewis EF, McMurray JJ, Califf RM, Velazquez EJ. Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Heart 2010 Apr 20. [Epub ahead of print]

Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer. 2010 Apr 13;102 Suppl 1:S2-9.

On behalf of the CANBESURE Study Group, Kakkar VV, Balibrea JL, Martínez-González J, Prandoni P Extended prophylaxis with bemiparin for prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study J Thromb Haemost 2010 Apr 30. [Epub ahead of print]

Prandoni P, Taher A. Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RE-COVER trial). Expert Opin Pharmacother 2010;11(6):1035-7

Prystowsky EN, Camm J, Lip GY, Allessie M, Bergmann JF, Breithardt G, Brugada J, Crijns H, Ellinor PT, Mark D, Naccarelli G, Packer D, Tamargo J. The Impact of New and Emerging Clinical Data on Treatment Strategies for Atrial Fibrillation. J Cardiovasc Electrophysiol 2010 Apr 8. [Epub ahead of print]

Raaz U, Kaeberich A, Maegdefessel L, Buerke M, Busshardt M, Schubert S, Russ M, Plehn A, Ebelt H, Werdan K, Schlitt A The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro. Thromb Haemost. 2010;103(4):808-14

Raslan AM, Fields JD, Bhardwaj A. Prophylaxis for venous thrombo-embolism in neurocritical care: a critical appraisal. Neurocrit Care. 2010 Apr;12(2):297-309.

Rudd KM, Dier JG. Comparison of two different models of anticoagulation management services with usual medical care. Pharmacotherapy 2010 Apr;30(4):330-8.

Spiezia L, Rossetto V, Campello E, Gavasso S, Woodhams B, Tormene D, Simioni P. Factor VIIa-antithrombin complexes in patients with arterial and venous thrombosis. Thromb Haemost. 2010 Apr 29;103(6). [Epub ahead of print]

Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010;49(4):259-68

Stein PD, Chenevert TL, Fowler SE, Goodman LR, Gottschalk A, Hales CA, Hull RD, Jablonski KA, Leeper KV Jr, Naidich DP, Sak DJ, Sostman HD, Tapson VF, Weg JG, Woodard PK; PIOPED III (Prospective Investigation of Pulmonary Embolism Diagnosis III) Investigators. Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism: a multicenter prospective study (PIOPED III). Ann Intern Med. 2010 Apr 6;152(7):434-43, W142-3

Ten Cate-Hoek AJ, Ten Cate H, Tordoir J, Hamulyák K, Prins MH Individually tailored duration of elastic compression therapy in relation to incidence of the postthrombotic syndrome J Vasc Surg 2010 Apr 10. [Epub ahead of print]

Tran H, Collecutt M, Whitehead S, Salem HH Prothrombin Complex Concentrates Used Alone in Urgent Reversal of Warfarin Anticoagulation Intern Med J 2010 Apr 12. [Epub ahead of print]

Trkulja V, Kolundzic R Rivaroxaban vs Dabigatran for Thromboprophylaxis After Joint-replacement Surgery: Exploratory Indirect Comparison Based on Meta-analysis of Pivotal Clinical Trials Croat Med J 2010 Apr 15;51(2):113-23.

Wang YL, Wu D, Nguyen-Huynh MN, Zhou Y, Wang CX, Zhao XQ, Liao XL, Liu LP, Wang YJ; for The Prevention of Recurrences of Stroke Study in China (PRESS-China) Investigators Antithrombotic management of ischemic stroke and transient ischemic attack in China: A consecutive cross-sectional survey Clin Exp Pharmacol Physiol 2010 Apr 26. [Epub ahead of print]

Weitz JI Potential of new anticoagulants in patients with cancer Thromb Res 2010;125 Suppl 2:S30-5

Witt DM, Delate T, Clark NP, Martell C, Tran T, Crowther MA, Garcia DA, Ageno W, Hylek EM; Warped Consortium Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users J Thromb Haemost 2010 Apr;8(4):744-9.

Yang L, Ge W, Yu F, Zhu H Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement--a systematic review and meta analysis Thromb Res 2010 Apr;125(4):e159-66. Epub 2009 Nov 25.

Aguilar MI, Freeman WD Treatment of coagulopathy in intracranial hemorrhage Curr Treat Options Neurol. 2010;12(2):113-28.

Arepally G, Bauer KA, Bhatt DL, Merli GJ, Naccarelli GV, Carter RD, Karcher RB, Berry CA, Keaton KL, Stowell SA The use of antithrombotic therapies in the prevention and treatment of arterial and venous thrombosis: a survey of current knowledge and practice supporting the need for clinical education Crit Pathw Cardiol 2010;9(1):41-8

Audebert HJ, Schenk B, Schenkel J, Heuschmann PU Impact of prestroke oral anticoagulation on severity and outcome of ischemic and hemorrhagic stroke in patients with atrial fibrillation Cerebrovasc Dis 2010;29(5):476-483

Benmira S, Banda ZK, Bhattacharya V Old Versus New Anticoagulants: Focus on Pharmacology Recent Pat Cardiovasc Drug Discov 2010 Mar 26 [Epub ahead of print]

Clayton RA, Gaston P, Howie CR Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement J Bone Joint Surg Br 2010;92(3):468

Colwell CW Jr, Froimson MI, Mont MA, Ritter MA, Trousdale RT, Buehler KC, Spitzer A, Donaldson TK, Padgett DE Thrombosis prevention after total hip arthroplasty: a prospective, randomized trial comparing a mobile compression device with low-molecular-weight heparin J Bone Joint Surg Am 2010;92(3):527-35

Cosmi B, Legnani C, Tosetto A, Pengo V, Ghirarduzzi A, Testa S, Prisco D, Poli D, Tripodi A, Palareti G; for the PROLONG Investigators (on behalf of FCSA, Italian Federation of Anticoagulation Clinics) Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the prolong study Thromb Haemost 2010 Mar 29;103(6). [Epub ahead of print]

Douma RA, Kok MG, Verberne LM, Kamphuisen PW, Büller HR Incidental venous thromboembolism in cancer patients: prevalence and consequence Thromb Res 2010 Mar 9. [Epub ahead of print]

Douma RA, le Gal G, Söhne M, Righini M, Kamphuisen PW, Perrier A, Kruip MJ, Bounameaux H, Büller HR, Roy PM Potential of an age adjusted D-dimer cut-off value to improve the exclusion of pulmonary embolism in older patients: a retrospective analysis of three large cohorts BMJ 2010 Mar 30;340:c1475. doi: 10.1136/bmj.c1475.

Eikelboom JW, O'Donnell M, Yusuf S, Diaz R, Flaker G, Hart R, Hohnloser S, Joyner C, Lawrence J, Pais P, Pogue J, Synhorst D, Connolly SJ Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment Am Heart J 2010;159(3):348-353.e1

Fareed J, Hull R Apixaban to prevent venous thromboembolism after knee replacement Lancet 2010;375(9717):779-80.

Folsom AR, Lutsey PL, Astor BC, Wattanakit K, Heckbert SR, Cushman M; for the Atherosclerosis Risk in Communities (ARIC) Study Chronic kidney disease and venous thromboembolism: a prospective study Nephrol Dial Transplant 2010 Mar 29. [Epub ahead of print]

Gao F, Zhou YJ, Wang ZJ, Shen H, Liu XL, Nie B, Yan ZX, Yang SW, Jia de A, Yu M Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation Circ J 2010 Mar 25;74(4):701-8. Epub 2010 Mar 6.

Hankey GJ, Eikelboom JW. Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurol 2010;9(3):273-284

Kristinsson SY, Pfeiffer RM, Björkholm M, Goldin LR, Schulman S, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood 2010 Mar 18. [Epub ahead of print]

Labropoulos N, Jen J, Jen H, Gasparis AP, Tassiopoulos AK. Recurrent deep vein thrombosis: Long-term incidence and natural history. Ann Surg 2010 Mar 10. [Epub ahead of print]

Lankeit M, Konstantinides S. Thrombolysis for pulmonary embolism: Past, present and future. Thromb Haemost. 2010 Mar 9;103(5). [Epub ahead of print]

Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010;375(9717):807-15

Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW, Wallentin L; on behalf of the ARISTOTLE Investigators. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: Design and rationale. Am Heart J 2010;159(3):331-339

Mackman N, Becker RC DVT: a new era in anticoagulant therapy. Arterioscler Thromb Vasc Biol. 2010;30(3):369-71

Maleux G, Marchal P, Palmers M, Heye S, Verhamme P, Vaninbroukx J, Verhaeghe R. Catheter-directed thrombolytic therapy for thoracic deep vein thrombosis is safe and effective in selected patients with and without cancer. Eur Radiol. 2010 Mar 28. [Epub ahead of print]

Mazzaglia G, Filippi A, Alacqua M, Cowell W, Shakespeare A, Mantovani LG, Bianchi C, Cricelli C. A national survey of the management of atrial fibrillation with antithrombotic drugs in Italian primary care. Thromb Haemost 2010;103(5). [Epub ahead of print]

Olsson SB, Rasmussen LH, Tveit A, Jensen E, Wessman P, Panfilov S, Wåhlander K Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation Thromb Haemost 2010;103(3):604-12

Palaniswamy C, Selvaraj DR. Periprocedural bridging anticoagulation: Current perspectives. Am J Ther 2010 Mar 11 [Epub ahead of print]

Perez A, Bartholomew JR Interpreting the JUPITER trial: statins can prevent VTE, but more study is needed. Cleve Clin J Med 2010;77(3):191-4

Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest 2010 Mar 18. [Epub ahead of print]

Pisters R, van Oostenbrugge RJ, Knottnerus IL, de Vos CB, Boreas A, Lodder J, Prins MH, Crijns HJ, Tieleman RG. The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines. Europace. 2010 Mar 26. [Epub ahead of print]

Rowe AS, Turner RM. Coagulation factor VIIa (recombinant) for warfarin-induced intracranial hemorrhage. Am J Health Syst Pharm 2010 Mar 1;67(5):361-5

Sheehan OC, Kyne L, Kelly LA, Hannon N, Marnane M, Merwick A, McCormack PM, Duggan J, Moore A, Moroney J, Daly L, Harris D, Horgan G, Williams EB, Kelly PJ. Population-based study of ABCD2 score, carotid stenosis, and atrial fibrillation for early stroke prediction after transient ischemic attack: The North Dublin TIA study. Stroke 2010 Mar 18. [Epub ahead of print]

Teachey DT Dabigatran versus warfarin for venous thromboembolism N Engl J Med 2010;362(11):1050

The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: Rationale and design of the ROCKET AF study Am Heart J 2010;159(3):340-347

Tulner LR, Kuper IM, van Campen JP, MacGillavry MR, Kwa VI, Koks CH, Beijnen JH, Brandjes DP Contraindications for anticoagulation in older patients with atrial fibrillation: A narrative review Curr Drug Saf 2010 Mar 7. [Epub ahead of print]

Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 2010 Mar 29;103(6). [Epub ahead of print]

Vavra KA, Lutz MF, Smythe MA Recombinant Factor VIIa to manage major bleeding from newer parenteral anticoagulants Ann Pharmacother 2010;44(4):718-26

Verheugt FW Novel oral anticoagulants to prevent stroke in atrial fibrillation Nat Rev Cardiol 2010;7(3):149-54

Agarwal S, Bennett D, Smith DJ Predictors of warfarin use in atrial fibrillation patients in the inpatient setting Am J Cardiovasc Drugs. 2010;10(1):37-48.

Armaganijan L, Eikelboom J, Healey JS, Morillo CA New pharmacotherapy for stroke prevention in atrial fibrillation: Update 2010.1. Adv Ther 2009;26(12):1058-71. Epub 2010 Feb 1.

Bauersachs RM, Riess H, Hach-Wunderle V, Gerlach H, Carnarius H, Eberle S, Rabe E, Schellong S Impact of gender on the clinical presentation and diagnosis of deep-vein thrombosis Thromb Haemost 2010 Feb 19;103(4). [Epub ahead of print]

Budhraja V The net clinical benefit of warfarin anticoagulation in atrial fibrillation Ann Intern Med 2010;152(4):265

Bussey H The net clinical benefit of warfarin anticoagulation in atrial fibrillation Ann Intern Med 2010;152(4):264-5

Chamorro A Dual antiplatelet therapy is not optimal for stroke prevention in patients with atrial fibrillation Int J Stroke 2010 Feb;5(1):28-9.

Clark P, Wu O, Greer IA, Lowe GD Venous thrombosis prevention - more than just guidelines Br J Haematol 2010 Feb 8. [Epub ahead of print]

Cohen M The thrombin hypothesis in ACS: a disappointing disconnect between bench data and bedside clinical trials Am J Med 2010;123(2):103-10

Cook DJ, Crowther MA Thromboprophylaxis in the intensive care unit: focus on medical-surgical patients Crit Care Med 2010 Feb;38(2 Suppl):S76-82.

Debergh I, Van Damme N, Pattyn P, Peeters M, Ceelen WP The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model Br J Cancer 2010 Feb 2. [Epub ahead of print]

Decousus H, Quéré I, Presles E, Becker F, Barrellier MT, Chanut M, Gillet JL, Guenneguez H, Leandri C, Mismetti P, Pichot O, Leizorovicz A for the POST (Prospective Observational Superficial Thrombophlebitis) Study Group Superficial venous thrombosis and venous thromboembolism: A large, prospective epidemiologic study Ann Intern Med 2010;152(4):218-224

Dentali F, Crowther M Antiphospholipid antibodies in critical illness Crit Care Med 2010 Feb;38(2 Suppl):S51-6.

Di Nisio M, van Sluis GL, Bossuyt PM, Büller HR, Porreca E, Rutjes AW Accuracy of diagnostic tests for clinically suspected upper extremity deep vein thrombosis: a systematic review J Thromb Haemost 2010 Feb 6. [Epub ahead of print]

Eikelboom JW, Wallentin L, Yusuf S, Ezekowitz MD, Reilly PA, Brueckmann M, Clemens A, Connolly SJ Does dabigatran improve stroke-prevention in atrial fibrillation? J Thromb Haemost 2010 Feb 9. [Epub ahead of print]

Eikelboom JW, Zelenkofske SL, Rusconi CP Coagulation Factor IXa as a target for treatment and prophylaxis of venous thromboembolism Arterioscler Thromb Vasc Biol 2010;30(3):382-7. [Epub 2010 Feb 5]

Gorin L, Fauchier L, Nonin E, de Labriolle A, Haguenoer K, Cosnay P, Babuty D, Charbonnier B Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1 Thromb Haemost 2010 Feb 2;103(3). [Epub ahead of print]

Goto S, Yamaguchi T, Ikeda Y, Kato K, Yamaguchi H, Jensen P Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome Atheroscler Thromb 2010 Feb 3. [Epub ahead of print]

Hankey GJ. Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs? Curr Opin Neurol. 2010 Feb;23(1):65-72.

Jaffer AK, Brotman DJ, Bash LD, Mahmood SK, Lott B, White RH. Variations in perioperative warfarin management: outcomes and practice patterns at nine hospitals. Am J Med 2010;123(2):141-50

Lopes RD, Starr A, Pieper CF, Al-Khatib SM, Newby LK, Mehta RH, Van de Werf F, Mahaffey KW, Armstrong PW, Harrington RA, White HD, Wallentin L, Granger CB. Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. Am J Med. 2010 Feb;123(2):134-40.

Mahan CE, Pini M, Spyropoulos AC. Venous thromboembolism prophylaxis with unfractionated heparin in the hospitalized medical patient: the case for thrice daily over twice daily dosing. Intern Emerg Med 2010 Feb 23. [Epub ahead of print]

Maynard G, Stein J. Designing and implementing effective venous thromboembolism prevention protocols: lessons from collaborative efforts. J Thromb Thrombolysis. 2010 Feb;29(2):159-66.

McBane RD, Wysokinski WE, Daniels PR, Litin SC, Slusser J, Hodge DO, Dowling NF, Heit JA. Periprocedural anticoagulation management of patients with venous thromboembolism. Arterioscler Thromb Vasc Biol 2010;30(3):442-8. [Epub 2010 Feb 5.]

Mismetti P, Baud JM, Becker F, Belmahdi F, Blanchard P, Constans J, Couturaud F, Debourdeau P, Drouet L, Dumarcet N, Ferrari E, Galanaud JP, Girard P, Hay B, Laporte S, Laroche JP, Leizorovicz A, Liard F, Mahe I, Meyer G, Oger E, Parent F, Quere I, Samama M. Guidelines for good clinical practice: Prevention and treatment of venous thromboembolism in medical patients. J Mal Vasc 2010 Feb 15. [Epub ahead of print]

Morell J, Sullivan B, Khalabuda M, McBride BF. Role of orally available antagonists of Factor Xa in the treatment and prevention of thromboembolic disease: Focus on rivaroxaban. J Clin Pharmacol 2010 Feb 2. [Epub ahead of print]

Niki Y, Matsumoto H, Hakozaki A, Mochizuki T, Momohara S Rheumatoid arthritis: a risk factor for deep venous thrombosis after total knee arthroplasty? Comparative study with osteoarthritis. J Orthop Sci. 2010;15(1):57-63

Ntep-Gweth M, Zimmermann M, Meiltz A, Kingue S, Ndobo P, Urban P, Bloch A. Atrial fibrillation in Africa: clinical characteristics, prognosis, and adherence to guidelines in Cameroon. Europace 2010 Feb 23. [Epub ahead of print]

Paulson R. Implementing deep vein thrombosis prophylaxis in hospital patients: another option. Am J Med. 2010 Feb;123(2):e13; author reply e15.

Pendergrast J. Urgent warfarin reversal: know your options. Can J Anaesth 2010 Feb 23. [Epub ahead of print]

Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol 2010 Mar;30(3):376-81. [Epub 2010 Feb 5.]

Poli D, Grifoni E, Antonucci E, Arcangeli C, Prisco D, Abbate R, Miniati M. Incidence of recurrent venous thromboembolism and of chronic thromboembolic pulmonary hypertension in patients after a first episode of pulmonary embolism. J Thromb Thrombolysis 2010 Feb 16. [Epub ahead of print]

Quan ML, Pinto DJ, Rossi KA, Sheriff S, Alexander RS, Amparo E, Kish K, Knabb RM, Luettgen JM, Morin P, Smallwood A, Woerner FJ, Wexler RR Phenyltriazolinones as potent Factor Xa inhibitors. Bioorg Med Chem Lett. 2010;20(4):1373-7

Samama MM, Martinoli JL, Leflem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E. Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor. Thromb Haemost 2010 Feb 2;103(4). [Epub ahead of print]

Sansone JM, del Rio AM, Anderson PA. The prevalence of and specific risk factors for venous thromboembolic disease following elective spine surgery. J Bone Joint Surg Am 2010;92(2):304-13

Schwammenthal Y, Bornstein N, Schwammenthal E, Schwartz R, Goldbourt U, Tsabari R, Koton S, Grossman E, Tanne D. Relation of effective anticoagulation in patients with atrial fibrillation to stroke severity and survival (from the National Acute Stroke Israeli Survey [NASIS]). Am J Cardiol. 2010 Feb 1;105(3):411-6. Epub 2009 Dec 22.

Sharma T, Mehta P, Gajra A. Update on fondaparinux: Role in management of thromboembolic and acute coronary events. Cardiovasc Hematol Agents Med Chem 2010 Feb 25. [Epub ahead of print]

Taimeh Z, Weksler B Review: recent advances in argatroban-warfarin transition in patients with heparin-induced thrombocytopenia Clin Appl Thromb Hemost 2010 Feb;16(1):5-12. Epub 2008 Dec 2.

Themistoclakis S, Corrado A, Marchlinski FE, Jais P, Zado E, Rossillo A, Di Biase L, Schweikert RA, Saliba WI, Horton R, Mohanty P, Patel D, Burkhardt DJ, Wazni OM, Bonso A, Callans DJ, Haissaguerre M, Raviele A, Natale A The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation J Am Coll Cardiol 2010;55(8):735-743

Ufer M Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development Thromb Haemost 2010 Feb 2;103(3). [Epub ahead of print]

Vedovati MC, Becattini C, Agnelli G Combined oral anticoagulants and antiplatelets: benefits and risks Intern Emerg Med 2010 Feb 11. [Epub ahead of print]

Albers GW Stroke: more protection for patients with atrial fibrillation Lancet Neurol 2010 Jan;9(1):2-4.

Bauersachs RM, Haas S Prophylaxis for thromboembolism in internal medicine and family practice Internist (Berl) 2010 Jan 28. [Epub ahead of print]

Blackshear RH, Crosson KC Reduction in Pulmonary Embolism after Total Joint Arthroplasty: Three Years of Experience with Extended-Release Epidural Morphine Pain Pract 2010 Jan 8. [Epub ahead of print]

Callejas Rubio JL, Lara Jiménez MA, Fernández Pugnaire MA, Ortego Centeno N Dabigatran in the treatment of a morbidly obese patient with recurring venous thrombosis Farm Hosp 2010;34(2):101

Caprini JA Risk assessment as a guide for the prevention of the many faces of venous thromboembolism Am J Surg 2010;199(1 Suppl):S3-10

Castelli R, Ferrari B, Cortelezzi A, Guariglia A Thromboembolic Complications in Malignant Haematological Disorders Curr Vasc Pharmacol 2010 Jan 1. [Epub ahead of print]

Cha SI, Lee SY, Kim CH, Park JY, Jung TH, Yi JH, Lee J, Huh S, Lee HJ, Kim SY Venous thromboembolism in Korean patients undergoing major orthopedic surgery: a prospective observational study using computed tomographic (CT) pulmonary angiography and indirect CT venography J Korean Med Sci 2010 Jan;25(1):28-34.

Chong BH, Chong JJ Heparin-induced thrombocytopenia associated with fondaparinux Clin Adv Hematol Oncol 2010;8(1):63-5

De Bono J, Nazir S, Ruparelia N, Bashir Y, Betts T, Rajappan K Perioperative management of anticoagulation during device implantation-The UK perspective Pacing Clin Electrophysiol 2010 Jan 27. [Epub ahead of print]

Eikelboom JW, Weitz JI Another oral thrombin inhibitor for stroke prevention in atrial fibrillation? Thromb Haemost 2010 Jan 13;103. [Epub ahead of print]

Eriksson BI, Turpie AG, Lassen MR, Prins MH, Agnelli G, Kälebo P, Wetherill G, Wilpshaar JW, Meems L; for the ONYX-2 study group. Prevention of venous thromboembolism with an oral Factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J Thromb Haemost 2010 Jan 17. [Epub ahead of print]

Gassanov N, Caglayan E, Erdmann E, Er F Dabigatran: a new therapeutic option for therapy and prophylaxis of thromboembolic diseases? Dtsch Med Wochenschr 2010 Jan 26. [Epub ahead of print]

Hannon N, Sheehan O, Kelly L, Marnane M, Merwick A, Moore A, Kyne L, Duggan J,Moroney J, McCormack PM, Daly L, Fitz-Simon N, Harris D, Horgan G, Williams EB, Furie KL, Kelly PJ. Stroke associated with atrial fibrillation--incidence and early outcomes in the north dublin population stroke study. Cerebrovasc Dis. 2010;29(1):43-9. Epub 2009 Nov 5.

Jiang J, Hu Y, Zhang J, Yang J, Mueck W, Kubitza D, Bauer RJ, Meng L, Hu P Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects Thromb Haemost 2010 Jan;103(1):234-41.

Jimenez D, Aujesky D, Diaz G, Monreal M, Otero R, Marti D, Marin E, Aracil E, Sueiro A, Yusen RD, The Riete Investigators Prognostic Significance of Deep Vein Thrombosis in Patients Presenting with Acute Symptomatic Pulmonary Embolism Am J Respir Crit Care Med 2010 Jan 28. [Epub ahead of print]

Kaatz S, Douketis JD, Zhou H, Gage BF, White RH Risk of stroke after surgery in patients with and without chronic atrial fibrillation J Thromb Haemost 2010 Jan 24. [Epub ahead of print]

Kerr J, Linkins LA. High incidence of in-hospital pulmonary embolism following joint arthroplasty with dalteparin prophylaxis. Thromb Haemost. 2010 Jan;103(1):123-8. Epub 2009 Oct 26.

Khoo CW, Lip GY. Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial. Expert Opin Pharmacother. 2010 Jan 28. [Epub ahead of print]

Lane DA, Lip GY. Anticoagulation intensity for elderly atrial fibrillation patients: Should we use a conventional INR target (2.0 to 3.0) or a lower range? Thromb Haemost. 2010 Jan 13;103. [Epub ahead of print]

Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, Kirchhof P, Marín F. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010 Jan;103(1):13-28. Epub 2009 Sep 30.

McAndrew CM, Fitzgerald SJ, Kraay MJ, Goldberg VM. Incidence of postthrombotic syndrome in patients undergoing primary total knee arthroplasty for osteoarthritis. Clin Orthop Relat Res 2010 Jan;468(1):178-81. Epub 2009 Jun 19.

Muntz JE, Michota FA. Prevention and management of venous thromboembolism in the surgical patient: options by surgery type and individual patient risk factors. Am J Surg 2010 Jan;199(1 Suppl):S11-20

Neviaser AS, Chang C, Lyman S, Della Valle AG, Haas SB. High incidence of complications from enoxaparin treatment after arthroplasty. Clin Orthop Relat Res. 2010 Jan;468(1):115-9. Epub 2009 Aug 11.

Owen A Antithrombotic treatment for the primary prevention of stroke in patients with non valvular atrial fibrillation: A reappraisal of the evidence and network meta analysis Int J Cardiol 2010 Jan 8. [Epub ahead of print]

Palareti G, Cosmi B. Emerging drugs for venous thromboembolism. Expert Opin Emerg Drugs. 2010 Jan 15. [Epub ahead of print]

Paty I, Trellu M, Destors JM, Cortez P, Boëlle E, Sanderink G. Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. J Thromb Haemost. 2010 Jan 17. [Epub ahead of print]

Pengo V, Cucchini U, Denas G, Davidson BL, Marzot F, Padayattil Jose S, Iliceto S. Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation. Thromb Haemost. 2010 Jan 13;103. [Epub ahead of print]

Rhodes DA, Severson EP, Hodrick JT, Dunn HK, Hofmann AA. Discontinuation of warfarin is unnecessary in total knee arthroplasty. Clin Orthop Relat Res. 2010;468:120-6.

Robert F. The potential benefits of low-molecular-weight heparins in cancer patients. J Hematol Oncol. 2010 Jan 14;3(1):3. [Epub ahead of print]

Robert-Ebadi H, Le Gal G, Carrier M, Couturaud F, Perrier A, Bounameaux H, Righini M. Differences in clinical presentation of pulmonary embolism in women and men. J Thromb Haemost. 2010 Jan 22. [Epub ahead of print]

Schulman S, Spencer FA. Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding. J Thromb Haemost. 2010 Jan 6. [Epub ahead of print]

Spinler SA. Atrial fibrillation: A promising new anticoagulant for stroke prevention. Nat Rev Cardiol 2010;7(1):10-1

Tulner LR, Van Campen JP, Kuper IM, Gijsen GJ, Koks CH, Mac Gillavry MR, van Tinteren H, Beijnen JH, Brandjes DP Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study Drugs Aging 2010;27(1):39-50.

Willeke A, Lindhoff-Last E Treatment of venous thromboembolism Internist (Berl) 2010;51(3):335-6, 338-43

Yong CM, Boyle AJ Factor Xa Inhibitors in Acute Coronary Syndromes and Venous Thromboembolism Curr Vasc Pharmacol 2010 Jan 1. [Epub ahead of print]

Castellone DD, Van Cott EM Laboratory monitoring of new anticoagulants Am J Hematol 2009;85(3):185-187. [Epub ahead of print]

Cohen AT Prevention of postoperative venous thromboembolism BMJ 2009 Dec 3;339:b4477. (Comment on: Sweetland et al)

Colwell CW The ACCP guidelines for thromboprophylaxis in total hip and knee arthroplasty Orthopedics 2009;32(12 Suppl):67-73

Dentali F, Ageno W Cerebral vein thrombosis Intern Emerg Med 2009 Dec 1. [Epub ahead of print]

Friedman RJ New oral anticoagulants for thromboprophylaxis after total hip or knee arthroplasty Orthopedics 2009;32(12 Suppl):79-84

Guédon-Moreau L, Kacet S Atrial fibrillation: challenge of antithrombotic treatment Ann Cardiol Angeiol (Paris) 2009 Dec;58 Suppl 1:S25-30

Hankey GJ. At last, a RE-LYable alternative to warfarin for atrial fibrillation. Int J Stroke. 2009 Dec;4(6):454-5.

Hellmann I, Ellis MH. Prevention of venous thromboembolism in medical patients: recent advances and future directions. Isr Med Assoc J 2009;11(12):753-7

Imberti D, Dall'Asta C, Pierfranceschi MG. Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review. Intern Emerg Med. 2009 Dec;4(6):471-7.

Ji JH, Shafi M, Sung JH, Moon CY, Park SE, Lee YS Thromboembolic complications after bilateral knee arthroscopic surgery patients Knee Surg Sports Traumatol Arthrosc 2009 Dec 24. [Epub ahead of print]

Klok FA, Zondag W, van Kralingen KW, van Dijk AP, Tamsma JT, Heyning FH, Vliegen HW, Huisman MV. Patient Outcomes After Acute Pulmonary Embolism: a Pooled Survival Analysis of Different Adverse Events. Am J Respir Crit Care Med. 2009 Dec 3. [Epub ahead of print]

Lachiewicz PF. Comparison of ACCP and AAOS guidelines for VTE prophylaxis after total hip and total knee arthroplasty. Orthopedics 2009;32(12 Suppl):74-8

Lafuente-Lafuente C, Mahé I, Extramiana F. Management of atrial fibrillation. BMJ. 2009 Dec 23;339:b5216

Lee BH, Park JS, Park JH, Park JS, Kwak JJ, Hwang ES, Kim SK, Choi DH, Kim YH, Pak HN. The Effect and Safety of the Antithrombotic Therapies in Patients with Atrial Fibrillation and CHADS Score 1. J Cardiovasc Electrophysiol. 2009 Dec 15. [Epub ahead of print]

Marmur JD, Bullock-Palmer RP, Poludasu S, Cavusoglu E. Avoiding intelligence failures in the cardiac catheterization laboratory: Strategies for the safe and rational use of dalteparin or enoxaparin during percutaneous coronary intervention J Invasive Cardiol. 2009 Dec;21(12):653-64.

Massoure PL, Sacher F, Derval N, Hocini M, Jais P, Haissaguerre M. Atrial fibrillation in elderly patients. Rev Prat. 2009 Dec 20;59(10):1365-9.[Article in French]

Ramacciotti E, Myers DD Jr, Wrobleski SK, Deatrick KB, Londy FJ, Rectenwald JE, Henke PK, Schaub RG, Wakefield TW. P-selectin/ PSGL-1 Inhibitors versus enoxaparin in the resolution of venous thrombosis: A meta-analysis. Thromb Res. 2009 Dec 3. [Epub ahead of print]

Rose AJ, Ozonoff A, Henault LE, Hylek EM. Anticoagulation for valvular heart disease in community-based practice. Thromb Haemost. 2009 Dec 18. [Epub ahead of print]

Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ; the RE-COVER Study Group. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. N Engl J Med. 2009 Dec 6. [Epub ahead of print]

Siller-Matula JM, Krumphuber J, Jilma B. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. Br J Pharmacol. 2009 Dec 24. [Epub ahead of print]

Sweetland S, Green J, Liu B, Berrington de González A, Canonico M, Reeves G, Beral V; Million Women Study collaborators Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study BMJ 2009 Dec 3;339:b4583.

Warwick D, Rosencher N The "Critical Thrombosis Period" in Major Orthopedic Surgery: When to Start and When to Stop Prophylaxis Clin Appl Thromb Hemost 2009 Dec 16. [Epub ahead of print]

Weber KL, Zuckerman JD, Watters WC 3rd, Turkelson CM Deep vein thrombosis prophylaxis Chest 2009 Dec;136(6):1699-700.

Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Noack H, Robinson PA, Dolan G, Brenkel IJ Economic evaluation of dabigatran etexilate for the preventionof venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement Thromb Haemost 2009 Dec 18. [Epub ahead of print]

Zikria J, Ansell J Oral anticoagulation with Factor Xa and thrombin inhibitors: Is there an alternative to warfarin? Discov Med 2009 Dec;8(43):196-203.

Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M; on behalf of the PROTECHT Investigators Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study Lancet Oncol. 2009 Nov;39(11):752-6.

Ahmad O, Ahmad KE, Dear KB, Harvey I, Hughes A, Lueck CJ Atrial Fibrillation and Anticoagulation in a Stroke Unit Population Intern Med J. 2009 Nov;39(11):752-6.

Apostolakis S, Shantsila E, Lip GY, Lane DA Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation" Thromb Haemost 2009 Nov;102(5):914-5.

Aujesky D, Mazzolai L, Hugli O, Perrier A Outpatient treatment of pulmonary embolism Swiss Med Wkly 2009;139(47-48):685-90

Bellamy L, Rosencher N, Eriksson B Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate Patient Prefer Adherence 2009 Nov 3;3:173-177.

Capri S, Ageno W, Imberti D, Palareti G, Piovella F, Scannapieco G, Moia M Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis Intern Emerg Med 2009 Nov 5. [Epub ahead of print]

Donadini MP, Douketis JD Combined warfarin-aspirin therapy: what is the evidence for benefit and harm and which patients should (and should not) receive it? J Thromb Thrombolysis 2009 Nov 15. [Epub ahead of print]

Ehrlich JR, Hohnloser SH Milestones in the management of atrial fibrillation Heart Rhythm 2009 Nov;6(11 Suppl):S62-7. Epub 2009 Sep 1.

Eikelboom JW, Quinlan DJ, O'Donnell M Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials Circulation 2009 Nov 17;120(20):2006-11. Epub 2009 Nov 2.

Eischer L, Eichinger S, Kyrle PA Age at first venous thromboembolism and risk of recurrence: a prospective cohort study Medicine (Baltimore) 2009 Nov;88(6):366-70.

Fassiadis N Rivaroxaban, the first oral, direct factor Xa inhibitor Expert Opin Pharmacother 2009 Nov 19. [Epub ahead of print]

Gómez-Outes A, Suárez-Gea ML, Pozo-Hernández C, Lassen MR, Raskob GE, Gallus A Apixaban or Enoxaparin for Thromboprophylaxis N Engl J Med 2009 Nov 19;361(21):2100-2101.

Hammerstingl C, Schmitz A, Fimmers R, Omran H. Bridging of chronic oral anticoagulation with enoxaparin in patients with atrial fibrillation: results from the prospective BRAVE registry. Cardiovasc Ther. 2009 Winter;27(4):230-8.

Hankey GJ. Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs? Curr Opin Neurol. 2009 Nov 25. [Epub ahead of print]

Harenberg J. Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Thromb Haemost. 2009 Nov;102(5):811-5.

Healey JS. Pro Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation Thromb Haemost 2009 Nov;102(5):912-3.

Hörl WH. Oral anticoagulation with coumarins for patients with atrial fibrillation and chronic kidney disease? Wien Klin Wochenschr. 2009;121(21-22):668-72.

Jaffer AK. Perioperative management of warfarin and antiplatelet therapy. Cleve Clin J Med. 2009 Nov;76 Suppl 4:S37-44.

Laux V, Perzborn E, Heitmeier S, von Degenfeld G, Dittrich-Wengenroth E, Buchmüller A, Gerdes C, Misselwitz F. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? Thromb Haemost. 2009 Nov;102(5):892-9.

Lu JP, Knudson MM, Bir N, Kallet R, Atkinson K. Fondaparinux for prevention of venous thromboembolism in high-risk trauma patients: a pilot study. J Am Coll Surg. 2009 Nov;209(5):589-94. 2009 Nov;209(5):589-94. Epub 2009 Sep 11.

No authors listed HOTLINE I, RE-LY, diabigatran gains ground on warfarin. Eur Heart J 2009 Nov;30(21):2542.

Piazza G, Goldhaber SZ. Physician alerts to prevent venous thromboembolism. J Thromb Thrombolysis. 2009 Nov 4. [Epub ahead of print]

Romera-Villegas A, Cairols-Castellote MA, Vila-Coll R, Martí-Mestre X, Colomé E, Iguaz I. Long-Term Use of Different Doses of Low-Molecular-Weight Heparin Versus Vitamin K Antagonists in the Treatment of Venous Thromboembolism .Ann Vasc Surg. 2009 Nov 23. [Epub ahead of print]

Sun JM, Kim TS, Lee J, Park YH, Ahn JS, Kim H, Kwon OJ, Lee KS, Park K, Ahn MJ Unsuspected pulmonary emboli in lung cancer patients: The impact on survival and the significance of anticoagulation therapy Lung Cancer [Epub ahead of print]

Sutedjo JL, Ng RK, Piazza G, Goldhaber SZ Medicare's new regulations for deep vein thrombosis as a "never event": wise or worrisome? Am J Med 2009 Nov;122(11):975-6.

Wittkowsky AK New oral anticoagulants: a practical guide for clinicians J Thromb Thrombolysis 2009 Nov 4. [Epub ahead of print]

Apostolakis S, Shantsila E, Lip GY New anticoagulants for the prevention of deep venous thrombosis: time to consider cost effectiveness? Pharmacoeconomics 2009;27(10):793-5.

Collet JP, Aout M, Alantar A, Coriat P, Napoléon B, Thomas D, Trosini-Desert V, Tucas G, Vicaut E, Montalescot G Real-life management of dual antiplatelet therapy interruption: the REGINA survey Arch Cardiovasc Dis 2009 Oct;102(10):697-710. Epub 2009 Oct 27.

Collins DR No longer need to RE-LY on Warfarin for stroke prevention? Ir Med J 2009 Oct;102(9):278-9.

Dagres N, Hindricks G, Kottkamp H, Sommer P, Gaspar T, Bode K, Arya A, Rallidis LS, Kremastinos DT, Piorkowski C Real-life anticoagulation treatment of atrial fibrillation after catheter ablation: Possible overtreatment of low-risk patients Thromb Haemost 2009;102(4):754-8.

De A, Roy P, Garg VK, Pandey NK Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery Blood Coagul Fibrinolysis. 2009 Oct 19. [Epub ahead of print]

Dunn A Oral anticoagulant therapy safely prevented stroke in older patients with atrial fibrillation Evid Based Med 2009;14(5):140.

Fanikos J, Piazza G, Zayaruzny M, Goldhaber SZ Long-term complications of medical patients with hospital-acquired venous thromboembolism Thromb Haemost 2009;102(4):688-93.

Farge D, Bosquet L, Kassab-Chahmi D, Mismetti P, Elalamy I, Meyer G, Cajfinger F, Desmurs-Clavel H, Elias A, Grange C, Hocini H, Legal G, Mahe I, Quéré I, Levesque H, Debourdeau P 2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: Report from the working group. Crit Rev Oncol Hematol 2009 Oct 2. [Epub ahead of print]

Fuji T, Fuijita S, Ujihira T, Sato T Dabigatran Etexilate Prevents Venous Thromboembolism After Total Knee Arthroplasty in Japanese Patients, With a Safety Profile Comparable to Placebo J Arthroplasty 2009 Oct 24. [Epub ahead of print]

Garcia D, Libby E, Crowther MA The new oral anticoagulants Blood 2009 Oct 30. [Epub ahead of print]

Griffiths GO, Burns S, Noble SI, Macbeth FR, Cohen D, Maughan TS FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer BMC Cancer 2009;9:355.

Grouzi E, Kyriakou E, Panagou I, Spiliotopoulou I Fondaparinux for the Treatment of Acute Heparin-Induced Thrombocytopenia: A Single-Center Experience Clin Appl Thromb Hemost 2009 Oct 13. [Epub ahead of print]

Heindl B, Spannagl M. New oral anticoagulants : Consequences for perioperative coagulation diagnostics and therapy. Anaesthesist. 2009 Oct 14. [Epub ahead of print] German.

Kohsaka S, Homma S. Anticoagulation for heart failure: selecting the best therapy. Expert Rev Cardiovasc Ther. 2009;7(10):1209-17.

Kucher N, Spirk D, Baumgartner I, Mazzolai L, Korte W, Nobel D, Banyai M, Bounameaux H. Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER). Ann Oncol. 2009 Oct 14. [Epub ahead of print]

Liakishev AA. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. Results of the RE-LY study. Kardiologiia. 2009;49(10):75-6.

Lyman GH. Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. Cancer. 2009 Oct 13. [Epub ahead of print]

Malato A, Saccullo G, Coco LL, Caramazza D, Abbene I, Pizzo G, Casuccio A, Siragusa S. Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular weight heparin. J Thromb Haemost. 2009 Oct 11. [Epub ahead of print]

Markel DC, York S, Liston MJ Jr, Flynn JC, Barnes CL, Davis CM 3rd; the AAHKS Research Committee. Venous Thromboembolism Management by American Association of Hip and Knee Surgeons. J Arthroplasty. 2009 Oct 16. [Epub ahead of print]

No authors listed Dabigatran: safer, more effective and easier to use than warfarin. Cardiovasc J Afr. 2009 Sep-Oct;20(5):311-3.

Palla A, Ribas C, Rossi G, Pepe P, Marconi L, Prandoni P. The clinical course of 1-year anticoagulated pulmonary embolism: results of a prospective, observational, cohort study. J Thromb Haemost. 2009 Oct 10. [Epub ahead of print]

Samama MM, Gerotziafas GT. Newer anticoagulants in 2009. J Thromb Thrombolysis. 2009 Oct 17. [Epub ahead of print]

Sood MM, Komenda P, Sood AR, Rigatto C, Bueti J. The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis? Chest. 2009;136(4):1128-33.

Stein PD, Hull RD, Matta F, Yaekoub AY. Anticoagulants for Acute Venous Thromboembolism: What We Think We Know and What the Data Show for Timing of Recurrent Events. Clin Appl Thromb Hemost. 2009 Oct 13. [Epub ahead of print]

Stein PD, Hull RD, Matta F, Yaekoub AY. Early Discharge of Patients With Venous Thromboembolism: Implications Regarding Therapy. Clin Appl Thromb Hemost. 2009 Oct 14. [Epub ahead of print]

Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. Health Technol Assess. 2009 Oct;13 Suppl 3:43-8.

Vardi M, Zittan E, Bitterman H Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism Cochrane Database Syst Rev 2009;(4):CD006771.

Weimar C, Weber R, Diener HC Antithrombotic medication for stroke prevention Expert Rev Cardiovasc Ther 2009;7(10):1245-54.

Yuet Wan Anticoagulation with dabigatran or rivaroxaban Drug Ther Bull 2009;47(10):116-20.

[No authors listed] Is dabigatran the ideal drug against thrombosis? Commentary to RE-LY Kardiol Pol 2009;67(10):1153-4

[No authors listed] Dabigatran is better than warfarin in patients with atrial fibrillation and stroke risk - Re-Ly studies Kardiol Pol 2009;67(10):1151-2

Amara W, Ben Youssef I, Kamel J, Ghrissi I, Faron M, Khouadja A, Sergent J Hemorrhagic risk of different perioperative anticoagulation protocols in patients implanted with a cardiac pacemaker or defibrillator: Retrospective analysis in patients implanted in a community hospital Ann Cardiol Angeiol (Paris) 2009 Sep 20. [Epub ahead of print]

Blackmer AB, Oertel MD, Valgus JM Fondaparinux and the Management of Heparin-Induced Thrombocytopenia: The Journey Continues Ann Pharmacother 2009 Sep 8. [Epub ahead of print]

Bonaca MP, Morrow DA SCH 530348: a novel oral thrombin receptor antagonist Future Cardiol 2009;5(5):435-42

Bover R, Pérez-Gómez F, Maluenda MP, Asenjo S, Pérez-Saldaña R, Igea A, Suárez M, Coleto D, Fernández C Long-Term Follow-Up of Atrial Fibrillation Patients in the NASPEAF Study. Prospective Evaluation of Different Antiplatelet Treatments. Rev Esp Cardiol 2009;62(9):992-1000

Camm AJ The RE-LY study: Randomized Evaluation of Long-term anticoagulant therapY: dabigatran vs. warfarin Eur Heart J 2009 Sep 21. [Epub ahead of print]

Connolly SJ, Crijns HJ, Torp-Pedersen C, van Eickels M, Gaudin C, Page RL, Hohnloser SH; for the ATHENA Investigators Analysis of Stroke in ATHENA: A Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter Circulation 2009 Sep 14. [Epub ahead of print]

Connolly SJ, Ezekowitz MD., Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, the RE-LY Steering Committee and Investigators Dabigatran versus Warfarin in Patients with Atrial Fibrillation N Engl J Med 2009;361(12):1139-51

De Assis MC, Rabelo ER, Avila CW, Polanczyk CA, Rohde LE Improved oral anticoagulation after a dietary vitamin k-guided strategy: a randomized controlled trial Circulation 2009;120(12):1115-22, 3 p following 1122. Epub 2009 Sep 8

Dentali F, Ageno W, Witt D, Malato A, Clark N, Garcia D, McCool K, Siragusa S, Dyke S, Crowther M; for the WARPED consortium Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists. A multi-centre, retrospective cohort study. Thromb Haemost 2009;102(3):501-504

Ellis DJ, Usman MH, Milner PG, Canafax DM, Ezekowitz MD The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation Circulation 2009;120(12):1029-35, 2 p following 1035. Epub 2009 Sep 8

Esmon CT Basic mechanisms and pathogenesis of venous thrombosis Blood Rev 2009 Sep;23(5):225-9.

Fernlöf G, Sjöström BM, Lindell KM, Wall UE Management of major bleedings during anticoagulant treatment with the oral direct thrombin inhibitor ximelagatran or warfarin Blood Coagul Fibrinolysis 2009 Sep 7. [Epub ahead of print]

Fitzmaurice DA, Hobbs FD Anticoagulant management in patients with atrial fibrillation Semin Thromb Hemost 2009;35(6):543-7. Epub 2009 Sep 28.

Freedman JE, Gersh BJ New therapies for stroke prevention in atrial fibrillation: the long road to enhanced efficacy Circulation 2009;120(12):1024-6.

Galanaud JP, Sevestre-Pietri MA, Bosson JL, Laroche JP, Righini M, Brisot D, Boge G, van Kien AK, Gattolliat O, Bettarel-Binon C, Gris JC, Genty C, Quere I; The OPTIMEV-SFMV Investigators Comparative study on risk factors and early outcome of symptomatic distal versus proximal deep vein thrombosis: Results from the OPTIMEV study Thromb Haemost 2009;102(3):493-500

Gómez-Outes A, Suárez-Gea ML, Blázquez-Pérez A, Pozo-Hernández C, Vargas-Castrillón E Will oral rivaroxaban improve clinically relevant outcomes and thromboprophylaxis management in the orthopedic patient? J Thromb Haemost 2009 Sep 18. [Epub ahead of print]

Harenberg J. New anticoagulants in atrial fibrillation. Semin Thromb Hemost. 2009;35(6):574-85. Epub 2009 Sep 28.

Hart RG, Halperin JL. Do current guidelines result in overuse of warfarin anticoagulation in patients with atrial fibrillation? Ann Intern Med 2009;151(5):355-6

Holmes M, Carroll C, Papaioannou D Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal. Health Technol Assess. 2009 Sep;13 Suppl 2:55-62.

Hylek EM. Antithrombotic prophylaxis in elderly patients with atrial fibrillation. Semin Thromb Hemost. 2009;35(6):548-53. Epub 2009 Sep 28.

Kahn SR. How I manage the post thrombotic syndrome Blood 2009 Sep 9. [Epub ahead of print]

Kakkar AK. Prevention of Venous Thromboembolism in the Cancer Surgical Patient J Clin Oncol. 2009 Sep 8. [Epub ahead of print]

Lee AY. Anticoagulation in the Treatment of Established Venous Thromboembolism in Patients With Cancer. J Clin Oncol. 2009 Sep 8. [Epub ahead of print]

Lepic K, Crowther MA A logical approach to surgical thromboprophylaxis Curr Opin Hematol 2009 Sep;16(5):397-401.

Levi M, de Peuter OR, Kamphuisen PW. Management strategies for optimal control of anticoagulation in patients with atrial fibrillation. Semin Thromb Hemost. 2009;35(6):560-7. Epub 2009 Sep 28.

Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. Semin Thromb Hemost. 2009 Jul;35(5):468-77. Epub 2009 Sep 8

Millar JA. Selection of medical patients for prophylaxis of venous thromboembolism based on analysis of the benefit-hazard ratio. Intern Med J. 2009;39(9):606-12.

Mismetti P, Laporte S. Dabigatran: clinical pharmacology. Ann Fr Anesth Reanim. 2009 Sep;28(9 Suppl):S8-14.

Nair CK, Holmberg MJ, Aronow WS, Shen X, Li H, Lakkireddy D. Thromboembolism in patients with atrial fibrillation with and without left atrial thrombus documented by transesophageal echocardiography. Am J Ther. 2009 Sep-Oct;16(5):385-92.

No authors listed Self-monitoring for patients on warfarin? Drug Ther Bull. 2009;47(9):98-101

Piazza G, Fanikos J, Zayaruzny M, Goldhaber SZ. Venous thromboembolic events in hospitalised medical patients. Thromb Haemost. 2009;102(3):505-10

Piccini JP, Hernandez AF, Zhao X, Patel MR, Lewis WR, Peterson ED, Fonarow GC; Get With The Guidelines Steering Committee and Hospitals. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol 2009;54(14)

Pisters R, de Vos CB, Nieuwlaat R, Crijns HJ. Use and underuse of oral anticoagulation for stroke prevention in atrial fibrillation: old and new paradigms. Semin Thromb Hemost. 2009;35(6):554-9. Epub 2009 Sep 28.

Rosencher N, Bellamy L. Dabigatran (Pradaxa): efficacy and safety. Ann Fr Anesth Reanim. 2009 Sep;28(9 Suppl):S15-22.

Sasaki S, Miyakoshi N, Matsuura H, Saitoh H, Kudoh D, Shimada Y. Prospective randomized controlled trial on the effect of fondaparinux sodium for prevention of venous thromboembolism after hip fracture surgery. J Orthop Sci. 2009;14(5):491-6. Epub 2009 Oct 3.

Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. 2009;151(5):297-305

Spectre G, Varon D New antiplatelet agents Curr Opin Hematol 2009 Sep;16(5):365-70.

Streiff MB Diagnosis and Initial Treatment of Venous Thromboembolism in Patients With Cancer J Clin Oncol 2009 Sep 8. [Epub ahead of print]

Subramaniam V, Davis RC, Shantsila E, Lip GY Antithrombotic therapy for heart failure in sinus rhythm Fundam Clin Pharmacol 2009 Sep 4. [Epub ahead of print]

Vorob'eva NM, Panchenko EP, Kirienko AI, Dobrovol'skiĭ AB, Titaeva EV, Ermolina OV, Balakhonova TV, Andriiashkin VV, Leont'ev SG Warfarin or enoxaparin: the choice for the patient with venous thrombosis in the first month of treatment Ter Arkh 2009;81(9):57-61.

Zinn A, Feit F Optimizing antithrombotic strategies in patients with concomitant indications for warfarin undergoing coronary artery stenting Am J Cardiol 2009 Sep 7;104(5 Suppl):49C-54C

Chan KE, Lazarus JM, Thadhani R, Hakim RM Warfarin Use Associates with Increased Risk for Stroke in Hemodialysis Patients with Atrial Fibrillation J Am Soc Nephrol 2009 Aug 27. [Epub ahead of print]

Chandrasekaran S, Ariaretnam SK, Tsung J, Dickison D Early mobilization after total knee replacement reduces the incidence of deep venous thrombosis ANZ J Surg 2009;79(7-8):526-9.

Crandall MA, Horne BD, Day JD, Anderson JL, Muhlestein JB, Crandall BG, Weiss JP, Osborne JS, Lappé DL, Bunch TJ Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors Pacing Clin Electrophysiol 2009 Aug;32(8):981-6.

Crowther MA, Warkentin TE Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents J Thromb Haemost 2009;7 Suppl 1:107-10.

De Caterina R The current role of anticoagulants in cardiovascular medicine J Cardiovasc Med (Hagerstown) 2009 Aug;10(8):595-604

Dobesh PP Economic burden of venous thromboembolism in hospitalized patients Pharmacotherapy 2009;29(8):943-53

Fitzmaurice D Atrial fibrillation and coagulation: Who and when? Blood Rev 2009 Aug 24. [Epub ahead of print]

Francis CW Prevention of Venous Thromboembolism in Hospitalized Patients With Cancer J Clin Oncol 2009 Aug 24. [Epub ahead of print]

Gage BF Can we rely on RE-LY? N Engl J Med 2009;361(12):1200-2. Epub 2009 Aug 30

Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, Miller C, Qi D, Ziegler PD The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study Circ Arrhythm Electrophysiol 2009;2(5):474-80. Epub 2009 Aug 4.

Karami-Djurabi R, Klok FA, Kooiman J, Velthuis SI, Nijkeuter M, Huisman MV. D-dimer Testing in Patients with Suspected Pulmonary Embolism and Impaired Renal Function Am J Med 2009 Aug 19. [Epub ahead of print]

Kearon C Balancing risks and benefits of extended anticoagulant therapy for idiopathic venous thrombosis. J Thromb Haemost 2009;7 Suppl 1:296-300.

Kessler CM. The link between cancer and venous thromboembolism: a review Am J Clin Oncol 2009;32(4 Suppl):S3-7.

Kössler J, Steigerwald U, Walter U. Anticoagulants of primary haemostasis. Hamostaseologie 2009;29(3):274-278

Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361:594-604.

Macfarlane AJ, Prasad GA, Chan VW, Brull R. Does regional anaesthesia improve outcome after total hip arthroplasty? A systematic review. Br J Anaesth 2009;103(3):335-45.

Neviaser AS, Chang C, Lyman S, Gonzales Della Valle A, Haas SB. High Incidence of Complications From Enoxaparin Treatment After Arthroplasty Clin Orthop Relat Res 2009 Aug 11. [Epub ahead of print]

Ordovás Baines JP Dabigatran and rivaroxaban, new oral anticoagulants for the treatment of venous thromboembolism Farm Hosp 2009;33(3):123-4

Palareti G, Cosmi B. Bleeding with anticoagulation therapy - Who is at risk, and how best to identify such patients. Thromb Haemost 2009;102(2):268-78.

Quist-Paulsen P, Næss IA, Cannegieter SC, Romundstad PR, Christiansen SC, Rosendaal FR, Hammerstrøm J. Arterial cardiovascular risk factors and venous thrombosis: results from a population based prospective study (the HUNT 2) Haematologica. 2009 Aug 27. [Epub ahead of print]

Sanoski CA. Clinical, Economic, and Quality of Life Impact of Atrial Fibrillation J Manag Care Pharm 2009;15(6 Supp B):1-9.

Schulman S Rivaroxaban in Orthopedic Surgery: A Change of Paradigm? Clin Appl Thromb Hemost 2009 Aug 10. [Epub ahead of print]

Schulman S, Reilly PA. Dabigatran Etexilate: Future Directions in Anticoagulant Treatment. Clin Appl Thromb Hemost 2009 Aug 13. [Epub ahead of print]

Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics 2009;10(8):1243-55.

Stangier J, Clemens A. Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor Clin Appl Thromb Hemost 2009 Aug 19. [Epub ahead of print]

Steffel J, Lüscher TF Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors J Cardiovasc Med (Hagerstown) 2009 Aug;10(8):616-23.

TRA*CER Executive and Steering Committees The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale Am Heart J 2009;158(3):327-334.e4.

Verdú A, Maestre A, López P, Gil V, Martín-Hidalgo A, Castaño JA Clinical pathways as a healthcare tool: design, implementation and assessment of a clinical pathway for lower-extremity deep venous thrombosis Qual Saf Health Care 2009;18(4):314-20.

Camporese G, Bernardi E Low-molecular-weight heparin for thromboprophylaxis Curr Opin Pulm Med 2009 Jul 9

Crandall MA, Bradley DJ, Packer DL, Asirvatham SJ Contemporary management of atrial fibrillation: update on anticoagulation and invasive management strategies Mayo Clin Proc 2009 Jul;84(7):643-62

Johanson NA, Lachiewicz PF, Lieberman JR, Lotke PA, Parvizi J, Pellegrini V, Stringer TA, Tornetta P 3rd, Haralson RH 3rd, Watters WC 3rd American academy of orthopaedic surgeons clinical practice guideline on. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty J Bone Joint Surg Am 2009 Jul;91(7):1756-7

Prandoni P, Pesavento R, Sørensen HT, Gennaro N, Dalla Valle F, Minotto I, Perina F, Pengo V, Pagnan A. Prevalence of heart diseases in patients with pulmonary embolism with and without peripheral venous thrombosis: findings from a cross-sectional survey. Eur J Intern Med 2009;20(5):470-3. Epub 2009 Jul 4

Scarvelis D, Anderson J, Davis L, Forgie M, Lee J, Petersson L, Ramsay T, Wells PS. Hospital mortality due to pulmonary embolism and an evaluation of the usefulness of preventative interventions Thromb Res 2009 Jul 30. [Epub ahead of print]

Schulman S, Melinyshyn A, Ennis D, Rudd-Scott L. Single-dose adjustment versus no adjustment of warfarin in stably anticoagulated patients with an occasional international normalized ratio (INR) out of range Thromb Res 2009 Jul 28 [Epub ahead of print]

Spencer FA, Emery C, Joffe SW, Pacifico L, Lessard D, Reed G, Gore JM, Goldberg RJ Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study J Thromb Thrombolysis 2009 Jul 24. [Epub ahead of print]

Turpie AG Direct Factor Xa and direct thrombin inhibitors: A clinical trial update Curr Opin Drug Discov Devel 2009 Jul;12(4):497-508

Ageno W Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials Expert Rev Cardiovasc Ther 2009;7:569-76

Amin A, Spyropoulos AC, Dobesh P, Shorr A, Hussein M, Mozaffari E, Benner JS Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start). Thromb Thrombolysis 2009 Jun 23. [Epub ahead of print]

Borris LC Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty Arch Orthop Trauma Surg 2009 Jun 30. [Epub ahead of print]

Bump GM, Dandu M, Kaufman SR, Shojania KG, Flanders SA How complete is the evidence for thromboembolism prophylaxis in general medicine patients? A meta-analysis of randomized controlled trials J Hosp Med 2009;4(5):289-97

Debourdeau P, Kassab Chahmi D, Le Gal G, Kriegel I, Desruennes E, Douard MC, Elalamy I, Meyer G, Mismetti P, Pavic M, Scrobohaci ML, Lévesque H, Renaudin JM, Farge D; on behalf of the working group of the SOR 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group Ann Oncol 2009 Jun 12 [Epub ahead of print]

Deinum J, Mattsson C, Inghardt T, Elg M Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637 Thromb Haemost 2009;101:1051-9

Garcia D Novel anticoagulants and the future of anticoagulation Thromb Res 2009;123 Suppl 4:S50-5

Halbfass P, Janko S, Dorwarth U, Riess G, Antoni D, Hoffmann E Dilemma of antithrombotic therapy in anticoagulated atrial fibrillation patients squeezed between thrombosis and bleeding events: a single-centre experience. Europace 2009 Jun 3 [Epub ahead of print]

Klok FA, Mos IC, Broek L, Tamsma JT, Rosendaal FR, de Roos A, Huisman MV Risk of arterial cardiovascular events in patients after pulmonary embolism. Blood 2009 Aug 20;114(8):1484-8. Epub 2009 Jun 23.

Kucher N, Puck M, Blaser J, Bucklar G, Eschmann E, Lüscher TF. Physician compliance with advanced electronic alerts for preventing venous thromboembolism among hospitalized medical patients. J Thromb Haemost 2009 Jun 9 [Epub ahead of print]

Masaki N, Suzuki M, Iwatsuka R, Mizukami A, Kumasaka L, Nagahori W, Ohno M, Matsumura A, Maruyama Y, Hashimoto Y Effectiveness of Risk Stratification According to CHADS2 Score in Japanese Patients With Nonvalvular Atrial Fibrillation. Int Heart J 2009;50(3):323-9

McAndrew CM, Fitzgerald SJ, Kraay MJ, Goldberg VM Incidence of Postthrombotic Syndrome in Patients Undergoing Primary Total Knee Arthroplasty for Osteoarthritis. Clin Orthop Relat Res 2009 Jun 19. [Epub ahead of print]

Mega J, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan E, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson C; on behalf of the ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009 Jun 16. [Epub ahead of print]

Nadar SK, Goyal D, Shantsila E, Banerjee P, Lip GY Fondaparinux: an overview. Expert Rev Cardiovasc Ther 2009 Jun;7(6):577-85

Ng HJ, Lee LH Trends in prevalence of deep venous thrombosis among hospitalised patients in an Asian institution. Thromb Haemost 2009;10:1095-9

Nokes TJ, Keenan J. Thromboprophylaxis in patients with lower limb immobilisation - review of current status. Br J Haematol 2009 Jun 10 [Epub ahead of print]

Nutescu EA, Spinler SA, Wittkowsky A, Dager WE Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009 Jun;43(6):1064-83

Park B, Messina L, Dargon P, Huang W, Ciocca R, Anderson FA Recent Trends in Clinical Outcomes and Resource Utilization for Pulmonary Embolism in the United States: Findings From the Nationwide Inpatient Sample. Chest 2009 Jun 12 [Epub ahead of print]

Pengo V, Cucchini U, Denas G, Erba N, Guazzaloca G, La Rosa L, De Micheli V, Testa S, Frontoni R, Prisco D, Nante G, Iliceto S; Italian Federation of Centers for the Diagnosis of Thrombosis and Management of Antithrombotic Therapies (FCSA) Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation 2009 Jun 9;119(22):2920-7

Pineo GF, Hull RD Economic and Practical Aspects of Thromboprophylaxis With Unfractionated and Low-Molecular-Weight Heparins in Hospitalized Medical Patients. Clin Appl Thromb Hemost 2009 Jun 10. [Epub ahead of print]

Prineas RJ, Soliman EZ, Howard G, Howard VJ, Cushman M, Zhang ZM, Moy CS The sensitivity of the method used to detect atrial fibrillation in population studies affects group-specific prevalence estimates: ethnic and regional distribution of atrial fibrillation in the REGARDS study J Epidemiol 2009;19(4):177-81. Epub 2009 Jun 27

Shantsila E, Lip GY, Chong BH Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest 2009 Jun; 135(6):1651-64

Sorensen SV, Dewilde S, Singer DE, Goldhaber SZ, Monz BU, Plumb JM Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. Am Heart J 2009;157:1064-73

Volkmann H, Walter M, Bergmann C, Rose E, Krpciar V, Vetter S Antithrombotic therapy in atrial fibrillation : When vitamin K antagonists? When aspirin? When heparine? When combinations of anticoagulant and antiplatelet drugs? Herzschrittmacherther Elektrophysiol 2009 Jun 20 [Epub ahead of print] German

Wakefield TW, McLafferty RB, Lohr JM, Caprini JA, Gillespie DL, Passman MA; Executive Committee of the American Venous Forum Call to action to prevent venous thromboembolism J Vasc Surg 2009 Jun;49(6):1620-3

Wells PS, Le Gal G, Tierney S, Carrier M Practical application of the 10-mg warfarin initiation nomogram Blood Coagul Fibrinolysis 2009 Jun 10. [Epub ahead of print]

APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial Circulation 2009;119:2877-85.

Camporese G, Bernardi E, Noventa F Prevention of deep venous thrombosis after knee arthroscopy: Recent advances Recenti Prog Med 2009;100(5):227-32.

Cook D, Tkaczyk A, Lutz K, McMullin J, Haynes RB, Douketis J Thromboprophylaxis for hospitalized medical patients: a multicenter qualitative study J Hosp Med 2009 May;4(5):269-75.

Cusick LA, Beverland DE The incidence of fatal pulmonary embolism after primary hip and knee replacement in a consecutive series of 4253 patients J Bone Joint Surg Br 2009 May;91(5):645-8

Eriksson BI, Kakkar AK, Turpie AG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement J Bone Joint Surg Br 2009 May;91(5):636-44

Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran Am Heart J 2009 May;157(5):805-10, 810.e1-2

Persson LM, Lapidus LJ, Lärfars G, Rosfors S Asymptomatic Deep Venous Thrombosis is Associated with a Low Risk of Post-thrombotic Syndrome. Eur J Vasc Endovasc Surg 2009 May 29 [Epub ahead of print]

Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. Thromb Haemost. 2009 May;101(5):938-42

Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol. 2009;54(11):999-1002

Prandoni P, Prins MH, Lensing AW, Ghirarduzzi A, Ageno W, Imberti D, Scannapieco G, Ambrosio GB, Pesavento R, Cuppini S, Quintavalla R, Agnelli G; AESOPUS Investigators Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med 2009 May 5;150(9):577-85

Squizzato A, Micieli E, Galli M, Gibson N, Gerdes VE, Dentali F, Buller H, Ageno W, Venco A Diagnosis and management of venous thromboembolism: Results of a survey on current clinical practice. Thromb Res 2009 May 19 [Epub ahead of print]

Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; for the RECORD4 Investigators Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial Lancet 2009 May 1 [Epub ahead of print]

Baker WL, Cios DA, Sander SD, Coleman CI Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States J Manag Care Pharm 2009 Apr;15(3):244-52

Borris LC Rivaroxaban, a new, oral, direct factor Xa inhibitor for thromboprophylaxis after major joint arthroplasty Expert Opin Pharmacother 2009 Apr;10(6):1083-8

Chin PL, Amin MS, Yang KY, Yeo SJ, Lo NN Thromboembolic prophylaxis for total knee arthroplasty in Asian patients: a randomised controlled trial J Orthop Surg (Hong Kong) 2009 Apr;17(1):1-5

De Caterina R, Kristensen SD, Renda G New anticoagulants for atrial fibrillation J Cardiovasc Med (Hagerstown) 2009 Apr 10

Enden T, Kløw NE, Sandvik L, Slagsvold CE, Ghanima W, Hafsahl G, Holme PA, Holmen LO, Njaastad AM, Sandbæk G, Sandset PM; For the Cavent Study Group Catheter-directed thrombolysis versus anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short term patency J Thromb Haemost 2009 Apr 30. [Epub ahead of print]

Hildemann SK, Bode C. Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1. Hamostaseologie. 2009;29:349–55.

Jiang X, Crain EJ, Luettgen JM, Schumacher WA, Wong PC Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro Thromb Haemost 2009 Apr;101(4):780-2

Lassen MR, Dahl OE, Mismetti P, Destrée D, Turpie AG AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery--TREK: a dose-ranging study. J Thromb Haemost 2009 Apr;7(4):566-72. Epub 2009 Jan 24

Merli GJ Deep-vein thrombosis in malignancy: How long should patients be treated, and with what? Catheter Cardiovasc Interv 2009 Apr 13;74(S1):S27-S34. [Epub ahead of print]

Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P, Goette A, Lewalter T, Ravens U, Meinertz T, Breithardt G, Steinbeck G. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009 Apr; 11(4):423-34 [Epub 2009 Jan 18]

Nicolau JC, Cohen M, Montalescot G Differences Among Low-Molecular Weight Heparins: Evidence in Patients With Acute Coronary Syndromes. J Cardiovasc Pharmacol 2009 Apr 10. [Epub ahead of print]

van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, Koudstaal PJ, Petersen P, Perez-Gomez F, Knottnerus JA, Boode B, Ezekowitz MD, Singer DE Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators Stroke 2009 Apr;40(4):1410-6. Epub 2009 Jan 29

Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, Mahaffey KW, Van de Werf F, Veltri E, Harrington RA; TRA-PCI Investigators Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study Lancet 2009 Mar 14;373(9667):919-28

Cohen AT, Maillardet L, Yavin Y Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence? Thromb Haemost 2009 Mar;101(3):422-7

Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, Singer DE; ATRIA Study Investigators Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study Circulation 2009 Mar 17;119(10):1363-9. Epub 2009 Mar 2

Johanson NA, Lachiewicz PF, Lieberman JR, Lotke PA, Parvizi J, Pellegrini V, Stringer TA, Tornetta P 3rd, Haralson RH 3rd, Watters WC 3rd Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty J Am Acad Orthop Surg 2009 Mar;17(3):183-96

Poller L, Keown M, Ibrahim S, Lowe G, Moia M, Turpie AG, Roberts C, van den Besselaar AM, van der Meer FJ, Tripodi A, Palareti G, Shiach C, Bryan S, Samama M, Burgess-Wilson M, Heagerty A, Maccallum P, Wright D, Jespersen J; European Action on Anticoagulation (EAA) A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program. Thromb Haemost 2009 Mar;101(3):487-94

Rietbrock S, Plumb JM, Gallagher AM, van Staa TP How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database. Thromb Haemost 2009 Mar;101(3):527-34

Rochat MC, Waeber G, Wasserfallen JB, Nakov K, Aujesky D Hospitalized women experiencing an episode of excessive oral anticoagulation had a higher bleeding risk than men. J Womens Health (Larchmt) 2009 Mar; 18(3):321-6

Spence D Mechanisms of thrombogenesis in atrial fibrillation. Lancet. 2009 Mar 21; 373(9668):1006

Stashenko GJ, Hargett CW, Tapson VFm Thrombolytic therapy for venous thromboembolism: Current clinical practice. J Hosp Med. 2009 Mar 5. [Epub ahead of print]

White RH, Keenan CR Effects of race and ethnicity on the incidence of venous thromboembolism Thromb Res 2009;123 Suppl 4:S11-7

Bounameaux H The novel anticoagulants: entering a new era Swiss Med Wkly 2009 Feb 7;139(5-6):60-4

Chapman NH, Brighton T, Harris MF, Caplan GA, Braithwaite J, Chong BH Venous thromboembolism - management in general practice Aust Fam Physician 2009 Jan-Feb;38(1-2):36-40

Dranitsaris G, Stumpo C, Smith R, Bartle W Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery Am J Cardiovasc Drugs 2009;9(1):45-58. doi: 10.2165/00129784-200909010-00005

Eikelboom JW, Karthikeyan G, Fagel N, Hirsh J American association of orthopedic surgeons and american college of chest physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? Chest 2009 Feb;135(2):513-20

Haas S New anticoagulants - towards the development of an "ideal" anticoagulant. Vasa 2009 Feb;38(1):13-29

Harenberg J Development of new anticoagulants: present and future. Semin Thromb Hemost 2008 Nov;34(8):779-93. Epub 2009 Feb 12

Lang D, Weinz C, Schwarz T, Kubitza D, Mueck W Metabolism and excretion of rivaroxaban - an oral, direct Factor Xa inhibitor - in rats, dogs and humans Drug Metab Dispos 2009 Feb 5 [Epub ahead of print]

Prandoni P, Kahn SR Post-thrombotic syndrome: prevalence, prognostication and need for progress. Br J Haematol 2009 Feb 12. [Epub ahead of print]

Tripodi A, van den Besselaar A Laboratory monitoring of anticoagulation: where do we stand? Semin Thromb Hemost 2009 Feb;35(1):34-41. Epub 2009 Mar 23.

Abrams PJ, Emerson CR Rivaroxaban: a novel, oral, direct factor xa inhibitor Pharmacotherapy. 2009;29:167-81

Beam DM, Courtney DM, Kabrhel C, Moore CL, Richman PB, Kline JA Risk of Thromboembolism Varies, Depending on Category of Immobility in Outpatients Ann Emerg Med 2009 Jan 7. [Epub ahead of print]

Bryniarski L, Pelc-Nowicka A, Zabojszcz M, Mirek-Bryniarska E Dual antiplatelet therapy and antithrombotic treatment: Recommendations and controversies Cardiol J 2009;16(2):179-189

Eikelboom JE, Weitz JI Dabigatran etexilate for prevention of venous thromboembolism Thromb Haemost 2009 101:2-4

Eriksson BI, Quinlan DJ, Weitz JI Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development Clin Pharmacokinet 2009;48(1):1-22. doi: 10.2165/0003088-200948010-00001

Farley TM, Lewis D, Macaulay TE In the pipeline: new oral anticoagulants for the prevention of venous thromboembolism Orthopedics 2009 Jan;32(1) pii: orthosupersite.com/view.asp?rID=35867.

Haas S Rivaroxaban - an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme. Eur J Haematol 2009 Jan 29 [Epub ahead of print]

Karthikeyan G, Eikelboom JW, Hirsh J New oral anticoagulants: not quite there yet. Pol Arch Med Wewn 2009 Jan-Feb;119(1-2):53-8

Labarère J, Sevestre MA, Belmin J, Legagneux A, Barrellier MT, Thiel H, Roux PL, Pernod G, Bosson JL; for the Association pour la Promotion de l'Angiologie Hospitalière (APAH) Low-Molecular-Weight Heparin Prophylaxis of Deep Vein Thrombosis for Older Patients with Restricted Mobility: Propensity Analyses of Data from Two Multicentre, Cross-Sectional Studies. Drugs Aging 2009;26(3):263-271

Lassen MR, Dahl OE, Mismetti P, Destrée D, Turpie AG AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery - TREK: a dose-ranging study. J Thromb Haemost 2009 Jan 24 [Epub ahead of print]

Monkman K, Lazo-Langner A, Kovacs MJ A 10 mg warfarin initiation nomogram is safe and effective in outpatients starting oral anticoagulant therapy for venous thromboembolism. Thromb Res. 2009 Jan 18. [Epub ahead of print]

Mosca L, Grady D, Barrett-Connor E, et al. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke 2009 Jan;40(1):147-55. Epub 2008 Oct 23.

Pomp ER, Doggen CJ, Vos HL, Reitsma PH, Rosendaal FR Polymorphisms in the protein C gene as risk factor for venous thrombosis. Thromb Haemost 2009;101:62-7.

Rasmussen MS, Jorgensen LN, Wille-Jorgensen P Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev 2009 Jan 21(1):CD004318.

Siragusa S, Caramazza D, Malato A How should we determine length of anticoagulation after proximal deep vein thrombosis of the lower limbs? Br J Haematol. 2009 Jan 16. [Epub ahead of print]

Spiess JL Can I stop the warfarin? A review of the risks and benefits of discontinuing anticoagulation J Palliat Med 2009 Jan; 12(1):83-7

Taliani MR, et al. Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities Thromb Haemost 2009; 101(3):596-598

Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM, Dolan G, Brenkel IJ Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery Clin Ther 2009 Jan; 31(1):194-212

van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, Koudstaal PJ, Petersen P, Perez-Gomez F, Knottnerus JA, Boode B, Ezekowitz MD, Singer DE Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators Stroke 2009;40(4):1410-6. Epub 2009 Jan 29.

Akl EA, Terrenato I, Barba M, Sperati F, Muti P, Schünemann HJ Extended perioperative thromboprophylaxis in patients with cancer. A systematic review. Thromb Haemost 2008;100:1

Arora RR, Rai F Antiplatelet Intervention in Acute Coronary Syndrome Am J Ther 2008 Dec 15. [Epub ahead of print]

Baroletti S, Piovella C, Fanikos J, Labreche M, Lin J, Goldhaber SZ Heparin-induced thrombocytopenia (HIT): Clinical and economic outcomes Thromb Haemost 2008;100:1130-5

Borris LC New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban Vasc Health Risk Manag 2008;4(4):855-62.

Bounameaux H, Perrier A Duration of anticoagulation therapy for venous thromboembolism Hematology Am Soc Hematol Educ Program 2008;2008:252-8

Chintala M, Shimizu K, Ogawa M, Yamaguchi H, Doi M, Jensen P Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease J Pharmacol Sci 2008;108(4):433-8

Francis CW New issues in oral anticoagulants Hematology Am Soc Hematol Educ Program 2008;2008:259-65

Hill CE, Duncan A Overview of pharmacogenetics in anticoagulation therapy. Clin Lab Med 2008 Dec;28(4):513-24

Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control. Thromb Res. 2008 Dec 3. [Epub ahead of print]

Pesce V, Patella V, Scaraggi A, Petrera M, Sammarco G Thrombocytopenia after total knee arthroplasty. Orthopedics 2008 Dec;31(12). pii: orthosupersite.com/view.asp?rID=32934.

Righini M, Le Gal G, Aujesky D, Roy PM, Sanchez O, Verschuren F, Kossovsky M, Bressollette L, Meyer G, Perrier A, Bounameaux H Complete venous ultrasound in outpatients with suspected pulmonary embolism. J Thromb Haemost 2008 Dec 20 [Epub ahead of print]

Tay KH, Lane DA, Lip GY Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: is clopidogrel any safer than aspirin when combined with warfarin? Thromb Haemost 2008; 100:955-7

Conget F, Otero R, Jiménez D, Martí D, Escobar C, Rodríguez C, Uresandi F, Cabezudo MA, Nauffal D, Oribe M, Yusen R Short-term clinical outcome after acute symptomatic pulmonary embolism Thromb Haemost 2008 Nov;100(5):937-42

Deitelzweig SB, Becker R, Lin J, Benner J Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism Thromb Haemost 2008 Nov;100(5):810-20

Franchini M, Mannucci PM Venous and arterial thrombosis: different sides of the same coin? Eur J Intern Med 2008 Nov;19(7):476-81. Epub 2008 Mar 20

Glurich I, Burmester JK, Caldwell MD Understanding the pharmacogenetic approach to warfarin dosing Heart Fail Rev 2008 Nov 8. [Epub ahead of print]

Heck CA, Brown CR, Richardson WJ Venous thromboembolism in spine surgery. J Am Acad Orthop Surg 2008 Nov;16(11):656-64

Hunt BJ The prevention of hospital-acquired venous thromboembolism in the United Kingdom Br J Haematol 2008 Nov 29 [Epub ahead of print]

Janjua M, Badshah A, Matta F, Danescu LG, Yaekoub AY, Stein PD Treatment of acute pulmonary embolism as outpatients or following early discharge. A systematic review. Thromb Haemost 2008 Nov;100(5):756-61

Kahn SR, Shrier I, Julian JA, Ducruet T, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Lamping DL, Johri M, Ginsberg JS Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008 Nov 18;149(10):698-707

Levy JH, Tanaka KA, Dietrich W Perioperative hemostatic management of patients treated with vitamin K antagonists Anesthesiology 2008 Nov;109(5):918-26

Milbrink J, Bergqvist D The incidence of symptomatic venous thromboembolic events in orthopaedic surgery when using routine thromboprophylaxis. Vasa. 2008 Nov;37(4):353-7

Millar JA Rational thromboprophylaxis in medical inpatients: not quite there yet. Med J Aust 2008 Nov 3;189(9):504-6.

Nieto JA, Camara T, Gonzalez-Higueras E, Ruiz-Gimenez N, Guijarro R, Marchena PJ, Monreal M; for the RIETE Investigators. Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008;100(5):789-796.

Roldán V, Marín F Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody. Thromb Haemost. 2008 Nov;100(5):754-5.

Rubboli A, Halperin JL Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Thromb Haemost. 2008 Nov; 100(5):752-3

Selby R, Geerts W, Ofosu FA, Craven S, Dewar L, Phillips A, Szalai JP Hypercoagulability after trauma: Hemostatic changes and relationship to venous thromboembolism. Thromb Res 2008 Nov 26 [Epub ahead of print]

Thachil J, Gatt A, Martlew V. Management of surgical patients receiving anticoagulation and antiplatelet agents Br J Surg 2008 Nov 7; 95(12):1437-1448 [Epub ahead of print]

Alonso-Coello P, Montori VM, Sola I, Schunemann HJ, Devereaux P, Charles C, Roura M, Diaz MG, Souto JC, Alonso R, Oliver S, Ruiz R, Coll-Vinent B, Diez AI, Gich I, Guyatt G Values and preferences in oral anticoagulation in patients with atrial fibrilation: physicians' and patients' perspectives. Protocol for a two-phase study. BMC Health Serv Res 2008 Oct 27;8(1):221. [Epub ahead of print]

Cohen M, Hoekstra J The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention Am J Emerg Med 2008 Oct;26(8):932-41.

Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S; on behalf of the ACTIVE W Investigators Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range Circulation 2008 Oct 27 [Epub ahead of print]

Eischer L, Gartner V, Schulman S, Kyrle PA, Eichinger S; for the AUREC-FVIII investigators (as listed in acknowledgements) 6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII Ann Hematol 2008 Oct 18. [Epub ahead of print]

Furusho H, Takamura M, Takata S, Sakagami S, Hirazawa M, Kato T, Murai H, Okajima M, Kaneko S Current Status of Anticoagulation Therapy for Elderly Atrial Fibrillation Patients in Japan Circ J 2008 Oct 14. [Epub ahead of print]

Janin S, Meneveau N, Mahemuti A, Descotes-Genon V, Dutheil J, Chopard R, Seronde MF, Schiele F, Bernard Y, Bassand JP Safety and efficacy of fondaparinux as an adjunctive treatment to thrombolysis in patients with high and intermediate risk pulmonary embolism. J Thromb Thrombolysis 2008 Oct 25 [Epub ahead of print]

Jolobe OM Intensity of anticoagulation in octogenarians with nonvalvular atrial fibrillation J Am Geriatr Soc 2008 Oct;56(10):1967-8

Komotar RJ, Starke RM, Connolly ES Jr Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent. Neurosurgery 2008 Oct;63(4):N10-1

Laporte S, Mismetti P, Decousus H; RIETE Investigators Clinical Predictors for Fatal Pulmonary Embolism in 15,520 Patients with Venous Thromboembolism: Findings from the Registro Informatizado de la Enfermedad Thrombo Embolica Venosa (RIETE) Registry. J Vasc Surg 2008 Oct;48(4):1063

Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, Flockhart DA, Arnett DK, Acton RT, Liu N VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 2008 Oct;9(10):1445-58.

Nieuwlaat R, Connolly S Stroke prevention in atrial fibrillation: better use of anticoagulation and new agents will lead to improved outcomes. Heart 2008 Oct 24 [Epub ahead of print]

Osborne NH, Wakefield TW, Henke PK Venous Thromboembolism in Cancer Patients Undergoing Major Surgery Ann Surg Oncol 2008 Oct 8 [Epub ahead of print]

Parvizi J, Azzam K, Rothman RH Deep venous thrombosis prophylaxis for total joint arthroplasty: American Academy of Orthopaedic Surgeons guidelines. J Arthroplasty 2008 Oct;23(7 Suppl):2-5

Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, Pinto D, Chen S, Bonacorsi S, Wong PC, Zhang D Apixaban metabolism and pharmacokinetics following oral administration to humans. Drug Metab Dispos 2008 Oct 2 [Epub ahead of print]

Ramos J, Perrotta C, Badariotti G, Berenstein G Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. Cochrane Database Syst Rev 2008 Oct 8;(4):CD005259

Rose AJ, Ozonoff A, Henault LE, Hylek EM Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost. 2008 Oct; 6(10):1647-54

Sandercock PA, Counsell C, Kamal AK Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev 2008 Oct 8; (4):CD000024

Testroote M, Stigter W, de Visser DC, Janzing H Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-leg immobilization Cochrane Database Syst Rev 2008 Oct 8;(4):CD006681.

Tick LW, Kramer MH, Rosendaal FR, Faber WR, Doggen CJ Risk factors for post-thrombotic syndrome in patients with a first deep venous thrombosis J Thromb Haemost 2008 Oct 4 [Epub ahead of print]

Walker AM, Bennett D Epidemiology and outcomes in patients with atrial fibrillation in the United States Heart Rhythm 2008 Oct; 5(10):1365-72 Epub 2008 Jul 17.

Bauer KA New anticoagulants Curr Opin Hematol 2008 Sep;15(5):509-15

Callaghan JJ, Warth LC, Hoballah JJ, Liu SS, Wells CW Evaluation of deep venous thrombosis prophylaxis in low-risk patients undergoing total knee arthroplasty J Arthroplasty 2008 Sep;23(6 Suppl 1):20-4

Douketis J, Cook D, Meade M, Guyatt G, Geerts W, Skrobik Y, Albert M, Granton J, Hébert P, Pagliarello G, Marshall J, Fowler R, Freitag A, Rabbat C, Anderson D, Zytaruk N, Heels-Ansdell D, Crowther M; Canadian Critical Care Trials Group Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study Arch Intern Med 2008 Sep 8;168(16):1805-12

Douketis JD Prevention of venous thromboembolism in hospitalized medical patients: addressing some practical questions Curr Opin Pulm Med 2008 Sep;14(5):381-8

Fuji T, Ochi T, Niwa S, Fujita S Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin J Orthop Sci 2008 Sep;13(5):442-51. Epub 2008 Oct 9

Hu D, Sun Y Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. Am Coll Cardiol 2008 Sep 2;52(10):865-8

Kwong LM, Happe LE, Horblyuk R, Farrelly E Decreased venous thromboembolism with injectable vs oral anticoagulation after discharge for major orthopedic surgery. J Arthroplasty 2008 Sep;23(6 Suppl 1):25-30.

Lee A VTE in Patients with Cancer-Diagnosis, Prevention, and Treatment. Thromb Res 2008 Sep 26 [Epub ahead of print]

Lopes RD, Piccini JP, Hylek EM, Granger CB, Alexander JH Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician. J Thromb Thrombolysis 2008 Sep 21. [Epub ahead of print]

Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kälebo P, Muelhofer E, Misselwitz F, Eriksson BI Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008 Sep; 100(3):453-61

Righini M, Bounameaux H Clinical relevance of distal deep vein thrombosis. Curr Opin Pulm Med 2008 Sep;14(5):408-13

Schelleman H, Limdi NA, Kimmel SE Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics 2008 Sep; 9(9):1331-46

Schellong SM Venous ultrasonography in symptomatic and asymptomatic patients: an updated review. Curr Opin Pulm Med 2008 Sep; 14(5):374-80

Seitz CS, Brocker EB, Trautmann A Management of allergy to heparins in postoperative care: subcutaneous allergy and intravenous tolerance. Dermatol Online J 2008 Sep 15;14(9):4

Seto AC, Kenyon K, Wittkowsky AK Discrepancies in identification of major bleeding events in patients taking warfarin. Pharmacotherapy 2008 Sep; 28(9):1098-103

Shen AY, Chen W, Yao JF, Brar SS, Wang X, Go AS Effect of race/ethnicity on the efficacy of warfarin : potential implications for prevention of stroke in patients with atrial fibrillation. CNS Drugs 2008; 22(10):815-25

Stangier J, Stähle H, Rathgen K, Roth W, Shakeri-Nejad K Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment. J Clin Pharmacol. 2008 Sep 30 [Epub ahead of print]

Tanne JH Most patients at risk of stroke fail to get adequate anticoagulation BMJ 2008 Sep 4; 337:a1529. doi: 10.1136/bmj.a1529.

Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P, Bengel F, Brady AJ, Ferreira D, Janssens U, Klepetko W, Mayer E, Remy-Jardin M, Bassand JP, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Zamorano JL, Andreotti F, Ascherman M, Athanassopoulos G, De Sutter J, Fitzmaurice D, Forster T, Heras M, Jondeau G, Kjeldsen K, Knuuti J, Lang I, Lenzen M, Lopez-Sendon J, Nihoyannopoulos P, Perez Isla L, Schwehr U, Torraca L, Vachiery JL; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008 Sep;29(18):2276-315. Epub 2008 Aug 30.

Trujillo-Santos J, Nieto JA, Tiberio G, Piccioli A, Di Micco P, Prandoni P, Monreal M; RIETE Registry Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry Thromb Haemost 2008 Sep;100(3):435-9

Wiedermann CJ, Stockner I Warfarin-induced bleeding complications - clinical presentation and therapeutic options Thromb Res 2008; 122 Suppl 2:S13-8

Zhou Z, Hu D An Epidemiological Study on the Prevalence of Atrial Fibrillation in the Chinese Population of Mainland China J Epidemiol 2008 Sep 8 [Epub ahead of print]

Acosta S, Alhadad A, Svensson P, Ekberg O Epidemiology, risk and prognostic factors in mesenteric venous thrombosis Br J Surg 2008 Aug 21. [Epub ahead of print]

Ageno W, Dentali F Venous thromboembolism and arterial thromboembolism. Many similarities, far beyond thrombosis per se Thromb Haemost 2008 Aug;100(2):181-3.

Aissaoui N, Martins E, Mouly S, Weber S, Meune C A meta-analysis of bed rest versus early ambulation in the management of pulmonary embolism, deep vein thrombosis, or both Int J Cardiol 2008 Aug 6. [Epub ahead of print]

Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T High Rate of Unprovoked Recurrent Venous Thrombosis is Associated with a High Thrombin Generating Potential in a Prospective Cohort Study J Thromb Haemost 2008 Aug 1. [Epub ahead of print]

Borris LC, Breindahl M, Lassen MR, Pap AF, Misselwitz F Differences in Urinary Prothrombin Fragment 1+2 Levels After Total Hip Replacement in Relation to Venous Thromboembolism and Bleeding Events J Thromb Haemost 2008 Aug 1. [Epub ahead of print]

Bungard TJ, Koshman SL, Tsuyuki RT Patient preferences for ongoing warfarin management after receiving care by an anticoagulation management service Am J Health Syst Pharm 2008 Aug 15;65(16):1498-500

Clark NP, Witt DM, Delate T, Trapp M, Garcia D, Ageno W, Hylek EM, Crowther MA Thromboembolic Consequences of Subtherapeutic Anticoagulation in Patients Stabilized on Warfarin Therapy: The Low INR Study Pharmacotherapy 2008 Aug;28(8):960-7

Gallus A Which patients with venous thromboembolism are at risk for fatal pulmonary embolism? Nat Clin Pract Cardiovasc Med 2008 Aug 5. [Epub ahead of print]

Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, Silver FL, Kapral MK Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated Stroke 2008 Aug 28 [Epub ahead of print]

Gulseth MP, Michaud J, Nutescu EA Rivaroxaban: an oral direct inhibitor of factor Xa Am J Health Syst Pharm 2008 Aug 15;65(16):1520-9

Ho WK, Hankey GJ, Eikelboom JW The incidence of venous thromboembolism: a prospective, community-based study in Perth, Western Australia. Med J Aust 2008 Aug 4;189(3):144-7

Hylek EM, Frison L, Henault LE, Cupples A Disparate Stroke Rates on Warfarin Among Contemporaneous Cohorts With Atrial Fibrillation. Potential Insights Into Risk From a Comparative Analysis of SPORTIF III Versus SPORTIF V. Stroke 2008 Aug 14

Levi M Self-management of anticoagulation Expert Rev Cardiovasc Ther 2008 Aug; 6(7):979-85

Akl EA, Barba M, Rohilla S, Terrenato I, Sperati F, Muti P, Schunemann HJ Low-Molecular-Weight Heparins are superior to Vitamin K Antagonists for the long term treatment of venous thromboembolism in patients with cancer: a Cochrane systematic review J Exp Clin Cancer Res 2008 Jul 18;27(1):21. [Epub ahead of print]

Audebert HJ, Schenk B, Tietz V, Schenkel J, Heuschmann PU Initiation of Oral Anticoagulation after Acute Ischaemic Stroke or Transient Ischaemic Attack: Timing and Complications of Overlapping Heparin or Conventional Treatment Cerebrovasc Dis 2008 Jul 15;26(2):171-177. [Epub ahead of print]

Barnes GD, Froehlich JB Anticoagulation: where we are and where we need to go J Thromb Thrombolysis 2008 Jul 18. [Epub ahead of print]

Beri A, Punnam SR Anticoagulation in Patients with Acute Ischemic Stroke and Atrial Fibrillation-a Balance of Risks and Benefits Ther 2008 Jul 21. [Epub ahead of print]

Brækkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Størmer J, Hansen JB Family history of myocardial infarction is an independent risk factor for venous thromboembolism - the Tromsø study J Thromb Haemost 2008 Jul 26 [Epub ahead of print]

Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor Rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study Blood 2008 Jul 11 [Epub ahead of print]

Camporese G, Bernardi E, Prandoni P, Noventa F, Verlato F, Simioni P, Ntita K, Salmistraro G, Frangos C, Rossi F, Cordova R, Franz F, Zucchetta P, Kontothanassis D, Andreozzi GM; KANT (Knee Arthroscopy Nadroparin Thromboprophylaxis) Study Group Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial Ann Intern Med 2008 Jul 15;149(2):73-82

Collen JF, Jackson JL, Shorr AF, Moores LK Prevention of venous thromboembolism in neurosurgery: a meta-analysis Chest 2008 Jul 18. [Epub ahead of print]

Douen AG, Sabih M, Pageau N Thrombus detection by echocardiography in patients with acute ischemic stroke and chronic or new-onset atrial fibrillation J Stroke Cerebrovasc Dis 2008 Jul-Aug;17(4):208-11

Dunning J, Versteegh M, Fabbri A, Pavie A, Kolh P, Lockowandt U, Nashef SA; on behalf of the EACTS Audit and Guidelines Committee